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ABSTRACT
When a patient is presented with locally advanced prostate cancer, it is possible to 
provide treatment with curative intent. However, once the disease has formed distant 
metastases, the chances of survival drops precipitously. For this reason, proper 
management of the disease while it remains localized is of critical importance. Treating 
these malignant cells with cytotoxic agents is effective at cell killing; however, the 
nonspecific toxicity profiles of these drugs often limit their use until the disease has 
progressed and symptom palliation is required. Incorporation of these drugs in 
nanocarriers such as polymers help target them to tumors with a degree of specificity, 
though major vascular barriers limit their effective delivery. In this dissertation, it is 
shown that plasmonic photothermal therapy (PPTT) can be used to help overcome some 
of these barriers and improve delivery to prostate tumors. First, the concept of using 
PPTT to improve the delivery of macromolecules to solid tumors was validated. This 
was done by measuring the tumor uptake of albumin. Next, the concept of targeting gold 
nanorods (GNRs) directly to the tumor’s vasculature to better modulate vascular response 
to heating was tested. Surface conjugation of cyclic RGD (Arg-Gly-Asp) to GNRs 
improved their binding and uptake to endothelial cells in vitro, but not in vivo. 
Nontargeted GNRs and PPTT were then utilized to guide the location of polymer 
therapeutic delivery to prostate tumors. #-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers, which were designed to be targeted to cells previously exposed to heat
shock, were used in this study. Treatment of tumors with PPTT facilitated a burst 
accumulation of the copolymers over 4 hours, and heat shock targeting to cells allowed 
them to be retained for an extended period of time. Finally, the tumor localization of the 
HPMA copolymers following PPTT was evaluated by magnetic resonance imaging 
(MRI). These results show that PPTT may be a useful tool to enhance delivery of 
polymeric drug carriers to locally advanced prostate tumors.
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Prostate cancer is a disease that afflicts a large percentage of men in the United 
States. The American Cancer Society’s “Cancer Facts and Figures” report estimates that 
in 2012 there will be 241,740 new cases and 28,170 deaths related to this disease.1 
Indeed, prostate cancer is one of the most prevalent forms of cancer, but also has one of 
the lowest mortality rates relative to its large number of cases. This somewhat 
encouraging statistic is due to the number of cases whose disease remains localized to the 
prostate gland (Stage I-II). When such cases are presented, removal of the prostate can 
generally provide cure. Once the disease has progressed beyond the prostatic capsule and 
invaded nearby tissue (Stage III), termed advanced localized prostate cancer, complete 
removal of the cancerous tissue becomes difficult. In these cases, radiotherapy often in 
combination with hormone therapy can provide curative treatment, though not with the 
same confidence. Unfortunately, once the disease has progressed and formed distant 
metastases often to the lymph and bone (Stage IV), patient survival reduces dramatically 
(29% 5-year survival rate). In these cases, treatment with hormone and/or chemotherapy 
only provides extension of life with symptom palliation.
2The large difference in patient survival when presented with Stage III vs. IV 
highlights the need to focus on therapies which target advanced localized disease and 
reduces the chances of disease progression. Radio- and hormone therapy offer many 
opportunities in this regard, though these therapies often suffer with adverse effects. 
Hyperthermia, particularly in combination with radiotherapy, is another effective form of
2 5localized therapy for prostate cancer. - Though difficulties in delivering therapeutic 
doses of heat in a diseased tissue specific manner limits its utility. Cytotoxic 
chemotherapy is effective at cancer cell killing, but systemic administration and 
distribution to healthy organs causes significant toxicity and is therefore not used to treat 
these patients. Methods to increase the localization of these agents and limit their 
accumulation in other organs therefore represent a rich area of investigational research.
A developing means of delivering therapies in a more localized and diseased 
tissue specific manner focus on using drug carriers or nanoparticles. Gold nanoparticles 
(AuNPs), for example, are able to strongly absorb light and transduce its energy in the 
form of heat.6 When localized in prostate cancer tissue, AuNP activated heating 
represents an effective way of producing hyperthermia with high control of thermal dose 
and tissue specificity. Termed plasmonic photothermal therapy (PPTT), such heating has 
been used to thermally ablate a wide variety of tumor models in mice including prostate
7 11cancer. - Similarly, polymeric drug carriers are able to preferentially accumulate in
12cancerous tissue and deliver therapeutic warheads at the site of disease. These polymer 
therapeutics can be tailor-made to solubilize poorly soluble drugs, retain them in 
circulation for extended periods of time, extravasate from the vasculature in tumors and
13be uptaken for controlled, intracellular chemical delivery. In this way, the nonspecific
3toxicity of these drugs can be dramatically reduced which may enable their use to treat 
localized disease.
The rational combination of therapies can improve treatment outcome through 
synergism. For example, hyperthermia is known to potentiate radiotherapy as well as 
chemotherapy and is therefore used in adjuvant therapy.3, 14-17 This is due to increased 
tumor blood perfusion and vascular permeability during heating.18-19 More recently, 
hyperthermia has been used to improve the delivery of nanocarriers such as liposomes
20 23due to these improvements in vascular dynamics with heating. - Indeed, treatment of 
tumors with hyperthermia is able to facilitate the accumulation of liposomes in a size, 
temperature and heating time dependent manner. Unfortunately, the limited ability to 
selectively deliver the appropriate dose of heat to promote liposome extravasation 
remains a significant barrier to success.
1.2: Aims and scope of this dissertation
The major focus of this dissertation is to utilize a targeted approach towards the 
combined treatment of advanced localized prostate cancer. As mentioned previously, 
PPTT can initiate hyperthermia in a tissue selective, localized and controllable manner. 
The use of a laser as the source of energy enables one to easily choose the location of 
heating and therefore the area of greater blood perfusion and permeability. Because of 
these reasons, PPTT is used in this dissertation to heat cancerous tissue and facilitate 
nanomedicine delivery.
In this work, polymer therapeutics are used to test the utility of PPTT to enhance 
delivery. Polymer therapeutics, and more specifically HPMA copolymers, are useful in
24this regard due to their multifunctional potential. In these systems, it is easy to 
conjugate drugs or therapeutic radionuclides, targeting moieties and imaging agents to the 
polymeric side chains. Also, their size and degradability can be tailor made to allow for 
clearance through the kidneys as well as greater tumor mass penetration. Such 
conjugates can have stealth-like characteristics which reduce nonspecific organ 
accumulation. These properties make HPMA copolymer-drug conjugates useful for 
directed delivery to localized prostate tumors.
The central hypothesis in this work is that PPTT can be used to direct the delivery 
of HPMA copolymers to prostate tumors (Figure 1.1). GNRs, which have a surface 
plasmon resonance (SPR) peak in the near-infrared (NIR) spectra, are first delivered to 
prostate tumors by intravenous administration and passive accumulation. Subsequent 
administration of HPMA copolymers provides blood availability o f these conjugates. 
Laser light heating of a prostate tumor then enhances blood perfusion and vascular 
permeability. These changes in vascular dynamics then facilitate their accumulation and 
tumor mass penetration. In this way, one might be able to enhance site specific delivery. 
This overall hypothesis was tested through the completion of four Specific Aims:
Specific Aim 1: To provide proof-of-concept by enhancing the delivery of 
albumin to mouse sarcoma tumors using PPTT.
To begin testing the central hypothesis, it was essential to first provide proof-of- 
concept. This was done by using PPTT to enhance the delivery of albumin, a model 
macromolecule, to mouse sarcoma tumors. To begin, GNRs were synthesized to have an 
SPR peak at 800 nm, then grafted with a surface coating of poly(ethylene glycol) (PEG).
4
5Figure 1.1: Scheme of concept showing that PPTT can be used to treat tumors with 
hyperthermia and therefore increase tumor blood flow and vascular permeability. This 
may then facilitate the delivery of macromolecules such as polymer therapeutics from 
the vasculature.
Characterization of these GNRs in terms of size, shape, charge, SPR peak and stability 
confirmed their properties and utility as photothermal antennas. To develop mouse 
sarcomas, CD1 mice were inoculated with S180 cells on each flank. Once appropriately 
sized tumors were obtained, GNRs were administered. Twenty-four hours later, Evans 
blue dye was administered to serve as a tracer of albumin due to their known affinity. 
Laser treatment of tumors then induced tissue heating which was maintained for 10 
minutes to enhance albumin delivery. Five hours after PPTT, the tumors were harvested 
and the Evans blue dye content was measured and compared to controls. Results from
25this study25 confirmed the main hypothesis by showing that PPTT could enhance the 
tumor delivery of albumin by 1.8-fold. This effect was seen when tumors were heated at 
either 43°C or 46°C, though greater tissue damage was observed at the higher 
temperature. Such results provided the necessary proof-of-concept information to 
continue with the project.
Specific Aim 2: To evaluate the potential of enhancing PPTT by targeting GNRs 
directly to the tumor’s vasculature
As the main goal of this dissertation was to use PPTT to modulate tumor vascular 
dynamics, it was hypothesized that targeting of GNRs directly to endothelial cells could 
provide greater control. Also, targeting to the vasculature may increase the concentration 
of GNRs in the tumor which may reduce the laser power needed to initiate PPTT. The 
RGDfK peptide was chosen here due to its known affinity to avp3 cell adhesion integrins 
as well as its proven track record of targeting angiogenesis in prostate tumors.26 GNRs 
were synthesized as before, though for the targeted conjugates prior attachment of
6
7RGDfK to PEG was done before PEGylation. Amino acid analysis of the resulting 
nanoparticles confirmed and quantified the presence of the peptide. The endothelial cell 
targeting potential of the resulting GNRs was then evaluated by imaging and quantifying 
binding and uptake with DU145 and human umbilical vein endothelial cells (HUVEC). 
These experiments showed that attachment of RGDfK to PEGylated GNRs facilitated 
binding and uptake with both cell lines, though this effect was most apparent with 
endothelial cells (20-fold increase). Competitive inhibition of binding with echistatin 
confirmed specificity to integrins. The system was then tested in vivo using a prostate 
tumor xenograft model. Unfortunately, rapid blood clearance of the targeted GNRs by 
the liver and spleen dramatically reduced the availability of these nanoparticles to target
27tumors relative to the untargeted GNRs. This study27 provided indication that vascular 
targeting GNRs, at least under the conditions tested, may not be a viable approach to 
improve the overall hypothesis, and therefore all subsequent studies used GNRs which 
were not targeted.
Specific Aim 3: To evaluate PPTT as a tool to enhance delivery of HPMA 
copolymers to prostate tumors.
Next, the overall hypothesis of the dissertation was tested by confirming PPTT 
could be used to enhance the delivery of HPMA copolymers to prostate tumors. In this 
study, an additional component was also tested. Previously, Pasqualini and coworkers
had shown that the WIFPWIQL peptide could be used to target prostate tumors via
28binding to glucose-regulated protein-78 (GRP78). Because this protein is a member of 
the heat shock protein-70 (HSP70) family, it was hypothesized that incorporation of this
peptide could enable these polymers to target cells which were previously treated with 
hyperthermia. To test this, cells were treated with hyperthermia followed by heat shock 
targeted HPMA copolymers to determine if this could increase conjugate binding and 
uptake. Indeed, prior treatment of cells with heat enabled significantly enhanced uptake 
of the targeted conjugates. Next this system was tested in vivo. Mice bearing prostate 
tumors were treated with PPTT and GRP78 receptor expression was confirmed by 
immunohistochemical (IHC) staining. Then, mice were administered radiolabeled 
untargeted or heat shock targeted HPMA copolymers and the animal’s right tumor was 
treated with PPTT. The left tumor was used in this case as an internal control. 
Evaluation of conjugate tumor delivery showed that treatment with PPTT resulted in a 
burst accumulation over 4 hours. After 4 hours, while the untargeted conjugates diffused 
back out of the tumor, the heat shock targeted HPMA copolymers were retained for an 
extended period of time. This observation is most likely due to GRP78 receptor
29expression after heating. Results from this study thus confirm the overall hypothesis of 
the dissertation that PPTT can be used to guide the location of HPMA copolymer 
delivery to prostate tumors.
Specific Aim 4: To visualize HPMA copolymer delivery enhancement by 
magnetic resonance and fluorescence imaging.
Effective drug delivery to tumors requires both transport through the vasculature 
as well as interstitium. Therefore, in this aim it is hypothesized that PPTT is also capable 
of increasing the distribution of these conjugates in tumors. To study this, gadolinium 
labeled HPMA copolymers were administered to mice bearing prostate tumors
8
immediately before treatment of the right tumor with PPTT. The left tumor served as 
internal, untreated control. MRI and fluorescence microscopy of both tumors showed 
that PPTT was capable of improving the tumor mass penetration of HPMA copolymers. 
Thermal enhancement of delivery, roughly 1.5-fold, to both the tumor center and
30periphery was observed. Results from this study further suggests that PPTT may be a 
useful tool to improve the delivery of polymer-drug conjugates.
1.3: Clinical relevance
The long term goal of the work described in this dissertation is to design a new 
treatment strategy for patients with advanced localized prostate cancer. In this context, 
the following is a description of the potential utility o f the aforementioned approach.
When a patient is presented with advanced localized prostate cancer, an 
alternative to radiotherapy or hormone therapy could be directed drug delivery using 
PPTT. In this case, patients would be administered AuNPs some time before drug 
treatment such that the nanoparticles would passively accumulate in the cancerous tissue. 
The oncologist would then access the prostate gland and surrounding areas via the urethra 
or rectum with a fiber optic. The polymer-drug conjugate would then be administered 
and the prostate gland and surrounding tissue would be radiated with laser light whose 
wavelength induces AuNP SPR and therefore tissue heating. PPTT is beneficial in this 
case as the physician can heat all suspected tissue without significant concern of damage 
to healthy tissue which does not contain the AuNPs. Tumor heating then increases 
vascular blood flow and permeability which facilitates polymer-drug conjugate delivery 
in these regions. Finally, once the therapeutic has cleared through the kidneys
9
(approximately 30-60 minutes) and is no longer available in the blood, laser treatment 
can be terminated leaving only the prostate cancer tissue with drug. In this way, the 
location of drug delivery can be dictated by the physician without significant concern of 
treatment side effects due to either the drug or hyperthermia.
In the following chapters of this dissertation, efforts towards the overall goal of 
the project will be discussed. In Chapter 2, a review of the literature relevant to this work 
will be provided. In Chapters 3-6, the scientific work used to complete Specific Aims 1­
4 respectively will be described in detail. Finally, in Chapter 7, the project’s conclusions 
and future directions will be discussed.
All of the experimental work described in Chapters 3-6 was performed and
29collected by Adam Gormley. However, the published paper from Chapter 5 was first 
co-authored by Adam Gormley and Nate Larson. Data collected by Larson and published 
in this paper are not included in this dissertation. As his thesis focuses on heat shock 
targeting of HPMA copolymers, the data he collected in this area will be included in his 
dissertation. These data include: a) synthesis and characterization of heat shock targeted 
HPMA copolymers with drug (aminohexylgeldanamycin) attached to its side chains, b) in 
vitro GRP78 receptor expression after heat shock, c) quantification of binding and uptake 
of heat shock targeted conjugates to prostate cancer cells, d) in vitro anticancer activity of 
these conjugates with and without hyperthermia, and e) pharmacokinetic modeling of the 
tumor and blood concentration data. The remaining data in that paper were collected by 
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The prevalence of cancer in the United States is substantial. In 2008, it was 
estimated that nearly 12 million Americans were alive who have had a history of cancer.1 
Such figures and statistics project that about 1,638,910 new diagnoses and 577,190 
deaths (or 1,500 people per day) will occur in 2012 alone. These numbers make 
malignant neoplasms the second leading cause of death in the United States by only a 
small margin.3
The costs associated with this disease from a health and economical standpoint 
are enormous. From the patient’s perspective, the implications of being diagnosed with 
cancer can be life threatening and quality-of-life reducing. In best-case scenarios where 
the prognosis is good, watchful waiting can add significant anxiety to the patient’s life.4 
In worst-case scenarios, severe side effects to both the disease and therapy are expected 
in addition to dramatically reduced life expectancy. As a result, there is a very high 
prevalence (0-58%) of major depression in cancer patients which can impact both mood, 
lifestyle and overall outcome.5
The financial costs associated with this disease are similarly harmful to both the 
individual and economy as a whole. In 2007, it is estimated that the combined direct and
indirect costs of cancer were $226.8 billion. In terms of direct medical expenditures (i.e. 
not including loss of productivity), the costs of cancer have doubled in the last 20 years.6 
This trend, however, is directly proportional to the number of new cases over the same 
period of time indicating that the cost per treatment is not likely the dominant contributor 
to this increase. In fact, there has been a slight decrease in the average medical 
expenditures per patient over time due to improved treatment technologies and a trend
n
towards increased outpatient procedures. While these figures are partially positive, as 
the prevalence of cancer continues to increase at the current rate, so will the financial 
burden on the United States’ healthcare system.
To best mitigate some of these personal and financial costs, clearly the best 
approach is prevention. This is often difficult, however, as genetic and environmental 
factors are the primary causes of cancer. Lifestyle choices such as maintaining a healthy 
diet, participating in daily exercise and abstaining from smoking and drinking are 
positively correlated with decreased risk. Given this and considering that the incidence 
of cancer continues to increase, an epidemiological survey of cancer types provides 
information where efforts may have the greatest impact. In 2012, it is estimated that 
cancer of the prostate, breast and lung will have the three highest numbers of new cases; 
241,740, 229,060 and 226,160 respectively. For this reason, significant attention and 
resources are provided to these three cancer types.
In this chapter, the topic of prostate cancer treatment will be discussed. An 
overview of prostate cancer such as disease development and progression will be 
followed by current treatment strategies including surgery, radiation, hormone and 
chemotherapy. In the context of improving drug delivery to prostate tumors, the field of
15
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polymer therapeutics will be introduced including advantages, limitations and methods 
for improving delivery. Finally, PPTT will be described and how this technique might be 
able to improve the delivery of polymer therapeutics to prostate tumors.
2.2 Prostate Cancer
The human prostate, a walnut sized gland surrounding the urethra just below the 
urinary bladder, functions to secrete seminal fluid during male ejaculation. The pH of 
this secretion is regulated to be slightly alkaline to prolong sperm survival in the acidic 
environment within the vaginal tract. As men age, the risk of developing prostate cancer 
increases. Very few (<0.1%) men under the age of 50 develop neoplasms in the
o
prostate. However, after about 60-65 years of life, the risk of developing abnormal 
tissue growth in the prostate rises exponentially. In fact, some autopsy studies suggest 
that most men over 85 years of age are likely to have some histological evidence of 
prostate cancer.9
2.2.1 Disease development and progression 
The causes of prostate cancer are mostly unknown. There appears to be a genetic 
basis behind this disease as mutations in several genes such as ribonuclease L (2',5'- 
oligoisoadenylate synthetase-dependent) (RNASEL) have been linked with familial 
prostate cancer.10 Additionally, there is also a large difference in the incidence of 
prostate cancer between men of different races and cultures. While Asian men in China 
have the lowest incidence in the world (1.9 per 100,000 per year), African-American men 
in the United States are at the greatest risk for developing prostate cancer (137 per
o
100,000 per year). The etiology of this disparity is likely to be a combination of genetic 
predisposition and differences in lifestyle associated with each culture.11 For example, 
variants on chromosome 8q24 are strongly associated with increasing prostate cancer
risk, a variant which is found more often in African-American men than those with
12European ancestry. Also, the high-fat diet of men from Western societies is described 
as a potential risk factor which is in contrast to Asian men who typically consume less fat 
and more soy.11
Given the high incidence of prostate cancer in men over 60, regular screening has 
become commonplace. By far the most common screening method has been by detection 
of prostate-specific antigen (PSA) levels in blood. PSA is a serine protease found mostly 
in seminal fluid. During conditions of abnormal tissue growth in the prostate, PSA may 
be released into the blood. Such characteristic increase in blood level concentration can
13therefore be used as an indicator of prostate tumor development. Men with PSA levels 
less than 4 ng/ml are generally considered at low risk with no further action required. As 
the PSA level reaches or rises above this threshold level, prostate biopsies may be
13recommended to confirm the presence or absence of neoplastic tissue. While this 
screening tool is highly regarded, controversy surrounding its overuse and resulting high 
rates of unnecessary biopsies and treatments has led many to question its role in regular 
medical exams.
A positive prostate cancer diagnosis after biopsy is typically graded based on the 
pervasiveness of the disease and staged accordingly. Patients whose tumors are locally 
confined to the prostate, have a Gleason score less than 6 and maintain a PSA level of 10 
ng/ml or less are generally considered low risk and have a 5-year survival rate of nearly
17
2 11100%. , Detection of cells in regional lymph nodes increases the overall risk, however 
the 5-year survival rate remains near 100%. Unfortunately, when cells have metastasized 
to distant organs such as the bone, have a Gleason score of 8 or more and a PSA level 
greater than 20 ng/ml, the prognosis drops dramatically. Patients in this category face a
5-year survival rate of 29% and make up the large majority of those who ultimately die of
2 11this disease. ,
2.2.2 Treatment
The treatment strategy for prostate cancer depends on the stage of the disease and 
the patient’s life expectancy. In many cases where the PSA level is <10 ng/ml and the 
disease is locally confined, watchful waiting may be sufficient.14-15 In such cases, the 
physician takes into account the patient’s age as well as the risks associated with 
treatment. For example, if an 85-year old patient is presented with low grade prostate 
cancer where the 15-year survival rate is high, it may not be necessary to receive 
treatment as it is unlikely that this patient will ultimately die of this disease. On the other 
hand, if the patient is 50 years of age and has a 20-year life expectancy, more aggressive 
action may outweigh the risks of therapy.16
2.2.2.1 Radical prostatectomy
When the tumors are confined to the prostate gland itself, the most common 
treatment option is to remove the entire prostate. First performed in 1904 at John
17Hopkins Hospital, a radical prostatectomy can be performed through either open 
surgery or laparoscopically. In both cases, three major concerns exist besides the usual
18
risks of surgery. First, the bundle of nerves which are responsible for erections are
located on either side of the prostate. This proximity may then result in erectile
18dysfunction (~14% of patients ) if the nerves are damaged during surgery. Second,
because the prostate gland is located just below the bladder and completely encircles the
18urethra, urinary incontinence is also possible (~7% of patients ). Finally, in locally 
advanced cases where some of the tumor mass is extracapsular, the boundaries of tumor 
mass invasion can complicate surgery as total resection may be difficult. Despite these 
complications, in general such procedures for local disease are considered curative with a 
strong history of success independent of procedure type.19
2.2.2.2 Radiotherapy
When the site of disease extends beyond the gland itself but remains localized to 
the surrounding tissue, the benefits of surgery may be limited. In such cases of locally 
advanced prostate cancer, the principle method for treatment is radiotherapy. The
delivery of therapeutic radiation to the prostate can be by external beam radiotherapy or
20brachytherapy. Both of these are considered to be curative treatments with equal
21efficacy and are often used in combination with hormonal therapy.21 In the case of 
external beam radiotherapy, a typical treatment includes an initial dose of 45-50 Gy of
the whole pelvis followed by dose escalation to about 78 Gy in a focused area around the
20prostate gland. Above this 78 Gy dose, undesirable side effects of therapy such as
22incontinence or rectal bleeding are likely. When brachytherapy is preferred, 60-120 
metal seeds which contain Iodine-125 or Palladium-103 are strategically inserted within
19
20the prostate. In this way, a continuous low-dose of radiation is emitted near the 
cancerous tissue.
Following treatment with surgery or radiotherapy, the PSA level of the patient is 
monitored to evaluate treatment efficacy and detect tumor recurrence. If treatment was 
successful, then the PSA level should recede to a normal level with minimal rise over 
time. However, if a rise in PSA concentration is detected after therapy, then it is likely 
that the disease remains intact. In cases where it is believed that the disease remains 
local, second-line therapy using either of the approaches described above is possible. On 
the other hand, if the PSA concentration rises rapidly after treatment, a sign of
23metastases, then more aggressive action is required with palliative intentions.
2.2.2.3 Androgen-ablation therapy
In 1941, Charles Huggins found that either castration or oestrogen therapy
24resulted in atrophy of the prostate gland as well as prostate cancer remission. Since 
this initial discovery, it is now understood that conversion of testosterone to 
dihydrotestosterone (DHT) and subsequent binding to the androgen receptor regulates 
cell growth and survival of prostate and prostate cancer cells.25-26 Such cell cycle 
dependence on circulatory androgens is therefore leveraged in the treatment of metastatic 
prostate cancer.
To deprive the prostate of androgens, several treatments can be employed either 
separately or in combination. These include surgical resection of the testes, 
administration of oestrogens, as well as inhibition of the pituitary gland using luteinizing 
hormone (LH)-releasing hormone (LHRH) receptor agonists. Each of these therapies
20
ultimately depletes the blood concentration of androgens and curtails the growth of
27prostate tumors.
Androgen-ablation therapy in patients with bone metastases works very well to
28alleviate painful symptoms for an average of 14-20 months. During this time, however,
adverse effects due to endocrine manipulation are expected. These include hot flashes,
28bone loss and fractures, loss of sexual function, and weight gain. After this period of 
time, an insensitivity to androgen depletion typically develops as androgen-independent
27prostate cancer cells are selected for survival. For this reason, hormonal therapy is not 
considered a curative line of therapy.
2.2.2.4 Chemotherapy
The most dangerous and deadly form of prostate cancer is hormone refractory, 
metastatic prostate cancer.11 In these cases, the last line of defense to relieve pain and 
extend life is cytotoxic chemotherapy. In general, the response of prostate cancer to most
29chemotherapeutic agents is disappointing. In the 1980s, a number of drugs were tested 
in Phase II studies where a partial or complete response to therapy was observed in only
305% of patients. This dampened enthusiasm, however, was reversed when new studies 
indicated that prostate cancer cells are particularly sensitive to mitotic spindle inhibitors
31 32such as paclitaxel and docetaxel. - These findings led to two major clinical trials
33 34investigating their utility against hormone-refractory prostate cancer. - Results from 
these studies indicate that treatment with Docetaxel can increase median survival by 18.9 
months with significantly reduced pain in 35% of patients. Since then, palliative
21
treatment o f hormone refractory, metastatic prostate cancer with chemotherapy has
35 37become the standard-of-care. -
2.2.2.5 Hyperthermia
A less common form of prostate cancer therapy, but one which is relevant to the 
present review, is treating tumors with hyperthermia. The treatment of neoplastic tissue 
with heat alone is tumoricidal for which there are several known reasons. The treatment 
of cells with heat results in cytotoxicity as a function of thermal dose (i.e. temperature
38and time). While there are several reasons for this, the main belief is that heat induces 
protein denaturation and irreversible aggregation. Under conditions of mild hyperthermia 
(<41°C), cells are thermotolerant due to HSP expression which prevents or refolds
39denatured proteins. As temperature and time is increased, the cells are not able to 
respond to the heat stress effectively and the cells undergo programmed cell death.40 
Such effects are more cytotoxic when the cell is undergoing mitosis thus making cancer 
cells more thermosensitive.38, 41
The other and more significant reason why tumors are sensitive to hyperthermia 
relates to its poorly formed vasculature and blood flow. Relative to healthy tissue, tumor 
vasculature is heterogeneous in architecture, largely devoid of smooth muscle and highly
42fenestrated. This has several consequences on the tumor microenvironment. First, 
because the microvascular density is highly variable, blood perfusion is sluggish and not 
uniformly distributed resulting in regions with high interstitial hypertension, hypoxia and 
acidosis.43 Second, tumor vasculature is hyperpermeable and therefore the transport of 
fluid as well as large and small molecules is unregulated.44 Lastly, the lack of a
22
significant basement membrane and smooth muscle layer in much of the tumor 
microvasculature limits the capacity of this tissue to respond to stress.
The natural response of healthy tissues to heat stress is to vasodilate, increase 
blood flow and ultimately dissipate the heat through greater tissue perfusion.45 Such 
activity is viable over a broad spectrum of temperatures (typically up to 50°C) and is 
therefore resistant to heat induced stress. In tumors, however, the above differences in 
the tumor microenvironment become problematic at elevated temperatures. Insufficient 
blood flow and perfusion, particularly in the hypoxic regions of the tumor, do not allow 
residual heat to be dissipated efficiently.46-47 As temperatures within the tumor rise above 
43°C, the weak microvasculature is unable to withstand the added stress and damage
48results followed by blood flow stasis. The added heat and lack of tissue oxygenation 
then causes a dramatic decrease in intratumor pH resulting in ischemia and cell death.49-50
Despite these apparent advantages of treating tumors with hyperthermia, practice 
in the clinic particularly in patients with prostate cancer has been slow. The primary 
reason for this has been due to difficulties in delivering therapeutic doses of heat only to 
the cancerous tissue.51 Current strategies such as interstitial or regional hyperthermia 
using micro- or radiowave emitters as well as whole body hyperthermia have been met
52with some degree of success, though direct control of tissue heating is limiting. For this 
reason, most have used clinical hyperthermia as an adjuvant therapy with either chemo- 
or radiotherapy.
23
2.2.2.6 Adjuvant hyperthermia and chemo- or radiotherapy
In the 1970s and 80s, it became apparent to the clinical community that 
hyperthermia alone was unlikely to be a standalone form of therapy for reasons 
mentioned above. Also around this time, however, it was discovered that hyperthermia 
significantly sensitizes cells and tissue to both chemo and radiotherapy.51 These findings 
reenergized enthusiasm for hyperthermia and a number of studies and clinical trials 
sought to determine the mechanism of synergism and its overall utility in the clinical 
setting.
Exposure of cancer cells to elevated temperatures was found in some cases to 
sensitize them to chemotherapeutic drugs.53-54 This effect was drug and temperature 
dependent. While hyperthermia is able to potentiate the activity of platinum-containing 
anticancer drugs at low temperatures55 as well as doxorubicin at higher temperatures,56-59 
other drugs such as docetaxel have only an additive or independent effect.60-61 
Experiments which attempt to elucidate the underlying mechanism for this thermal 
enhancement, typically expressed as a thermal enhancement ratio (TER), suggest that 
heat facilitates membrane transport resulting in higher cytoplasmic drug loading.56, 58
In clinical trials, adjuvant hyperthermia with chemotherapy has had mixed results 
but are mostly encouraging. For example, in cases where the patient has peritoneal 
surface malignancies such as with ovarian or cervical cancer, the use of hyperthermic 
intraperitoneal chemotherapy with cisplatin is shown to improve overall outcome.62-64 In 
the case for prostate cancer, there are very few reports suggesting that this technique is 
valuable most likely due to the insensitivity of drugs like docetaxel to hyperthermia.65
24
25
Combining hyperthermia with radiotherapy is also synergistic and has been 
shown to provide greater benefit in patients than hyperthermia plus chemotherapy.51 The 
underlying mechanisms which provide this synergism are somewhat controversial, 
though several hypotheses are supported by experimental findings. At the cellular level, 
it is believed that heat inhibits the cells’ ability to repair radiation-induced DNA 
damage.66 This process is heavily dependent on treatment sequence and timing as well as 
temperature such that maximum efficacy is achieved when heat (>43°C) and radiation 
exposure are applied concurrently.67 At the whole tissue level, changes in blood 
perfusion during heating are believed to be responsible for radiosensitization. In general, 
cancer cells are less sensitive to radiation in hypoxic environments. During mild 
hyperthermia (<43°C), increased blood perfusion and therefore reoxygenation of the 
hypoxic tumor environment decreases the survival rate of cells during exposure.67
Clinical trials which study the potential of adjuvant hyperthermia and 
radiotherapy to treat locally advanced prostate tumors are also mixed.68-71 Each of these 
trials show some benefit of combining heat with radiation, however patient survival and 
overall outcome were typically no different than those treated with radiation alone.
2.2.3 Treatment limitations and the need for targeted therapies 
It was mentioned earlier that when prostate cancer is localized, it is probable that 
the disease can be treated with curative intentions. In many of these cases, however, 
watchful waiting is chosen because the risks may outweigh the benefits of therapy despite 
the high cure rate. When the disease has metastasized beyond the prostate and invaded 
other organs such as the bone, more aggressive therapy is required. These therapies are
however quite harmful and are thus limited by non-specific toxicities. This highlights a 
significant need for improvement.
The concept of developing therapies which are targeted to specific cells while 
leaving the healthy ones intact is credited to Paul Ehrlich who postulated “we have to
72learn how to aim chemically.” Indeed, when the goal is to impose a pharmacologic or 
physical effect on diseased tissue, any collateral damage to healthy tissue can have 
devastating consequences. Ehrlich’s concept of the magic bullet ultimately led to the 
development of today’s chemotherapeutic strategies which have some pharmacologic 
bias towards cancerous cells, though uptake in non-intended cells remains still the 
greatest challenge.
With advances in polymer chemistry and antibody based therapies in the 1970s, 
macromolecular based targeted therapies were born. In systems like those conceptualized
73by Helmut Ringsdorf,73 large carriers can be used to target sites of disease and deliver 
therapeutic payloads. Such targeted therapies are an important component of a field now 
coined “nanomedicine,” and represent a significant improvement in cancer therapies
74which limit side effects while maximizing treatment efficacy. Indeed, such targeted 
therapies have attracted widespread attention in oncology and are likely to provide
75substantial benefits in future prostate cancer therapies.
2.3 Polymer Therapeutics
The use of polymers in medicine has been evolving since their introduction during 
World War II. Polymers can be tailor made with numerous properties depending on the 
monomers used, their stoichiometic ratios, the molecular weight, as well as the degree of
26
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crosslinking among many other design parameters. Also, recent advances in synthetic 
techniques such as with living free radical polymerization allow these polymers to be 
synthesized with a high degree of control. In this way, polymers can be designed to be 
biocompatible, biodegradable, stimuli responsive, functionalizable and bioactive.76
One of the greatest uses of polymers as biomaterials lies in their capability to be 
designed for controlled delivery of bioactive agents. In most cases where drugs or 
proteins are used to impose therapeutic action, it is advantageous to control its local or 
systemic concentration within the therapeutic index as a function of time. For example, a 
bolus dose of free drug may only temporarily bring the drug’s concentration within a 
therapeutic range prior to rapid redistribution and elimination. As most drugs are more 
effective when this concentration is maintained over longer periods of time, many 
biomedical devices and therapeutics leverage the tailorability of polymers to control 
chemical delivery. Examples of such systems include drug-eluting stents, hydrogels and 
transdermal patches.
In the context of developing controlled delivery systems for systemic disease,
77water-soluble polymers have proven very useful. The incorporation of drugs or 
therapeutic macromolecules within polymeric drug carriers provides several distinct 
advantages. First, for drugs which are poorly miscible in blood plasma, the highly water- 
soluble backbone of the polymers provide enough hydrophilicity to dissolve the drugs
78 79without the need of other excipients. - This characteristic is of particular importance
considering the large number of new drugs which exhibit poor absorption, distribution,
80metabolism, and excretion (ADME) due to poor aqueous solubility. Second, by 
incorporating drugs within carriers, it is possible to substantially alter their
81pharmacokinetics to provide longer plasma retention. Third, the macromolecular size
of these conjugates allow them to preferentially accumulate in neoplastic tissue due to the
82leaky nature of its vascular. Fourth, the wide diversity of available linker chemistries
83enables one to control both the drug release mechanism and rate. Fifth, as many drugs 
and therapeutic proteins are easily degraded by plasma components such as enzymes, the 
polymers are able to provide some protection. Finally, the multifunctional nature of 
many of the polymeric systems allow for the incorporation of other moieties such as
84 85targeting groups or imaging agents for targeting and theranostic applications. -
2.3.1 Polymer therapeutic types 
The wide diversity of available polymer chemistries, architectures and linkers 
provide a rich environment for investigational research in the development of new 
polymer therapeutics. Some of these designs are currently being used in the clinic, and 
many more are in clinical trials.86 While these parameters offer a large number of 
possible polymer therapeutic designs, the majority fall into four basic categories: 
polymer-protein conjugates, polymer-DNA complexes, polymeric micelles and polymer-
87drug conjugates.
2.3.1.1 Polymer-protein conjugates
88Since the early 1980’s, the biotechnology industry has grown substantially. 
Starting with the development of recombinant insulin, many large pharmaceutical and 
small biotech companies have been developing a wide range of therapeutic proteins and 
peptides with striking clinical impact. While many hurdles such as cost of production are
28
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prohibitive, more often it is their poor plasma solubility, stability, immunogenicity and
89half-life which compromise their therapeutic potential. One approach many companies 
and drug delivery scientists have taken to improve their biocompatibility is to link them 
to water-soluble polymers such as PEG.90 Conjugation of PEG in this way can help mask 
the protein’s surface to reduce immune detection and degradation.91 Addition of PEG 
can also increase the solubility o f the protein, provide charge shielding as well as increase 
its molecular weight which ultimately improves its pharmacokinetics and
92biodistribution.
Because of these apparent benefits, the process of protein PEGylation has become 
an industry standard. PEG is most often the polymer of choice here due to high water- 
solubility and flexibility, low immunogenicity and toxicity, and the number of available 
conjugation chemistries.90 It is also a Food and Drug Administration (FDA) approved 
material which helps companies obtain fast approval for their therapeutics relative to 
similar polymers which are not yet found in the clinic. This has led to a wide variety of 
PEGylated proteins which are currently being used in the clinic such as PEG-L- 
asparaginase (Oncaspar®), PEG-interferon-a (PEG-Intron®) and PEG-granulocyte 
colony-stimulating factor (Neulasta®).87 While such PEGylation is most commonly used, 
other polymers such as styrene maleic anhydride (SMA),93 hydroxyethyl starch (HES),94 
and dextrin,95 are also used.
2.3.1.2 Polymer-DNA complexes
The field of gene delivery has likewise been met with many opportunities as well 
as challenges. Many diseases such as muscular dystrophy and cystic fibrosis are caused
30
by defective genes which may be effectively treated by gene replacement. Unfortunately, 
gene replacement or supplementation is difficult due to biological barriers for gene 
delivery.96 Currently, the two main methods for delivering genes are by using either
97recombinant viruses or synthetic vectors such as polymer-DNA complexes. Both 
mechanisms of delivery have weaknesses, however significant concerns over the 
immunogenicity of viral vectors have caused many to focus on polymeric systems called 
polyplexes.
Polyplexes are typically formed by complexing negatively charged DNA with 
cationic polymers. When such systems form, large DNA coils which are typically 
several hundred nanometers in hydrodynamic diameter are condensed into toroidal or
98spherical particles which are significantly smaller in size (tens of nanometers). Of 
particular importance in the formation of these polyplexes is the ratio of +/- charges as 
this determines the final size and shape of the particle as well as the residual charge. For 
example, while complete neutralization of charges is advantageous in terms of particle 
pharmacokinetics, colloidal instability often necessitates some residual charge.99 Control 
over these features mostly arrives from the choice of cationic polymers and from their 
size, architecture and composition. Linear copolymers of PEG-poly(L-lysine)100 and
PEG-poly(ethyleneimine) (PEI)101 with amino terminated pendant groups as well as
102branched polymers of PEI and poly(amidoamine) (PAMAM) dendrimers are among 
the most commonly used polymers in this regard. Use of these polymers also serves a 
similar function as was described for polymer-protein conjugates. They are able to 
protect the DNA from nuclease degradation and immune detection as well as improve 
overall pharmacokinetics and diseased tissue specificity through targeting. Despite
31
significant progress in gene delivery using nonviral vectors, the barriers for gene delivery 
have limited this class of polymer therapeutics and none have obtained clinical success to 
date.103
2.3.1.3 Polymeric micelles
Another class of polymer therapeutics takes advantage of the poor aqueous 
solubility of most drugs by incorporating them within the hydrophobic domains of 
polymeric micelles. Polymeric micelles form by the self-assembly of amphiphilic 
polymers into colloidal dispersion.104 Therefore, by sequestering hydrophobic drugs 
within the core of micelles which are protected by a highly hydrated corona, these drugs 
can be easily transported in the blood and specifically delivered to the site of interest 
upon micelle disassembly. The formation of micelles from amphiphilic compounds are a 
common occurrence due to the minimization of free energy when the monomeric 
amphiphiles reach a certain concentration.105 This critical micelle concentration (CMC) 
varies greatly depending on the nature of the surfactant and the temperature of the 
solution. The process of micelle self-assembly can result in a wide variety of shapes and 
sizes, though most micelles used for drug delivery are spherical and 10-80 nm in size.
The composition of the polymers which form into micelles for drug delivery 
varies. Polymers can be polymerized to form homopolymers, or copolymerized as 
random, block or graft copolymers. While homopolymers are unable to form into 
micelles, copolymerization with hydrophilic and hydrophobic monomeric units can result 
in the formation of micelles, particularly as di- or tri-block copolymers. The choice of 
hydrophilic and hydrophobic monomers is also important. Given the biocompatibility
and hydrophilicity of PEG, most micelles have PEG based coronas.106-107 Though other 
hydrophilic polymers such as poly(N-isopropylacrylamide) (PNIPAAm)108-109 and 
poly(#-vinyl-2-pyrrolidone) (PVP)110 are also used. The choice in the composition of the 
hydrophobic cores is more variable. Many use poly(lactic-co-glycolic acid) (PLGA) due 
to its known biodegradability.106, 111 Others incorporate poly(styrene),112 poly(propylene 
oxide) (PPO),113 and poly(caprolactone)114 blocks due to their hydrophobic character. 
Taken together, the combination of these hydrophilic and hydrophobic blocks allow for 
the formation of highly stable and tailorable micelles for drug delivery. A common 
example of such systems is Pluronic® micelles made from PEG-PPO-PEG tri-block 
copolymers.115
Using these miceller drug delivery carriers, it is possible to achieve drug loading 
efficiencies between 5 and 25% wt.116 Because these otherwise poorly soluble drugs are 
able to be retained in the plasma for extended periods of time, many of these micelle
117systems are being evaluated in clinical studies. Examples include NK105, a PEG-
118poly(aspartate) micelle loaded with paclitaxel, NC-6004 which is a PEG-poly(glutamic 
acid) micelle with cisplatin,119 NK012 which is a PEG-poly(glutamate) micelle with a 
SN-38 payload,120 and SP1049C Pluronic®-doxorubicin micelle.121 In the future, it will 
be exciting to see the outcome of these clinical trials and the emergence of newer 
formulations.
2.3.1.4 Polymer-drug conjugates
While polymeric micelles carry drugs by noncovalently sequestering them within 
their hydrophobic cores, polymer-drug conjugates act by covalently linking the drugs to
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87 122 123the polymer backbone. , - Conjugation of drugs to polymers offer the same 
advantages as the other polymer therapeutics, i.e.: increased drug solubility, prolonged 
plasma retention, improved biodistribution, protection from immune detection and 
degradation, macromolecular size and added multifunctionality. Unlike the other 
systems, however, by tailoring the linker chemistry it is possible to provide a high degree 
of control over drug release mechanism and rate with improved overall stability. The 
linking of drugs to the polymer via a pH sensitive or hydrolysable bond is one such 
example, though these methods for drug release often lack the necessary sensitivity 
towards release in the tumor compartment, or suffer from poor stability and premature 
drug release.124-126 Kopecek and coworkers have investigated a number of linker
127 134chemistries which are susceptible to enzymatic degradation in the lysosome. - The 
end result was the identification of the oligopeptide sequence Gly-Phe-Leu-Gly (GFLG) 
which degrades in the presence of cathepsin B in the lysosome, a tetrapeptide now used
83 133in most HPMA copolymer-drug conjugates. , Much work remains, however, to 
optimize linker chemistries for sufficient drug release in tumors.
In the scope of polymer-drug conjugates, many designs exist. The most 
fundamental of these, like in other polymer therapeutics, relates to the choice in polymer 
backbone. Most are water-soluble and offer a range of conjugation chemistries. Below is 
a brief description of the most commonly used polymers.
Similar to PEG-protein conjugates, PEG-drug conjugates offer high water- 
solubility, flexibility, low immunogenicity and toxicity and can be produced with low 
polydispersities. PEG is also available with many different functional groups at its
135terminal ends, and so conjugation to drugs is straightforward using click chemistry.
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Unfortunately, because only two drug molecules can be attached per linear polymer 
chain, low drug loading (1.7 wt%) reduces the efficacy of these systems as exemplified 
by the fact that only one PEG-drug conjugate has been evaluated in clinical trials (PEG-
camptothecin).136
PGA potentially represents one of the most clinically relevant polymers for use as
137a polymer therapeutic, mainly due to its biodegradability. Formed by the 
polymerization of glutamic acid monomers, enzymatic degradation of its amide bonds 
results in the formation of degradation products which are non-toxic. Drugs can be 
conjugated to its backbone by taking advantage of the y-carboxylic acid side chains and 
released by enzymatic degradation. A major advantage of these systems relative to the 
non-degradable synthetic polymers such as PEG is that their molecular weight can be
138kept high so that they are not excreted through the kidneys. This significantly 
lengthens their plasma pharmacokinetics and thus the opportunity for accumulation in 
cancerous tissue. A major disadvantage though is the high density of negative charges on 
these polymers as each pendant group contains a carboxylic acid which can initiate rapid 
reticuloendothelial system (RES) uptake. Several PGA-drug conjugates are currently 
being evaluated in clinical trials,139-141 though the most promising of these (PGA- 
paclitaxel or CT-2103) has recently shown disappointing results in phase III clinical 
trials.142-143
Dextrin and HES are two other biodegradable polymers for use as polymer-drug 
conjugates. Both are naturally derived, generate nontoxic degradation products and are 
approved for use in humans. Dextrin is derived from corn starch and can be fractionated 
to obtain large or small molecular weight linear polymers. Subsequent succinylation
provides sites for drug conjugation and therefore can be used as a long circulating drug 
carrier.144 HES is derived from waxy maize starch and has a highly branched like 
structure and is currently used as a plasma expander due to its high molecular weight and 
hydrophilicity.94 Drug or protein conjugation can be obtained by modification with 
hexamethylene diamine or N-carbobenzyloxy glutaminyl glycine.145 Though native 
dextrin and HES are degradable, attachment of drugs or proteins may reduce their rate of 
degradation and therefore concerns over long-term toxicity with repeated infusions raise 
similar issues as with synthetic, nondegradable polymers.146
While most of the synthetic polymers used in drug delivery have a linear 
structure, PAMAM dendrimers are unique due to their highly branched architecture. 
Starting with an ethylenediamine core, stepwise addition of methyl acrylate, then
147 148ethylenediamine increases the size and generation with each step. - For example, 
Michael addition of methyl acrylate to ethylenediamine results in a 0.5 generation or 
G0.5 PAMAM dendrimer which has four branches with methyl ester terminating 
functional groups.149 Subsequent amidation of the esters creates the first full generation 
dendrimer, G1.0. With this method, full and half generation PAMAM dendrimers can be 
created up to G10.0 after which point charge shielding and steric hindrance prevent 
further generations from being easily synthesized. The resulting dendrimers typically 
have very low polydisersities (1.0005-1.10), and have very high charge densities on their 
surface.148
The large number of available functional groups provides many sites for drug 
attachment. Early examples of this concept by Duncan and colleagues showed the 
conjugation of cisplatin where high drug loading (20-25 wt%) and tumor accumulation
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was observed.150 Since then, many more combinations of dendrimers and anticancer 
drugs have been applied including G4.0-doxorubicin,151 G4.0-camptothecin,152 G3.5- 
SN38,153-154 and G5.0-methotrexate.155 One of the advantages of these conjugates relates 
to the dendrimer’s ability to cross biological barriers such as the intestinal epithelia.154, 
156-163 Though studies which show significant dendrimer toxicity due to their high 
surface charge, particularly full generation amino terminated dendrimers, provide some 
cautionary examples of their use.164-166
Of all the polymers which have been investigated for use as polymer-drug 
conjugates, HPMA copolymers are probably the most studied in detail.167 Led by the 
pioneering work of Kopecek and colleagues,168 followed by collaboration with Duncan, 
HPMA copolymers have proven to be a versatile platform for the development of 
anticancer polymer therapeutics. The reason for this relates to their known 
biocompatibility, ease of synthesis and available multifunctionality.169 The HPMA 
monomer provides these copolymers with high water-solubility, and copolymerization 
with side chains containing drugs, targeting moieties and imaging agents makes these 
conjugates multifunctional.
Given their utility as drug carriers, many HPMA copolymer-drug conjugates have
170been tested in clinical trials. The first of these polymer-drug conjugate was PK1, a
171HPMA copolymer-doxorubicin conjugate. This landmark study provided initial 
excitement with these conjugates as polymer conjugation enabled patients to be dosed 
with four- to five-fold more doxorubicin compared to free drug. Unfortunately, poor 
phase II outcomes where only six of 62 patients showed signs of partial response
172dampened this enthusiasm. Similarly, when a new conjugate (PK2) which contained
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galactosamine for active tumor targeting was tested, few patients benefited from this
173 174therapeutic. - Since these initial results using HPMA copolymers in the clinical 
setting, more conjugates have entered clinical trials such as HPMA copolymer-
126 175 177 178 179paclitaxel, -camptothecin, - and -platinates. - Excluding HPMA-camptothecin 
which had problems with nonspecific drug release, each of these conjugates have also 
shown only partial response in patients.
2.3.2 Limitations of polymer therapeutics 
As discussed above, polymer therapeutics provide clear advantageous to treat 
disease over small molecular weight drugs. They are water-soluble, have prolonged 
plasma half-life, can distribute to diseased tissue with higher specificity, may overcome 
multidrug resistance, and reduce overall toxicity such that higher maximum tolerated 
doses (MTDs) can be achieved. Despite these indications for improved treatment 
performance, the number of available polymer therapeutics in the market remains limited. 
The reasons for this have to do with problems with the therapeutics’ overall design as 
well as the biological barriers that prevent them from reaching the target. Such 
challenges include carrier toxicity, insufficient release rate, instability, uptake by RES, 
limited therapeutic scalability and characterization, as well as suboptimal delivery and 
tissue mass penetration. Detailed discussion of each of these is beyond the scope of this 
Chapter, though for more information the reader is encouraged to read a comprehensive 
review elsewhere.86
Of the limitations which were just listed, possibly the most influential barrier to 
success is limited tumor delivery and penetration. A common method for displaying
tumor accumulation data is by calculating the percent injected dose per gram of tissue 
(%ID/g). Using these units, a nanomedicine is considered to have high tumor 
localization when above 10 %ID/g. If you consider, however, that most tumors used in 
preclinical studies are on average 50 mg by weight, then the total dose delivered to the 
tumor is only 0.5 %ID. Translating this idealized scenario in mice bearing subcutaneous
tumors to humans, where the average cost o f treatment using an approved polymer
180 181therapeutic is about $30,000 not including hospital costs, - then only about $150 
worth of therapeutic is actually imposing any therapeutic effect. The remaining $29,850 
is either urinated out or accumulates in organs o f the RES where toxicity occurs. This 
major imbalance coupled with severe side effects that patients have to endure highlights 
the need for improved methods for drug delivery.
2.4 Methods and Tools for Improved Delivery to Solid Tumors
For a particular drug or therapeutic protein within a nanocarrier to go from the
injection to the subcellular target (protein, nucleic acid, etc), it must successfully navigate
182multiple barriers. Upon injection, the therapeutic must become soluble in the blood
183plasma and be resistant to protein opsonization. If significant opsonization occurs and
forms a protein corona, phagocytic detection and RES clearance is probable. As most
drug delivery systems require prolonged blood circulation to be efficacious, the 
therapeutic must then avoid both RES and renal clearance for an extended period of time
(several hours to days). As the nanomedicine enters the tumor’s vasculature, it must then 
permeate through the vascular endothelium and enter the tumor interstitial space. In
order to have maximal effect, it must then be transported through the dense interstitial
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184 185space and reach cells which are distant from the tumor’s viable vasculature. - As 
macromolecules are unable to diffusively cross the cell’s plasma membrane, they must 
then bind to the cell’s surface and initiate endo- or phagocytic uptake. If bound via 
degradable linker, the drugs must then be cleaved from the polymeric carrier and escape 
the endosome. Finally, binding to the target protein, or transport through the nuclear 
envelope and subsequent binding to nucleic acids represents the last step before therapy 
can initiate. Given this daunting journey, it is perhaps not surprising then that much less 
than 1% of the injected dose actually has any effect.
Given this grand challenge, many strategies are employed by drug delivery 
scientists to improve outcome. In the following sections, some of these strategies are 
reviewed in the context of improving the delivery of nanomedicines to solid tumors.
2.4.1 Passive targeting and the EPR effect 
It has been known for a long time that the blood vessels which supply solid 
tumors are disorganized and have higher than average permeability to
186 187macromolecules. - In the 1970s, this increased permeability was leveraged to screen
188for tumors by scintigraphy using gallium-67 which has known affinity for transferrin. -
189 Then, in 1986 when Maeda and colleagues were studying the tumor delivery of 
SMANCS (SMA-neocarzinostatin), they observed that this hyperpermeability in 
combination with poor lymphatic drainage caused the micelles to accumulate and be
93retained in tumors. Recognizing the contributions of hyperpermeability and poor 
drainage, they described their observation by coining the phrase ‘Enhanced Permeability 
and Retention’ (EPR) effect.190 Since this landmark paper,93 the EPR effect has been
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applied ubiquitously to describe the passive delivery of macromolecules and 
nanomedicines to solid tumors.
The underlying principles and translatability of EPR remain somewhat 
controversial, particularly considering that most studies are performed in rodents bearing 
fast growing, subcutaneous tumors. However, studies with these tumor models provide 
some insight. When one initially compares the vasculature of tumors versus healthy 
tissue, it is apparent that tumor vessels form with an abnormal and disorganized 
architecture.43, 191-192 The spatial distribution of blood vessels lacks order and continuity 
which ultimately generates a heterogeneous distribution of tissue which is poorly
193perfused. The structure of individual blood vessels is also poorly formed and lacks
smooth muscle. The endothelial cells have overlapping and branched morphologies with
82large intercellular and transcellular openings up to 4.7 |im in size. These large fenestrae 
then explain tumor blood vessel leakiness which allows macromolecules such as albumin 
to permeate.
The disorganized and tortuous nature of tumor vasculature coupled with 
macromolecular hyperpermeability and limited lymphatic drainage has a consequential 
impact on the tumor microenvironment.194 Poor plasma drainage and increased red blood 
cell accumulation causes a significant increase in the viscosity of the blood in tumors.195 
This increased viscosity provides resistance to flow and may be responsible for overall
42decreased blood flow in tumors. The higher concentration of albumin and other 
proteins in this tissue also causes hypertension which increases the tumor’s interstitial 
pressure.196-197 This too limits the degree of convective transport of small and large 
molecules into the tumor interstitial space. Finally, high cell and extracellular matrix
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(ECM) density provides more resistance to convective and diffusive transport of
198macromolecules. Taken together, these transport barriers reduce the availability of 
oxygen and other essential nutrients in tumors thereby creating large regions which are 
hypoxic and necrotic.199
In the context of delivering nanomedicines to solid tumors, these transport 
barriers become exaggerated due to their large size. The population of intercellular
openings in the tumor’s vasculature is highly heterogeneous in size, location and density.
82While some may exist as large as several microns in size, the majority are 1-2 |im. This 
size cutoff thereby excludes particles which are greater than roughly 1.5 |im from taking 
advantage of the EPR effect.200 Also, as much of the transport of molecules out of the 
tumor’s vasculature and through the interstitial space depends on diffusion, the size of the 
particle will dictate how far it can travel. As described by the Stokes-Einstein equation, 
larger particles will have less diffusive transport than smaller particles and therefore may 
not access cancerous cells which are distant from the vasculature. Also, given that the
density of the ECM in tumors is prohibitively high for effective diffusive transport over
201long distances,201 larger particles such as liposomes and inorganic colloids may lack
202 203overall effectiveness even though they are within the size range of EPR. -
Despite these barriers, the passive delivery of nanomedicines such as polymer 
therapeutics by EPR remains a viable approach. Many drug delivery systems from 
polymer therapeutics, to monoclonal antibodies to AuNPs rely on EPR to selectively 
accumulate in cancerous tissue.204 And while issues such as human translatability and 
pervasive distribution throughout the whole tumor mass raise significant concerns over
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the effectiveness of this approach, it is partially responsible for the 20 plus biologicals 
and nanomedicines available in the clinic.
2.4.2 Receptor-mediated active targeting 
Monoclonal antibody therapies have received significant attention in the last two 
decades and many are currently used in the clinic. When properly humanized and 
protected from the immune system, they are able to circulate for extended periods of time
205and bind with high specificity and affinity to their target receptors on cancer cells. In 
this way, antibodies can directly initiate cancer cell apoptosis upon binding, tag cancer 
cells for immune detection and elimination, or be used as carriers for drugs and 
radionuclides.206 Such systems therefore represent a series of emerging nanomedicine 
based technologies which utilize receptor-mediated active targeting to deliver 
therapeutics with high cellular specificity.
Inspired by Paul Ehrlich’s concept of targeted therapies, many drug delivery 
scientists aim to improve the delivery of their ‘magic bullets’ by conjugating a wide 
variety of biomolecules which have known specificity to cancer cell receptors. Popular 
examples of targeting approaches include antibodies against epidermal growth factor 
receptor (EGFR) such as anti-HER2,207-209 folate receptor targeting with folic acid,210-212
213216 217 221transferrin receptor targeting, - and angiogenesis targeting with RGD. - Each of 
these examples have proven selectivity towards cancerous tissue due to overexpression of 
the targeted receptors.
Many liposomal based systems have been functionalized with antibody or 
antibody fragments for this purpose.208, 222-224 In some cases, this approach has resulted
225in increased delivery of the targeted liposomes relative to control liposomes. In most
208 226examples, however, equal or less tumor accumulation is achieved. , Such results do 
not necessarily preclude these systems from being more valuable than the untargeted 
systems. Unless the targeting ligand is used to target the tumor’s vasculature, passive
227delivery by EPR is the necessary first and often delivery-limiting step. Then, as the
nanocarriers diffuse through the tumor interstitium, receptor-mediated targeting may
228facilitate cellular binding and uptake and therefore drug delivery.
Due to the known advantages of this approach, clinical translation of an actively
173targeted HPMA copolymer-doxorubicin conjugate was attempted. Galactosamine, a 
derivative o f galactose, has known affinity for asialoglycoprotein receptors which are
229overly expressed in liver and hepatocellular tissue. When linked to an HPMA
230copolymer containing doxorubicin, liver targeting was achieved in both rats and mice.230-
232 173 174These results led to pursuing this conjugate in a Phase I clinical trial. - Results 
from these studies showed that targeting to the liver was high (15-20 %ID), but that 
targeting to hepatic tumors was substantially lower (3.3 %ID). Additionally, relative to 
its untargeted PK1, targeting to the liver significantly lowered the MTD of this conjugate. 
Such accumulation in the healthy liver tissue is thus limiting and highlights the need for 
active targeting improvements.
Based on the number o f reports which provide conflicting support for active 
targeting, there are clearly a large number of challenges that may reduce the viability of 
this approach. From a formulation or colloidal dispersion standpoint, functionalization 
with antibodies, antibody fragments, peptides, etc may reduce the overall stability of the 
nanocarriers in water or plasma. Once in the blood, these ligands which are designed to
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be biorecognizable may then facilitate RES clearance and dramatically reduce blood 
circulation time. Then, as was the case for the HPMA copolymer-galactosamine 
conjugates, targeting to healthy cells which also express the targeted receptor may expose 
these cells to the drug and result in unwanted toxicity. Other examples of variables 
which may impact active targeting viability include ligand-receptor binding affinity, 
receptor expression heterogeneity within the same tumor or across patient populations 
and receptor saturation. Each of these barriers prevent the majority of active targeted 
nanomedicines from having real clinical benefit and a better understanding of these 
events is ultimately required.
2.4.3 Pharmacologic enhancement of delivery 
As mentioned in Section 2.4.1, there are several tumor microenvironment 
characteristics that resist diffusive and convective transport of drugs and nanomedicines. 
These characteristics are: 1) vascular heterogeneity, 2) high blood viscosity, 3) sluggish 
blood flow, 4) elevated interstitial pressure, 5) poor lymphatic drainage, and 6) dense
233interstitial matrix due to abnormally high cellular and ECM densities. Though most 
often discussed in the context of improving delivery, neither EPR, a natural phenomenon, 
nor receptor-mediated targeting act to alleviate any of these major delivery barriers. This 
may be because these barriers are a direct consequence of tumor physiology which 
cannot be easily resolved by changing the design of the therapeutic. Therefore, efforts 
which aim to improve delivery by decreasing the contribution of each of these barriers 
have focused on pharmacologic based interventions.
One method which Maeda, Jain and others have used to increase tumor blood 
flow and transmural pressure (ratio of arterial pressure to tumor interstitial pressure) 
between the vasculature and tumor interstitial space is to elevate overall blood
234 238pressure. - It was previously observed that raising the mean arterial blood pressure to
239150 mmHg using angiotensin II results in a marked increase in tumor blood flow. This 
effect was found to be selective to cancerous tissue. The mechanism behind this 
phenomenon is most likely related to the inability of tumor microvessels to respond to 
elevated blood pressure by autoregulatory contraction as well as increased transmural
234pressure which drives convective transport. To show then that this technique can be 
used to improve the delivery of macromolecules, Maeda and colleagues artificially raised 
the blood pressure in mice using angiotensin II followed by administration of
235SMANCS. Treatment in this way resulted in a 1.2-1.8-fold increase in overall tumor 
delivery while less accumulation occurred in the bone marrow and small intestine. 
Translating this concept into a clinical setting, patients with a variety of carcinomas were 
co-administered angiotensin II and SMANCS and evaluated for tumor delivery and 
overall outcome.236 Similar to their previous findings, hypertension was able to improve 
the delivery of SMANCS as well as overall response to the drug. This pharmacologic 
based technique is thus an interesting and clinically relevant approach for improving the 
delivery of nanomedicines.
Similar approaches using other vasoactive drugs to modulate tumor blood flow 
and permeability have been tried.240 Maeda and others have leveraged nitric oxide (NO) 
as a tool to vasodilate surrounding blood vessels to permit greater blood flow and
234 241therefore drug delivery. , Indeed, topical application of nitroglycerin on the tumor
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241resulted in 2 to 3-fold enhancement of polymer-drug conjugate delivery. Alternatively,
242when inhibitors of NO were tested, significant decreases in tumor blood flow occured. 
Interestingly, when vasoconstrictor drugs other than angiotensin II such as phenylephrine 
were tested for similar purposes, no changes or slight decreases in tumor blood flow were
243observed.
Vascular disrupting agents (VDAs), drugs or proteins which act on the already 
established tumor vasculature, have also been tested. For example, tumor necrosis factor- 
a (TNF-a), a major proinflammatory cytokine, acts strongly on vascular endothelial cells 
and increases vascular permeability by formation of large intercellular gaps.244 
Administration then of TNF-a is capable of enhancing EPR and the delivery of
245macromolecules. Because systemic administration of TNF-a produces significant 
toxicity, delivery by adsorption to AuNPs is being evaluated in a Phase II clinical trial.246 
Using this delivery scheme, AuNP-TNF-a conjugates were also able to improve
247macromolecular permeability.
Because of its known effect on macrophages to stimulate TNF-a production, 5,6- 
dimethylxanthenone-4-acetic acid (DMXAA) has also been tested for its capacity to 
increase tumor vascular permeability. Administration of DMXAA in mice with or
248without TNF receptor or gene knockdown was found to enhance EPR. Because 
enhanced permeability occurred in mice with or without TNF receptor or gene 
knockdown, these authors suggest that DMXAA can improve vascular permeability in a 
TNF-a independent manner. Though VDAs have shown to increase vascular 
permeability, they are also well known to reduce tumor blood flow,249 and an appropriate
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balance of dose may therefore be required to leverage the full potential of these drugs to 
improve macromolecular delivery.
Unlike VDAs whose target is already established vasculature, antiangiogenic 
drugs aim to prevent the formation of new tumor blood vessels. In the 1970’s, Judah 
Folkman postulated that tumor growth is dependent on continual angiogenesis and that
250inhibition of this process might stunt its growth. Since this landmark paper, a large 
number of groups have investigated the utility of this line of therapy, and many 
antiangiogenic therapies are used clinically. More recently, Rakesh Jain has described an 
alternative use of antiangiogenic therapy which at first seems counter intuitive.191 The 
inhibition of angiogenic stimulators such as vascular angiogenic growth factor (VEGF)
251initiates vascular remodeling. This remodeling process effectively prunes those 
vessels which are characteristically leaky and immature and thus limit blood flow. The 
result is a “normalization” of the tumor’s vasculature to a state which has improved blood 
flow and therefore tissue perfusion.43 The impact of this vessel normalization was 
observed when antiangiogenic therapy was combined with radiation therapy. Increased 
vascular function and therefore tumor oxygenation due to antiangiogenic normalization
252has been shown to synergistically improve radiation therapy. When anti-VEGF 
antibodies were used to decrease colon adenocarcinoma microvessel density, increased
253tumor perfusion and chemotherapeutic delivery was achieved. While increased blood 
flow and decreased intratumoral pressure occur after this process, it is likely that 
decreased vessel leakiness and therefore EPR will also result. To study this, Jain et. al. 
evaluated the passive delivery of differently sized nanoparticles after vascular 
normalization. Indeed, antiangiogenic treatment did reduce vascular pore size suggesting
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that smaller nanocarriers are required for efficient delivery after vascular 
normalization.254
Each of the previously described methods for enhancing drug delivery 
pharmacologically has used drugs which act on the tumor’s vasculature to improve blood 
flow and/or vascular permeability. This is because drug delivery is primarily 
vascularization limited. However, improving local blood flow and permeability may not 
necessarily improve overall outcome because the dense tumor interstitium limits the
185diffusivity of small and large molecules. High cellular and ECM density coupled with 
high interstitial fluid pressure (IFP) resists transport in a size dependent manner. One 
method then to improve overall delivery is to reduce interstitial density and IFP. For 
example, treatment of tumors with chemotherapy initiates cell death and therefore
255reduces cellular density. This decompression then allows for greater transport of drug 
after repeated drug administration. Direct injection of ECM enzymes such as collagenase 
produces a similar result. Digestion of ECM components increases the diffusion of 
macromolecules in a size dependent manner.256 For this reason, many now are 
developing multistage nanoparticle systems which are initially large for prolonged blood 
circulation, but then break apart into smaller particles or release free drug once in the
257-259tumor space.
2.4.4 Physical enhancement of delivery 
Tumor blood vessels are also subject to externally applied forces to increase blood 
flow and permeability. If the location of the diseased tissue is known, the physician may 
be able to treat the region with either ultrasound or heat for this purpose. Each of these
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may be useful tools for enabling the clinician to play a more active role in choosing the 
location of enhanced drug delivery.
Ultrasound has been used primarily for medical imaging due in part to its low cost 
and safety. The absorption of ultrasound by various tissues can also be used with 
therapeutic intentions.260 High-intensity and focused ultrasound (HIFU) can ablate tissue 
through heating and is used in some cases in the treatment of prostate cancer.261 Another 
interesting application of ultrasound in the context of the current review topic is in its 
ability to improve the delivery of macromolecules across biological barriers.262 
Depending on the frequency and intensity of the ultrasound, acoustic cavitations can 
occur in tissue during ultrasound treatment. These cavitations produce mechanical 
deformations and cell-cell junction disruption which causes normally semi-permeable 
barriers to become hyperpermeable.263 For example, Mitragotri and Langer have used 
ultrasound to permeabilize skin and enable transdermal adsorption of proteins.264 The 
transport of drugs, macromolecules and nucleic acids through the plasma membrane can 
also be improved using ultrasound through sonoporation.265-266 In regards to 
transvascular transport, the effect is similar. Ultrasound treatment of the blood-brain 
barrier, an endothelial lining with characteristically tight cell-cell junctions, temporarily
267 268disrupts this tissue and allows for drug delivery to the brain. - In tumors, such 
treatment can also improve transvascular delivery.269 Increased vascular permeability 
from ultrasound treatment is capable of improving the tumor accumulation of drug
270carrying macromolecules. This effect is, however, significantly less advantageous in 
tumor tissue relative to that observed with the BBB as this tissue is already permeable to
271macromolecules.
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In Section 2.2.2.6, the advantages of combining hyperthermia with chemotherapy 
were introduced. At the cellular level, hyperthermia is able to improve the intracellular 
delivery of small molecular weight drugs that can provide synergistic treatment.54 When 
these drugs are incorporated within nanocarriers such as a polymer therapeutic, the same 
may also be true but by a different mechanism. Recent findings, for example, have 
shown that hyperthermia can increase the rate o f both endo- and phagocytosis which may
272 273then potentiate macromolecular uptake and intracellular delivery. - Another level of 
synergism is obtained when the temperature does not significantly exceed 43°C where 
severe vascular damage occurs. At such elevated temperatures (41-43°C), tumor blood
274flow can increase roughly two-fold. This change in blood flow then increases the 
overall availability o f macromolecules to extravasate. Unfortunately, the extent o f this 
increased blood flow is not to the same degree as healthy tissue due to the lack of a 
smooth muscle layer and the overall tortuous nature of intravascular circulation.45, 48 In 
fact, many suggest that this observed increase is actually due to changes in surrounding 
blood vessels which supply the tumor and therefore force more blood inflow.
A consequence of this forced blood perfusion then is increased vascular pressure. 
Similar then to the tumor microvascular changes which occur with elevated blood 
pressure, the weak endothelial layer is not able to resist this pressure and heat adequately
275 276and increased vascular permeability results. - Such increased permeability is 
believed to be a result of cytoskeletal disaggregation in endothelial cells leading to
38 277 279further expansion of the intercellular junctions that already surround them.38, 277-279 This 
increase in vascular permeability and therefore EPR has been leveraged to improve 
nanomedicine delivery. Initial studies in this area focused on the extravasation of
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280 283liposomes when combined with hyperthermia. - The application of heat facilitated 
the extravasation of PEGylated liposomes in a time and temperature dependent manner.
In most cases, a low thermal dose (temperature < 42°C, time < 30 min) does not result in
281a substantial increase in liposomal delivery. As the thermal dose is increased, so does 
the delivery of liposomes where a 47-fold increase has been observed using intravital
283microscopy. Of particular interest in these studies was the use of temperature 
sensitive liposomes which could release their drug contents with temperature. A similar 
study using hyperthermia to enhance the delivery of HPMA copolymers was also
284completed, however in this case, no thermal enhancement of delivery was observed.
These studies then led Dewhirst and colleagues to more carefully evaluate the
285 288increased permeability and its impact on nanoparticle delivery. - In one study, the 
thermal dose was varied and the extravasation of liposomes was imaged using intravital
287microscopy. They observed that at temperatures below 40°C, no increased 
extravasation occurred. As the tumors were treated with temperatures above 40°C, 
liposomes began to extravasate in a temperature and time dependent manner. This 
increased vascular permeability continued up to 6 hours after heat treatment, after which
287time the tumor permeability recovered to normal levels. They explain this to be 
because of endothelial cell repair after this time. Heating of tumors above 43°C resulted 
in vascular hemorrhaging. When they compared these effects as a function of 
nanoparticle size, major differences between small (~7 nm) and large (100-400 nm)
285nanoparticles were observed. The smaller systems, albumin in this case, were 
relatively unaffected by treatment with hyperthermia. The larger nanoparticles, 
liposomes between 100 and 400 nm, on the other hand had low tumor accumulation
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without hyperthermia but had significantly enhanced delivery with hyperthermia. This 
too was size dependent with the 100 nm liposomes having the greatest tumor delivery 
with hyperthermia, though still just as good as albumin without heat treatment. The 
explanation provided in this paper for this size dependency relates again to the increased 
pore size with heat treatment. While the smaller particles can freely extravasate due to 
the relative large size of the intercellular openings in the endothelial layer, larger particles 
may be more restricted due to their similar size. When the tissue is heated and these 
openings are enlargened, this resistance may play less of a dominant role allowing them
to permeate to a larger extent. When tested in a feline tumor model, similar enhancement
286of delivery was observed. Unfortunately, these nanoparticle systems continue to suffer 
with heterogenous tissue distribution and poor interstitial penetration after thermal
therapy.289
2.4.5 New delivery enhancement methods 
Each of the above listed techniques will not likely be sufficient as a standalone 
means of enhancing the delivery of polymer therapeutics. Passive delivery by EPR 
remains the most attractive means of enhancing delivery, and many groups tailor the 
physicochemical properties of these conjugates to maximize the EPR effect. 
Unfortunately, as seen with the large number of clinical trials which do not show 
significant benefits, this alone will not translate these technologies into viable 
therapeutics with real benefit for patients. Clearly more efforts to enhance site specific 
delivery are required. In this context, delivery enhancement mechanisms which are more 
tumor selective are preferred. Hyperthermia, for example, has a degree of selectivity
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towards cancerous tissue, however the means of delivering the appropriate thermal dose 
without harming the surrounding healthy tissue remains a challenge. Therefore, an 
alternative means of delivering heat with greater tumor selectivity is preferred to enhance 
the accumulation of polymer therapeutics in prostate tumors.
One such method that has been applied to deliver heat in a localized fashion to
261 290 291treat prostate cancer is HIFU. , - HIFU treatment of localized prostate cancer is 
performed by inserting a trans-rectal ultrasound probe and positioning it such that it may 
provide focused ultrasound on the prostate gland. Initially, an ultrasound crystal used for 
imaging is utilized to determine the correct position of the probe to ensure that only the 
prostate tissue itself will be treated. Then, another crystal which is capable of delivering 
therapeutic doses of energy is turned on and the targeted tissue is heated through 
constructive interference of the ultrasound waves at the focal point. In this way, well 
defined regions of tissue are heated.
HIFU is currently approved for use in Europe and Asia for the treatment of 
prostate cancer, and it is likely that it will also be approved for use in the United States in 
the near future. Despite these apparent advantages for using HIFU to deliver heat, it has 
a few limitations. Mainly, its use is not selective towards cancerous tissue and therefore 
proper focusing of the probe on only the cancerous tissue is critical. This can be difficult 
considering that the margins of what is cancerous and normal are often unknown, 
particularly by ultrasound imaging. In cases when the disease remains localized to the 
gland itself (Stage I and II), this is not too problematic as complete ablation of the entire 
gland is acceptable. When it is locally advanced, however, the proximity of the 
cancerous tissue to the rectal wall makes treatment difficult. Also, slight movement of
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either the patient or probe during treatment may have unintended consequences. Finally, 
due to the focused nature of the beam, it is difficult to uniformly heat large regions of 
tissue during therapy. For these reasons, though likely to provide significant treatment 
value in the near future, HIFU may not represent the ideal tool for treating prostate cancer 
tissue with heat.
2.5 Plasmonic Photothermal Therapy (PPTT)
A recent method of selectively delivering heat to tumor tissue takes advantage of 
the plasmonic properties of colloidal gold. Of special interest in this regard is the unique 
capacity of these colloids to scatter and absorb light. Under conditions of particle SPR, 
strong light absorption results in particle heating. When located within a tumor mass, 
direct tissue heating can occur with laser light excitation. Termed PPTT, this heating 
process can be used as a means to induce tumor hyperthermia with therapeutic
292-294intentions.292 294
In the following sections, AuNPs will be introduced as well as a description of 
their properties. Their use as antennas for PPTT will then be described as well as the 
potential of using this technology to enhance the delivery of other nanomedicines such as 
polymer therapeutics to prostate tumors.
2.5.1 AuNPs and SPR induced heating
Gold has captured human attention long before Egyptian alchemists described it 
as the perfect metal. As a colloid, the colors that dispersed AuNPs create led to their use 
in stained glass during the Roman Empire. However, the origin of this color remained
unknown until 1857. In his Bakerian lecture, Michael Faraday described colloidal gold
295particles (or sols) that are able to scatter and absorb light in a size dependent manner. 
These revolutionary findings ultimately laid the foundation for the field o f plasmonics 
and colloidal chemistry.
When an electrical potential is applied to metallic gold, the electrons which lie in the 
conduction band of its atoms will become mobile and move in the direction of the electrical 
field. As the electrical field generated from photons is also capable of remodeling the spatial 
charge distribution in gold, it is possible to control electron wave propagation by light 
excitation. When the spatial distribution of these mobile electrons is confined near their 
mean-free path (~40-50 nm), it is possible to coherently excite these electrons into 
resonance.296 Because the surface represents the main boundary conditions for such gold 
structures, this coherent oscillation of free electrons produces SPR. Though SPR can be 
found on many roughened gold surfaces, due to the inherent nanoscale size of AuNPs, SPR 
represents the principal contributor to their unique optical properties.
Under conditions o f SPR the free electrons are excited into the conduction band and
297oscillate in-phase with the electromagnetic radiation. This in effect polarizes the surface of 
the AuNPs and creates a dipole (Figure 2.1 A).296 Such polarization of these conductive 
electrons gives rise to both strong light scattering and absorption under conditions of 
resonance (Figure 2.1 B). This light scattering is due to the fact that the oscillating dipole 
also acts as an emitter of electromagnetic radiation whose frequency is equal to that of the 
incident light wave. Meanwhile, the intense light absorption results from the heavier ionic 
core of the nanoparticle which acts as a restoring force to the induced dipole. The pioneering 
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Figure 2.1: Scheme showing the interactions of light with GNRs. When photons pass 
near GNRs, the electrical field is capable of remodeling the spatial organization of its 
electrons (A). Under conditions of SPR, strong light absorption can occur over a 
tunable range of wavelengths (B).
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298he derived Maxwell’s equations to describe their extinction cross-section. For particles 
which are considered small relative to the wavelength of light (2R < 25 nm), the Mie theory
is reduced to the following relationship: 299
9aV s3m2 e2(a) . 0 1a t  =------- —  * r / x * Y -----Equation 2.1
c L£1 (Y)+ 2Sm J +£2 (Y)
where V is the volume of the particle, ro is angular frequency of the electromagnetic radiation, 
c is the speed of light, and sm and s(ro) = 81(ro)+is2(ro) are the dielectric functions of the 
surrounding medium and the particle’s material respectively. Here, conditions of resonance 
are fulfilled when s1(ro) = -2sm where the extinction cross-section is inversely proportional to 
the imaginary part of gold’s dielectric function. In this relationship, the intrinsic size 
influence on light extinction originates from the dependency of gold’s dielectric function on 
particle diameter [s = s(ro,R)]. For particles larger than 25 nm, however, they are not able to 
be homogeneously polarized as equation 2.1 assumes and therefore higher-order modes of 
Mie’s equations dictates that oext directly depends on particle radius.299 Such extrinsic size 
effects means that as particle size increases, so does the wavelength of light which induces 
SPR.
Besides the dependence on particle size, the shape of AuNPs significantly contributes 
to their light extinction cross-section. For anisotropic AuNPs, i.e., aspect ratio (AR) > 1.0 
such as with GNRs, two plasmon absorption bands develop; one for the short axis 
(transverse) and another for the elongated axis (longitudinal) (Figure 2.1 B). Because of the 
anisotropic nature of these particles, unlike uniform spheres, there exists a polarization
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dependency on light extinction. Therefore, Richard Gans extended Mie’s theory to average 
light extinction over all orientations for prolate and spheroidal particles.300-301 In this way the 
following relationship was developed indicating that oext is dependent on AR instead of size:
r ( 1 / P > :
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where Pj are the depolarization factors along the three axes A, B and C with A > B = C as 
with GNRs and
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Here the resonant condition is fulfilled when si = -sm(1-PA)/PA. From this model it is 
observed that as AR of the GNR is increased, the location of SPR is red shifted. For 
example, GNRs with an AR = 2.1, 3.0 and 3.7 have a Vax at 610, 709 and 780 nm
301respectively. An important point to be made about anisotropic AuNPs such as GNRs is 
that by increasing AR, the SPR peak is red shifted significantly such that Vax can be located 
in the NIR or infrared (IR) spectrum. Such SPR in the NIR spectrum is advantageous for 
PPTT or imaging because penetration of light through tissue is greater at these wavelengths
302than that of visible light (though still limited to only a few centimeters).
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When the incident light wave is absorbed by the particle, excitation of the dense 
population of free electrons is enough to result in electron-electron scattering and therefore 
thermalization of the electron gas around the gold surface (Figure 2.2).303-304 The heat 
generated in the electron gas is subsequently cooled by electron-phonon coupling where the
305energy is transferred to the gold lattice. Finally, phonon-phonon coupling of the hot lattice 
to the surrounding medium results in energy transfer and Joule heating of the suspending 
fluid. The calculations required to compute heat generation as a function of incident light 
power are complex and typically require finite element models to solve the involved partial 
differential equations (PDEs) and are therefore beyond the scope of this Chapter. However, 
for such information using small (R < 25 nm) spheres, the following reference is provided.306 
That being said, as the light extinction cross-section is equal to the sum of the light 
absorbance and scattering cross-sections (oext = oabs + osca), one can more easily determine the 
efficiency of energy conversion to heat by first calculating oabs then dividing this by oext. For 
AuNPs which are spherical, this calculation is relatively straightforward by applying Mie’s 
equations. For GNRs, however, where this polarization dependency exists, the absorbance 
cross-section can be calculated by integrating the resistive heating over the volume of the
307particle and dividing by the incident power density. Similarly, the scattering cross-section 
can be found by integrating the outgoing electromagnetic energy flux over the boundaries 
within which it exists:
2 \ U a d '  _l\Efa,\2 d n
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Figure 2.2: Sketch of the energy relaxation processes after excitation of 
nonequilibrium electrons in a GNR. Te, Te-ph, and xph-m are the characteristic times for 
internal thermalization of the electron gas, electron-lattice phonon thermalization, and 
particle phonon-milieu energy exchanges, respectively (adapted from 296).
where Uav is the power adsorbed by the particle in the form of ohmic losses, n is the 
refractive index of suspending fluid and and are the amplitudes of the incident 
and far electric field respectively. In this reference, the finite element method was also 
employed to solve for resistive heating as a function of volume and it was found that due to 
the large light absorption cross-section of GNRs relative to their scattering cross-section, an
307efficiency of 93% is expected. Experimentally this value was found to be much less 
(60%), however AuNPs of this shape (rods vs. shells) were found to be the most efficient at 
photothermal conversion.
When describing the use of GNRs for PPTT, there are some practical issues that must 
be considered which may impact their light absorption and energy conversion capacity. The 
intensity of induced SPR under NIR excitation is heavily influenced by dephasing of the 
coherent plasmon oscillations. In general, such dephasing is a natural phenomenon such as 
when electron-surface scattering occurs. However, when exposed to the complex biological 
environment, a variety of changes to their physicochemical properties may amplify such 
dephasing and therefore reduce their energy conversion efficiencies. For example, 
adsorption of proteins and other biomolecules to the gold’s surface is possible upon exposure 
to blood. In such situations, by a process known as chemical interface damping (CID), the 
empty lowest unoccupied molecular orbital (LUMO) of the adsorbed molecules may couple 
to the resonating, surface free electrons of the gold.296 Such CID would therefore dephase 
this coherence and result in broadening and reduction of plasmon light adsorption. Similarly, 
as exposure to blood with a significant electrolyte concentration results in reduction of 
electrostatic repulsion of charged particles, the GNR suspension may flocculate. Under 
conditions of such sterically stabilized flocculation, the decreased separation distance
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between GNRs may allow some resonant energy transfer between particles and therefore 
broadening and reduction of plasmon light adsorption. Both examples therefore highlight the 
need for a GNR suspension whose polymer coating is sufficiently dense that adsorption of 
biomolecules and flocculation is minimized so that heat conversion efficiency is maximized.
2.5.2 Delivery to tumors 
The strong light absorption and heat conversion efficiency of AuNPs makes these 
nanoconstructs particularly apt as antennas for PPTT. However, their effectiveness is 
precluded by their ability to localize in tumor masses which are accessible by fiber optics. 
In some cases, they can be injected directly into the tumor mass immediately before laser
308radiation. However, in situations where the boundaries of cancerous and healthy tissue 
are unknown, as is the case for advance localized prostate cancer, direct injection cannot 
be selective towards neoplastic tissue and unwanted damage can result during therapy. In 
this situation, systemic administration and delivery by EPR may be required to provide 
malignant selectivity.
In order to deliver AuNPs via EPR, they must be non-toxic and long circulating. 
Fortunately, as a bulk metal, gold has well known biocompatibility. However, the 
nanoscale size and diverse surface chemistry of AuNPs may have more impact on their 
overall biocompatibility than of the metal itself. For example, the size and shape of
309 312AuNPs have been shown to influence uptake and toxicity. - This design parameter 
though seems to be less important than surface chemistry. The surfactant 
cetyltrimethylammonium bromide (CTAB), which is used during GNR synthesis, is well
313known to be toxic to cells and therefore must be removed prior to exposure.
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Nanoparticle charge, which is a consequence of surface chemistry, has a significant 
impact on cellular toxicity. Those with strong positive surface charges or zeta potentials 
are known to be toxic towards cells.314 Similarly, particle size, shape and surface charge 
can have a significant impact on blood retention and biodistribution where less charged
315and elongated AuNPs often have greater biodistribution characteristics.
The importance of particle surface chemistry and zeta potential has more to do 
with protein opsonization and immune detection than direct interactions with the cell 
surface. Within seconds of exposure to blood plasma, the particle’s surface quickly 
adsorbs proteins.316 As the blood contains a large diversity of plasma proteins with 
different physicochemical properties, one would expect that adsorption would be 
heterogeneous with preferences for some proteins, but not others. It has been observed 
that while 69 different proteins can adsorb to a AuNP’s surface (compared to over 3700 
available proteins in plasma), there is preferential binding for albumin, apolipoprotein,
317 318immunoglobulins, complement, and fibrinogen. - This is particularly the case for 
fibrinogen which has the highest adsorption to gold, despite its lower concentration in 
plasma relative to more abundant proteins such as albumin. While gold-thiolate bond 
formation or Van der Waals adsorption may be the principle reason for strong protein 
adsorption, charge-charge interactions between the particle’s surface and the protein 
dominate the extent to which some proteins adsorb because these forces occur over 
longer distances. As protein adsorption is often unwanted particularly when exposed to 
biological milieu, preparation of self-assembled monolayers with long, flexible organic 
chains such as PEG provide steric hindrance preventing such components from accessing
319the gold surface and adsorbing. PEGylation of the particle’s surface in this way is a
320well proven method to extend their blood circulation.
Once in circulation, they are able to extravasate into the tumor interstitium due to 
EPR and therefore accumulate in the diseased tissue with a degree of specificity. 
However, as previously discussed, this delivery is heterogeneous through the tumor 
volume. Microscopy studies have provided some insight into the intratumoral 
distribution of nanoparticles. A comparison of GNRs and gold nanoshells showed that 
both are primarily located in the peripheral regions of the tumor and remained within
321close proximity of the tumor vasculature. This was most apparent for GNRs which 
showed greater tumor accumulations than shells. These results are not surprising given 
their size and therefore hindered ability to permeate through the dense tumor interstitium.
203Similar findings have been observed with liposomes. This heterogeneous delivery then 
has consequences on the pattern of tissue heating which is observed to also be
322heterogeneous.
2.5.3 PPTT and tumor ablation 
The concept of PPTT was originally described by West and colleagues using gold
323nanoshells. In this landmark paper, they developed NIR absorbing PEGylated gold 
nanoshells which were delivered to breast carcinoma xenografts and heated with a NIR 
laser. Laser radiation (4 W/cm2) of the tumors resulted in significant tumor heating (AT 
= 37.4°C) and substantial tissue damage. When mice were treated with the same therapy 
and the tumors were allowed to grow, photothermal treatment resulted in cure of all
324tumors. Since these initial reports, a large number of papers have described use of this
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207 294 308 325 328technique to thermally ablate tumors both in vitro and in vivo. , , , - In these 
studies, NIR absorbing GNRs or gold nanoshells were used to generate high temperatures 
to damage vasculature and through direct cell killing.
The mechanism by which heating causes vascular damage and cell death has been 
discussed in Section 2.2.2.5, and it is likely that PPTT does this primarily in the same 
way. The presence of heating AuNPs in the proximity of or within cells causes direct cell 
killing through an additional mechanism. When AuNPs are heated by surface plasmon 
excitation, the temperature on the particle’s surface can become hot enough to produce
329microbubbles. This is particularly the case when the laser light is provided in short 
(femtosecond) pulses where cavitations can occur. When the nanoparticles are then 
located within cells or on the plasma membrane, the microbubbles can cause mechanical 
damage. The result is organelle damage, increased plasma membrane permeability and
330 333membrane blebbing. - This advantage of localizing the particles on the cell’s plasma 
membrane is therefore taken advantage of when active targeting is employed where
334 336greater cell death due to increased membrane blebbing occurs. -
With respect to the types of AuNPs available for PPTT, a wide variety of designs 
exists. The most important of these relates to the particle’s size and shape. AuNPs which 
are either very small (< 5 nm) or very large (>1 |im) do not typically exhibit strong 
plasmon light absorption nor favorable biodistribution and are therefore not commonly 
used. Therefore, most fall within this size range. The particle’s shape is an important 
parameter in terms of its biodistribution, but more importantly its light extinction cross­
section. Gold nanospheres, for example, typically have an SPR peak around 550 nm 
whereas GNRs and gold nanoshells are typically within the NIR spectra. Because light
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302penetrates most tissue maximally in the NIR range,302 gold nanospheres are not typically 
used for PPTT. When comparing GNRs with gold nanoshells, the two most commonly 
used nanoparticles for PPTT, GNRs exhibit higher light absorption in the NIR spectra per
307 337unit size as well as faster heating dynamics. , Many other AuNP shapes exist such as
338stars, cages, triangles, rattles, etc., and future work comparing their utility in tumor 
therapy against GNRs and nanoshells will be intriguing.
Clinical translation of PPTT will likely face many challenges and opportunities. 
Since their initial paper in 2003, West and colleagues have started a company 
(Nanospectra Biosciences, Inc., Houston, Texas) using gold nanoshells to treat patients 
with head and neck cancer in a Phase I trial. One preclinical study using a naturally 
occurring canine brain tumor model provided initial and encouraging results that such
339therapy may ultimately be useful. However, concerns over patient long term toxicity 
due to AuNPs in the liver and spleen will need to be thoroughly addressed.
2.5.4 PPTT and combination therapy 
The majority of studies applying PPTT for tumor therapy have been done with 
tissue ablative intentions. Tumor heating above 50°C, well above the temperature 
required to ablate its vasculature, is not difficult to achieve using low-powered laser
308 323 324 327diodes and therefore cure of subcutaneous tumor models is widely reported. , - ,
O f interest, however, is the possibility o f using the precise control over heating to 
modulate the tumor microenvironment to facilitate the potency of other therapeutics. As 
mentioned in Section 2.4.4, several labs have used hyperthermia for this purpose to 
improve the delivery of liposomes.280, 285-287, 340 The methods these groups have used to
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treat the tumors with heat do not offer tissue selective control of heating in a well defined 
manner. Heating with a water bath provides a source of heat exterior to the skin at a 
predefined temperature, though direct control of temperature within the tumor core 
cannot be easily manipulated. Also, this method for delivering heat is not a clinically 
viable approach to heat most tumors. Treatment with high-energy radiofrequency probes 
can injure the tissue upon insertion of the probe and produces regions of high heat or hot 
spots immediately adjacent to the probe’s surface and is not selective towards the 
cancerous tissue.341 For these reasons, PPTT may offer an advantage due to its selectivity 
towards cancerous tissue, depth of heat generation in tumors less than a few centimeter 
and precise control of heat delivery by modulating laser power output. Additionally, 
because the AuNPs do not permeate far from the tumor’s leaky vasculature, providing the 
sources of heat directly near blood vessels may offer better control of blood flow and 
vascular permeability.
There are a few studies where mild PPTT was used to improve the outcome of 
other therapies. In one example, gold nanoshells were used to mildly heat colorectal
342tumors between 42-45°C in combination with radiotherapy. The aim here was to 
increase overall blood perfusion in tumors using PPTT so that radiotherapy could be 
more effective. It was observed that treatment with mild PPTT does in fact increase the 
blood perfusion of tumors and that combined treatment with radiotherapy provides a 
greater outcome than either treatment alone. This study also observed significant 
vascular collapse when higher laser powers were used which could also improve overall
342outcome in the clinical setting.
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Three additional studies reported by the Bhatia and Sailor groups used GNR 
mediated PPTT to improve the delivery of liposomes, micelles and magnetic 
nanoworms.343-345 In each of these experiments, GNRs were used to heat tumors between 
43-45°C for up to 30 minutes. In the first of the three papers, they were able to improve 
the localization of doxorubicin-loaded liposomes as well as nanoworms by increasing the
343tumor’s blood perfusion and permeability with PPTT. Next, they replaced these with 
temperature sensitive liposomes and micelles so that the heating could also trigger drug 
release in addition to overall accumulation.344 Similar to those findings by Dewhirst and
283others,283 treatment of the tumors with heating by PPTT increased the extravasation and 
drug release from these temperature sensitive nanomedicines. Finally, by increasing the 
temperature to 45°C to ensure vascular damage and ultimately clot formation, they 
followed this therapy with fibrin binding nanoworms and liposomes to facilitate 
localization to the site of clot formation after PPTT.345 Each of these studies, in addition 
to the previously described study, highlights the potential role of PPTT to act 
synergistically with both chemo and radiation therapy.
2.5.5 Advantages and disadvantages 
Compared to current methods for delivering heat to tumors for treatment with 
hyperthermia, PPTT offers many advantages which have already been discussed. The 
extravasation of nanoparticles through the leaky vasculature of tumors provides some 
selectivity towards cancerous tissue. This is in contrast to radiofrequency and ultrasound 
based ablation technologies where the tumor margins must be known in order to avoid 
healthy tissue damage. The use of laser light to deliver heat is also advantageous as the
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power output and site of illumination is easy to control using standard fiber optics which 
are already used in the clinic for laser light surgery. Also, direct heating of cells and 
tissue using nano-antennas as energy converters localizes the heat directly within the site 
of interest. All of these advantages among others make this technology promising.
There are several major disadvantages of PPTT that are worth discussing. First, 
intravenously administered AuNPs over 10 nm ultimately distribute mainly to the liver 
and spleen.346 This highlights a significant concern over their safety as they are non- 
degradable and not readily excreted. Second, the limited penetration depth of NIR light 
(< 2 cm) limits PPTT to tumors which are small in size and easily accessible with a fiber 
optic. Similarly, though the AuNPs are typically injected intravenously, PPTT is a 
localized therapy and may not be valuable to treat distant metastases. Finally, 
heterogeneous nanoparticle distribution in the tumor and limited access of tumor margins 
with the laser light increases the possibility of nonablative rims existing after therapy 
which may ultimately recur. Each of these disadvantages represents significant barriers 
to success which will likely limit this technology from existing as a standalone form of 
therapy.
2.6 Conclusions and Implications for Prostate Cancer Therapy
When a patient is presented with locally advanced prostate cancer that is 
unresectable, radiotherapy represents the primary form of care. Chemotherapy is an 
attractive means of treating these tumors, however the toxicity profile of the available 
drugs outweigh the benefits and is therefore not used until the disease has formed distant 
metastases. Strategies to alter drug pharmacokinetics using nanocarriers are under heavy
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development and it is anticipated that these efforts will yield substantial benefits for 
patients with prostate cancer. The challenges which this field faces have been discussed 
in detail, and it is clear that alternations in carrier chemistry and delivery strategies will 
provide the best outcome. Also, as it remains unlikely that a single form of therapy will 
provide the desired outcome alone, understanding the potential of future combination 
therapies remains an important area of study. With this in mind, treatment designs which 
aim to improve drug delivery using a combination therapy approach are likely to be of 
significant future value.
As PPTT matures and enters clinical evaluation, its potential use when used in 
combination with other therapies is worth investigating. Hyperthermia has long been 
known to be synergistic with both chemo and radiation therapy, and given PPTT’s 
advantages, it is likely that the same will also be true for it. Therefore, it is natural to 
consider PPTT as a combination therapy tool to synergistically improve the therapeutic 
ratio of nanomedicines including polymer therapeutics. This approach may in the future 
help those suffering from prostate cancer and other diseases where localized 
hyperthermia can improve treatment outcome.
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CHAPTER 3
GOLD NANOROD MEDIATED PLASMONIC PHOTOTHERMAL 
THERAPY: A TOOL TOENHANCE MACROMOLECULAR
DELIVERY
3.1 Introduction
It is well known that the permeability of tumor blood vessels is higher than that of 
tissues with a healthy morphology.1 EPR mainly due to large intercellular gaps between 
endothelial cells in tumor blood vessels allow for the diffusion of macromolecules out of 
the bloodstream enabling nanocarriers to deliver therapeutic anticancer drugs to
2 3cancerous cells. - Under conditions of elevated temperatures and increased blood 
perfusion, it has been found that this tumor microvascular permeability is significantly 
increased.4-5 For example, the extravasation of Evans blue dye (EBD), a dye with high 
albumin affinity and therefore serving as a macromolecule indicator, as well as liposomes 
have been shown to be enhanced under conditions of hyperthermia.4, 6-10 This is believed 
to be due to endothelial cell injury and can therefore be used to enhance the passive 
delivery of nanocarriers.11-14
Despite the apparent advantages of using heat for either tumor ablation or 
enhancing the delivery of macromolecules, clinical use of tumor hyperthermia is difficult
Reprinted with permission from the International Journal of Pharmaceutics 
Reference: Gormley, A. J.; et al., Int. J. Pharm. 2011, 415, 315-318.
due to limited ability to deliver sufficient heat in target regions without harming native 
tissue.15 More recently several laboratories have taken advantage of unique nanoscale 
events that occur when light is absorbed by plasmonic gold nanostructures. In brief, 
when light with a wavelength that matches the tunable SPR o f gold nanostructures meets 
these particles, coherent oscillations o f electrons in the conduction band allow the light to 
be absorbed and photothermal conversion to occur.16 When such particles are localized 
within tissue with the intention of using this technique as a tool to induce hyperthermia, 
termed PPTT, effective heating is possible.17 With PPTT, many groups have achieved 
tumor selective temperatures from 50°C to over 70°C, well above the threshold required 
for vascular damage.18-22
In this chapter, PPTT is used as a tool to induce both severe (46°C) and moderate 
hyperthermia (43°C). GNRs were used in this study as they are known to have higher 
absorption and scattering coefficients per unit size when compared to other architectures
23such as spheres or shells. By quantifying EBD extravasation in tumors receiving PPTT, 
it is shown that such a technique may be used as a means of enhancing the permeability 
o f tumor vessels and therefore enhancing the delivery o f nanocarriers.
3.2 M aterials and Methods
GNRs were synthesized with an SPR peak between 800-810 nm using the seed-
24mediated growth method. After centrifugation and washing three times with deionized 
(DI) water, PEG (methoxy-PEG-thiol, 5 kD, Creative PEGWorks #PLS-604) was added 
to the GNR suspension (optical density (OD) = 10) at a final PEG concentration of 100 
|iM and stirred for 1 hour. The PEG-GNR mixture was then dialyzed (3.5 K MWCO,
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Spectrum Labs #132594), centrifuged, washed and concentrated to remove unreacted 
PEG.
Mouse sarcoma S-180 cells were propagated by intraperitoneal injection (5 x 106 
S-180 cells in 1 ml phosphate buffered saline (PBS)) in female CD-1 mice (4-6 weeks 
old) and allowed to grow until 15% weight gain was observed. Animals were then 
euthanized by CO2 gas inhalation and the cells were harvested from the abdominal cavity. 
The cells were then washed to remove blood, diluted and subcutaneously injected into 
each flank of the animal (2 x 106 cells/flank in 200 |il PBS) while anesthetized with 
isofluorane. Tumors were then allowed to grow until average tumor volume reached 50­
100 mm3 (usually 7-10 days).
The animals were separated randomly into groups. Half received 200 |il of GNRs 
(9.6 mg/kg, OD = 120) and the other half saline by intravenous injection through the tail 
vein. After 24 hours, enough time for the GNRs to accumulate in the tumor at 1.22% 
injected dosed based on previous experiments and other reports in the literature,19 the 
animals were anesthetized and the areas around the tumors were shaved and swabbed
25with 50% propylene glycol to facilitate laser penetration. After 20 minutes, EBD (10 
mg/kg in 200 |il saline) was injected intravenously and a 33 gauge needle thermocouple 
(Omega #HYP0-33-1-T-G-60-SMPW-M) was inserted into the center of the tumor to 
record temperatures. Then, an 808 nm fiber coupled laser diode (Oclaro #BMU6-808-02- 
R01) with collimating lens (Thorlabs #F810SMA-780, spot size = 7 mm) was directed 
over the right tumor and radiated. Two different laser powers were used in this study (1.6 
and 1.2 W/cm ) such that one group received severe and the other moderate tumor 
hyperthermia. After 10 minutes of radiation, the laser was turned off and tumors were
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allowed to cool for two minutes before removal of the temperature probe. The left tumor 
did not receive laser treatment to serve as an internal control.
The thermal doses in these experiments were chosen based on reports in the 
literature. It is known that tumor vascular perfusion and permeability occurs maximally
27between 42-43°C. Above this temperature range, damage to the microvascular network 
occurs leading to vascular ablation. Because of this, the experiment sought to test 
delivery when the temperature was between 42-43°C (1.2 W/cm ). Because enhanced 
delivery is also expected even with tumor ablation, the experiment also tested 46°C (1.6 
W/cm2). This test was important to confirm ablation at this temperature. The length of 
laser treatment (10 min) was chosen based on results using a similar model which shows
othat 10 minutes of heating at 42°C is enough to enhance the delivery of albumin.
After the animals were allowed to rest for 5 hours, enough time for the EBD to be 
cleared from the blood,26 the animals were sacrificed by CO2 inhalation. Both tumors 
were collected, weighed and the EBD was extracted in 1.5 ml of formamide for 48 hrs at 
60°C. The EBD content was then measured spectrophotometrically at 620 nm and 
divided by the weight of the tumor.26 The extravasation of EBD was then calculated as a 
ratio of the right (treated) to left (untreated) tumor and expressed as a TER.
3.3 Results and Discussion
The injection of PEGylated GNRs (60 x 15 nm ± 6 x 2 nm, SPR = 800 nm, Figure 
3.1) in mice is well tolerated and no signs of distress or toxicity have been observed in 
this and other experiments. Immediately after initiation of laser treatment, temperatures 
inside the tumor climb rapidly and reach equilibrium within a few minutes (Figure 3.2).
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Figure 3.1: Characterization of GNRs. (A) Transmission electron micrograph (TEM) 
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Figure 3.2: Intratumoral temperatures during PPTT or laser alone. Laser power = 1.6
2 2 W/cm (A) and 1.2 W/cm (B). Error bars represented as ±standard deviation.
Though treatment with laser alone (absence of GNRs) does result in some tissue 
heating, the presence of GNRs significantly amplifies the degree of heat generation at 
both laser powers tested. The temperatures inside the tumors in the last 10 seconds of 
laser treatment were averaged and the changes in temperatures as well as final
temperatures are listed in Table 3.1. When groups were treated with PPTT using a laser
2 2power equal to 1.6 W/cm and 1.2 W/cm , the average equilibrium temperature inside the 
tumors reaches 46.3°C and 43.6°C, respectively. Therefore, by changing the laser power 
alone, severe and moderate hyperthermia was able to be achieved.
After animal sacrifice five hours post laser treatment, the tumors were dissected 
out. In the animals receiving PPTT at 1.6 W/cm , significant bleeding was observed in 
most tumors due to conditions of severe hyperthermia. Additionally, the areas around the 
tumor were deeply colored in EBD indicating that the heat generated in the tumors 
caused the surrounding tissue to also heat. Though definitive conclusions cannot be 
made as to why this heating of normal tissue results in increased delivery of EBD, it is 
probable that the vessels dilated in response to insult and therefore the resulting increase 
in blood perfusion aided the delivery of EBD. In all other experimental groups, including 
animals treated with PPTT at 1.2 W/cm , no obvious hemorrhaging and local 
discoloration of surrounding tissue was observed.
Quantification of EBD in treated and untreated tumors, expressed as a ratio, 
indicates that PPTT does in fact enhance the delivery of macromolecules (Table 3.1 and 
Figure 3.3). When the average tumor temperature during PPTT was 46.3°C and 43.6°C, 
the extravasation of EBD was enhanced 1.82 and 1.68-fold respectively. Though the 
TER is statistically different between groups with and without GNRs (p<0.01), no
107
108
Table 3.1: Thermal enhancement ratio (TER)
Group AT (°C) Max T (°C) TER
aPPTT. 1.6 W/cm2 13.7 ± 2.9 46.3 ± 1.3 1.82 ± 0 .40
bLaser. 1.6 W/cm2 
'"’PPTT. 1.2 W/cm2 
cLaser, 1.2 W/cm2
8.3 ± 1.8 
9.6 ± 2 .3  
6.0 ± 1.1
41 .2±  1.7 
43.6 ± 1.9 
39.3 ± 0.8
1.05 ± 0.15 
1.68 ± 0 .65  
0.94 ± 0 .25
Numbers expressed as: mean ± standard deviation
aN = 7 
bN = 6 
CN = 10
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Figure 3.3: Evans blue dye (EBD) delivery TER. **Indicates a statistically significant 
difference (p<0.01) by one-way analysis of variance (ANOVA). Error bars 
represented as ±standard deviation
statistical difference is observed between both groups that received PPTT at different 
laser intensities. As expected, when laser treatment was applied without the presence of 
GNRs, the TER was around 1.0, indicating that the heat generated by laser alone, used 
under these study conditions, did not increase tumor microvascular permeability.
Hyperthermia enabled drug delivery has several limitations. There exists a very 
narrow window (roughly 42°C < T < 43°C) where increased blood perfusion and
27permeability is observed without severe vascular damage. This is supported by the fact 
that in the present study, at 1.6 W/cm without the presence of GNRs, the tumor 
temperature reached 41.2°C but did not result in any increased EBD delivery. Therefore, 
using standard techniques o f inducing hyperthermia in the clinic, maintaining a tumor 
temperature within this therapeutic window is difficult. Also, non-specific heating of 
surrounding healthy tissue may increase the probability o f drug delivery within those 
regions where undesired toxicity is likely to occur.
PPTT has the potential to partially address these issues. Control of laser beam 
power and alignment may enable clinicians to precisely control thermal dose in a directed 
way. Also, PPTT represents a targeted approach to hyperthermia. As GNRs primarily 
partition out o f the blood due to EPR, it is unlikely that GNRs will reside in surrounding, 
healthy tissue. This provides a degree o f safety i f  the laser beam were to radiate such 
tissue. This can be further improved with the attachment o f targeting moieties such as 
peptides and antibodies. Unfortunately, because the heat distribution is dependent on 
GNR localization, a significant disadvantage is that tumor tissue without GNRs will not 
receive thermal therapy.
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A mouse sarcoma model was used in this study because o f its known and well 
characterized permeability to albumin. Indeed, much of the work characterizing the EPR 
effect using EBD was performed using this animal model.1 This model was also chosen 
for practical reasons due to its low cost, ease of tumor production and availability in the 
lab at the time of the experiment. However, because the intention of this dissertation is to 
treat prostate cancer, differences in animal models must be considered. It is possible that 
the inherent leaky nature of this model will provide artificially high values of enhanced 
delivery. Therefore, all future studies will be performed using prostate tumor models.
3.4 Conclusions
Using PPTT as a tool to induce hyperthermia and therefore increase the perfusion 
and permeability o f tumor blood vessels may represent a new approach to augmenting 
macromolecular drug delivery. It has been shown that PPTT can be used to precisely 
control tumor temperature so that either moderate or severe tumor hyperthermia is 
obtained. This approach can therefore be used to increase the delivery o f 
macromolecules such as albumin in the present paper. More detailed studies of resulting 
vascular events and delivery o f macromolecular therapeutics for treatment o f solid 
tumors is necessary.
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CHAPTER 4
BIOLOGICAL EVALUATION OF RGDFK-GOLD 
NANOROD CONJUGATES FOR PROSTATE 
CANCER TREATMENT
4.1 Introduction
The ability to precisely control material geometries with nanoscale dimension has 
enabled researchers with new and powerful tools not available when the same materials 
are in their bulk form. Examples of this include self-assembled structures from 
nanoparticle precursors,1 precise control of reaction catalysis by modulation of 
nanoparticle shape and size,2 as well as the fabrication of materials from nanotubes with 
unprecedented tensile strength and moduli. The unique optical properties of metal 
colloids whose dimensions are significantly smaller than the wavelength of light are a 
particular example as particle vibrations give rise to size and shape dependent light 
absorption and scattering phenomenon.4 For this reason, AuNPs have received 
significant attention in medicine due to their utility in disease detection and therapy.5
AuNPs in a variety of shapes, e.g., spheres, shells, and cages can act as 
multifunctional platforms. In addition to their use as optical imaging based contrast 
agents,6-8 AuNPs are able to serve as delivery vehicles for drugs9-10 and antennas for
Reprinted with permission from the Journal of Drug Targeting 
Reference: Gormley, A. J.; et al., J. Drug Target. 2011, 19, 915-924.
PPTT.11-14 Current methods for tumor delivery leverage the vasculature’s EPR which 
occurs due to both enlarged endothelial intercellular gaps as well as the lack of a 
functioning lymphatic system.15-16 This technique for delivery is ubiquitous in drug 
delivery to solid tumors and is partially responsible for much of the success observed in 
that field.17-19
One approach to improve the delivery and tumor retention of AuNPs is to employ
active targeting by conjugation of targeting moieties to their surface. Examples of such
20 21targeting strategies include conjugation of anti-EGFR and anti-HER2 antibodies,20-21 folic
22 23acid, as well as nuclear localizing peptides. In this way selective delivery to tumor 
specific markers can potentially improve the degree of tumor localization compared to 
passive strategies.
One set of targets that have received significant attention in the last decade are the 
avp3 integrins which regulate cell adhesion to extracellular matrix proteins. Able to bind 
with high affinity to the RGD sequence of matrix proteins such as fibronectin and
24vitronectin, avp3 integrins coating the angiogenic endothelium can be used as targets for
25nanoconstructs with surface modified variations of the RGD peptide. Of particular 
interest in this regard is use of the monocyclic RGDfK peptide which has higher affinity 
for avp3 integrins and greater tumor targeting characteristics than linear RGD.26-27 This 
technique for tumor targeting has been well characterized and validated using HPMA
28 35copolymers28-35 and has resulted in significant prostate tumor efficacy with both 
geldanamycin36 and docetaxel37 attached to the side chains.
38In the context of using GNRs as antennaes for PPTT, their active delivery to 
sites of tumor angiogenesis by RGDfK targeting may be advantageous. The vasculature
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which feeds cancerous cells has minimal organization and is devoid of smooth muscle 
ultimately impeding the capacity of this tissue to respond to heat stress. Transient 
increases in blood flow and vascular permeability up to 43°C is typically followed by 
vascular collapse, hemorrhage and circulatory stasis as temperatures rise above this 
threshold level.39-41 During conventional hyperthermia or that induced by PPTT using 
passive delivery approaches, tumor mass heating ultimately causes vascular damage once 
the whole tumor volume has been heated above 43°C. We ultimately hypothesize, 
however, that by directing GNRs to the tumor’s vasculature using cyclic RGD, greater 
control of vascular dynamics during heating is possible (Figure 4.1). To begin testing 
this hypothesis, in the present Chapter we first evaluated the in vitro cellular uptake and 
in vivo biodistribution of PEGylated GNRs functionalized with RGDfK.
4.2 M aterials and Methods
4.2.1GNR synthesis and characterization
42GNRs were synthesized using the seed-mediated growth method. Optimization 
of silver nitrate content and seed amount yielded GNRs with an aspect ratio such that the 
SPR peak was between 800-810 nm. GNRs were then centrifuged (6,000 rcf, 30 
minutes) and washed three times with DI water to remove excess CTAB. For the 
untargeted GNRs, PEG (50 mg, methoxy-PEG-thiol, 5 kD, Creative PEGWorks #PLS- 
604) was added to the GNR suspension (100 ml, 100 |ig/ml, OD = 10) at a final PEG 
concentration of 100 |iM and stirred for 1 hour. This was done to reduce the extent of 
protein adsorption and improve circulation time.43 The PEG-GNR suspension was then 
thoroughly dialyzed (3.5 K MWCO, Spectrum Labs #132594) and sterile filtered.
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Figure 4.1: Scheme of GNR delivery mechanism. (A) GNRs do not accumulate in 
normal tissue due to tight endothelial gaps in the vasculature. (B) GNRs can passively 
diffuse in malignant tissue by EPR effect. (C) Active targeting may increase GNR 
concentration at the vascular bed and localize them to heat sensitive vasculature.
Finally, the GNR suspension was centrifuged, washed three times with DI water to 
remove unreacted PEG and concentrated to a final concentration of 1.2 mg/ml (OD = 
120). Final product was stored at 4°C for a maximum of 2 months due to polymer 
shedding over time before use.
Targeted GNRs were synthesized by first reacting ortho-pyridyl-disulfide-PEG- 
succinimidyl ester (OPSS-PEG-NHS, 5 kD, Creative PEGWorks #PHB-997, 50 mg) with 
RGDfK (New England Peptide, Inc., 6 mg) in anhydrous DMSO (5 ml) and three drops 
of diisopropylethylamine (DIPEA) while stirring for 24 hours at room temperature. 
Dithiothreitol (DTT, 7 mg) was then added to the reaction mixture and stirred for an 
additional 2 hours to reduce the disulfide and obtain a free thiol at the end of the PEG- 
RGDfK polymer. The mixture was then dialyzed (3.5 K MWCO, Spectrum Labs 
#132594) and lyophilized to obtain the final product followed by confirmation of peptide 
attachment by amino acid analysis. Finally, the thiol-PEG-RGDfK polymer was grafted 
to the gold surface in the same way as the untargeted GNR conjugate.
GNR size and shape were measured by TEM (FEI Tecnai T12) after drop-casting 
the GNR suspension onto a copper grid. The GNR light absorption profile was measured 
before and after PEGylation using a spectrophotometer (Jasco V-650) and the stability of 
these conjugates was measured the same way after 30 minutes in 3.5% NaCl. GNR 
concentration was determined by inductively coupled plasma mass spectrometry (ICP- 
MS, Agilent 7500ce) against a gold and internal (irradium) standard. The zeta potential 
of the conjugates was measured in DI water by measuring the particle’s electrophoretic 
mobility using laser doppler velocimetry (Malvern Instruments Zetasizer Nano-ZS). 
Finally the RGDfK content on the gold was determined by amino acid analysis.
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4.2.2 Cell culture
The binding and uptake was evaluated for targeted (RGDfK) and untargeted 
GNRs in two cell lines obtained from ATCC (Manassas, VA); DU145 prostate cancer 
and human umbilical vein endothelial cells (HUVEC). DU145 cell lines were cultured in 
Eagle’s Minimum Essential Medium with Earle’s Balanced Salt Solution (ATCC) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Thermo Scientific HyClone, 
Logan, UT). HUVEC cell lines were cultured in Clonetics Endothelial Cell Basal 
Medium-2 supplemented with 2% FBS, hydrocortisone, hFGF-B, VEGF, R3-IGF-1, 
ascorbic acid, hEGF, GA-1000 and heparin (Lonza EGM-2 BulletKit). Cell lines were 
cultured at 37°C in 100% humidity with 5% CO2. All cells were kept within logarithmic 
growth and while DU145 cells were kept under 20 passages, HUVEC cells were 
discarded after seven.
4.2.3 Dark field microscopy 
Cells were plated on sterile cover slips coated with fibronectin and allowed to 
grow until 50% confluent. The media was then replaced with either fresh media or media 
containing either the RGDfK or untargeted GNRs (10 |ig/ml). Cells were allowed to 
incubate for 24 hours followed by aspiration of GNR containing media and three washing 
steps with PBS followed by fixation for 10 minutes with 4% paraformaldehyde before 
mounting to a slide with mounting medium. To detect association (binding and uptake) 
of GNRs with the cells, slides were then imaged with an Olympus BX41 microscope 
coupled to the CytoViva 150 Ultra Resolution Imaging (URI) System (CytoViva Inc.,
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Auburn, AL) using a 100x oil objective.44-45 A DAGE XLM (DAGE-MTI, Michigan 
City, IN) digital camera and software was used to capture and store images.
4.2.4 ICP-MS
To quantify binding and uptake, cells were plated in 24-well plates and allowed to 
grow to 70% confluency. After incubation with GNRs and washing with PBS as 
described above, cells were lysed with 100 mM sodium hydroxide for 20 minutes while 
shaking and the protein content for each well was determined using a bicinchoninic 
(BCA) protein assay (Micro BCA Protein Assay Kit, Thermo Scientific Inc., Rockford, 
IL). The lysate was then transferred to Teflon vials, digested and evaporated three times 
with fresh trace-metal grade aqua regia, then resuspended in 5% trace-metal grade nitric 
acid before being analyzed by ICP-MS for gold content quantification against a gold and 
internal standard. All groups were done in triplicates.
4.2.5 TEM
For visualization of uptake by TEM, cells were grown to 50% confluency on 
fibronectin coated ACLAR® plastic films before 24 hr incubation with GNRs. Cells were 
then washed three times with PBS and fixed with 2.5% glutaraldehyde and 1% 
paraformaldehyde in 0.1M sodium cacodylate with sucrose and calcium chloride. 
Samples were then dehydrated with washes of increasing concentrations of ethanol and 
embedded in an epoxy resin before sectioning with an ultramicrotome. All samples were 
then imaged using a FEI Tecnai T12 microscope (University of Utah Core Research 
Facilities, Salt Lake City, UT).
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4.2.6 Competitive inhibition of binding 
Confirmation of RGDfK-GNR specificity to avp3 integrins was performed by 
competitive inhibition of binding with echistatin. In brief, HUVEC cells were grown to 
50% confluency on fibronectin coated cover slips. The media was then removed and 
replaced with cold binding buffer (20 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 2 mmol/L 
CaCl2, 1 mmol/L MgCl2, 1 mmol/L MnCl2, 0.1% bovine serum albumin) containing 
RGDfK-GNRs (10 |ig/ml) and HUVECs were co-incubated at 4°C for 2 hours with or 
without 50 nM echistatin (Sigma-Aldrich). Cells were then washed three times with cold 
binding buffer, mounted to a slide and imaged by high-resolution dark field microscopy.
4.2.7 Biodistribution in prostate tumor bearing mice 
Six-week-old female athymic (nu/nu) mice were obtained from Charles River 
Laboratories (Davis, CA) and used in accordance with the Institutional Animal Care and 
Use Committee (IACUC) of the University of Utah. To initiate prostate cancer
nxenografts, mice were anesthetized using 4% isofluorane and 10 DU145 cells in 200 |il 
PBS were injected bilaterally on the flank of each animal. Tumors were then allowed to 
grow until average tumor volume reached 50-100 mm (usually 10-21 days).
The animals were separated randomly into two groups. Half received untargeted 
GNRs and the other half RGDfK-GNRs (9.6 mg/kg in 200 |il, OD = 120) by intravenous 
injection through the tail vein. The animals were allowed to rest for 6, 24 and 48 hours 
before sacrifice by CO2 inhalation. After sacrifice, blood was collected using a 
heparinized needle from the inferior vena cava and the animals were perfused with at 
least 20 ml of saline by cardiac puncture. Blood and organs such as the liver, spleen,
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lungs, heart and kidneys were collected and weighed as well as the tumors. Each sample 
was refluxed in 4 ml of fresh trace-metal grade aqua regia at 90°C for 24 hrs, and then 
dried at 130°C. Subsequently, samples were dissolved in 4 ml of 5% trace-metal grade 
nitric acid before quantification of gold content by ICP-MS against a gold and internal 
standard.
4.3 Results
4.3.1 GNR synthesis and characterization 
GNRs were synthesized with an SPR peak at 800 nm corresponding to a size of
60.5 x 15.0 ± 6.4 x 2.0 nm with an aspect ratio equal to 4.0 (Figure 4.2, Table 4.1). After 
PEGylation, with or without RGDfK, there was minimal change in absorption profile and 
the nanoparticles had strong stability in the presence of 3.5% NaCl. Zeta potential 
measurements indicate that while the untargeted (methoxy terminated) GNRs had a slight 
negative charge (-10.0 mV), the RGDfK-GNRs had a strong negative charge (-44.1 mV). 
Amino acid analysis confirmed the presence of RGDfK on the targeted GNRs with a
11 3concentration equal to 5.6 x 10- MRGDfK / |igAu or roughly 3.0 x 10 RGDfKs per GNR.
4.3.2 Binding and uptake by dark field microscopy and ICP-MS 
Because GNRs scatter light to a very high extent, the binding and uptake of both 
the untargeted and targeted (RGDfK) GNRs were visualized by high-resolution dark field 
microscopy (Figure 4.3 A). Captured images show that GNRs were associated with 
cultured cells to a different extent and do not affect overall cell morphology and the 




Figure 4.2: Characterization of GNRs. (A) Light absorption profile and (B) TEM of 
GNRs. Panel A shows the absorbance profile of CTAB stabilized GNRs (GNRs), 
CTAB stabilized GNRs with 3.5% NaCl (GNRs + NaCl) as well as RGDfK-PEG- 
GNRs with and without 3.5% NaCl (RGDfK-GNRs ± NaCl). Without the polymer 
coating, GNRs aggregate in the presence of NaCl, whereas those stabilized with PEG- 
RGDfK are stable in the presence of salt.
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Table 4.1: Physicochemical characteristics of GNRs.
Size (nm) SPR Charge Peptide Content
60.5 x 15.0 800 nm
Untargeted -10.0 mV NA
± 6.5 x 2.0 RGDfK -44.1 mV 5.6 x 10~11 MRGDfK/|Jg (Au)
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both cell lines tested (DU145 and HUVEC).Internalized GNRs were primarily located in 
the perinuclear regions of the cells. Similarly, it appeared that the RGDfK-GNRs had 
slightly more uptake in DU145 cells than the untargeted GNRs, though this difference 
was not statistically significant after quantification by ICP-MS (Figure 4.3 B). After 
incubation of the targeted (RGDfK) GNRs with HUVECs however, significant binding 
and uptake was observed. ICP-MS analysis revealed that these binding and uptake events 
were roughly 20-fold higher for the targeted GNRs than the untargeted GNRs for 
HUVECs (Figure 4.3 B).
4.3.3 Binding and uptake by TEM 
GNR uptake patterns by cells were typically as agglomerates and within 
membrane enclosed vacuoles (Figure 4.4). In some cases, the agglomerates were found 
in vesicles with multiple membranes suggesting possible association within the 
endoplasmic reticulum (ER). Despite significant uptake and GNR loading within the 
cells no obvious evidence of intracellular structure and organelle damage was observed. 
These observations and the fact that there were no visible changes o f cell culture 
confluence after incubation with GNRs, provide evidence related to the overall 
biocompatibility of the nanoparticles. Though in all cases uptake was observed by cells, 
the uptake of RGDfK-GNRs in HUVECs was significantly higher than that of any other 
cell line and particle combination.
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A DU 145 HUVEC B
Figure 4.3: GNR binding and uptake. (A) high-resolution dark field microscopy and 
(B) ICP-MS after 24 h incubation with either RGDfK modified or untargeted GNRs 
(10 |ig/mL). RGDfK-GNRs show increased binding and uptake relative to untargeted 
GNRs in both cell lines; however, this difference was most significant (roughly 20­
fold) with HUVECs. Error bas represented as ±standard deviation (N = 3).
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Figure 4.4: GNR uptake by TEM. Representative images of RGDfK (A-C) and 
untargeted (D) GNRs in HUVECs after 24 hours incubation. Arrows point to location 
of GNRs within the cell. Some GNRs were found within multiple membranes (panel 
B) near the nucleus.
4.3.4 Competitive inhibition of binding 
As echistatin is known to bind to avp3 cell adhesion integrins with very high 
affinity,46 competitive binding inhibition o f the RGDfK targeted receptors with this 
protein is possible. Incubation of HUVECs with RGDfK-GNRs at 4°C for 2 hours in 
binding buffer alone resulted in some GNR binding along the cell’s surface as visualized 
as small green-yellow dots observable by dark field microscopy (Figure 4.5 A). To 
confirm the specificity of this binding, co-incubation with echistatin (50 nM) resulted in 
almost complete inhibition of GNR binding to the cell’s surface (Figure 4.5 B).
4.3.5 Biodistribution in prostate tumor bearing mice 
To test the fate of the angiogenesis targeted GNRs compared to untargeted GNRs, 
their biodistribution was evaluated in prostate tumor bearing mice. Results indicate that 
while much of the untargeted GNRs remained in circulation after 6 hrs, the targeted 
(RGDfK) GNRs were no longer circulating (Figure 4.6 A). When comparing the tumor 
accumulation of both particle types, the untargeted GNRs had 7.6-fold higher tumor 
localization (1.22% injected dose) compared to the RGDfK conjugated GNRs (0.16% 
injected dose) at all time points (Figure 4.6 B). Gold analysis of other organs revealed 
that while the untargeted GNRs showed significant uptake by the liver and spleen, this 
effect was more pronounced with the targeted GNRs, particularly by the spleen (Figure 
4.7). Over time the untargeted GNRs were increasingly found in both of these organs 
due to their longer circulation time whereas the targeted GNRs had maximal organ 
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Figure 4.5: Binding inhibition with echistatin. RGDfK-GNRs binding to HUVECs in 
(A) absence and (B) presence of the avp3 inhibitor echistatin (50 nM) at 4°C for 2 h in 
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Figure 4.6: Tumor and blood accumulation of GNRs. Comparison of targeted 
(RGDfK) and untargeted gold content by ICP-MS in (A) blood and (B) tumors of 
mice bearing prostate cancer xenografts at 6, 24 and 48 hours postinjection. After 6 
hours, the RGDfK-GNRs were mostly removed from the blood, while the same was 
true for untargeted GNRs after 24 hours. Error bars represented as ±standard deviation 
(N = 3).
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Figure 4.7: Biodistribution of gold content by ICP-MS: (A) untargeted and (B) 
targeted (RGDfK) GNRs in prostate cancer bearing mice. Error bars represented as 
±standard deviation (N = 3).
blood. Upon dissection of the animals, the differences in hepatic and splenic uptake of 
the two GNR types were apparent as the liver and spleen from animals receiving RGDfK- 
GNRs were visibly darker than their untargeted counterparts.
4.4 Discussion
Among the many varieties of inorganic nanoparticles investigated for use in
47nanomedicine, AuNPs have been applied extensively. Reasons for this include their 
ease of synthesis and surface modification with low cost materials, their stability in most 
environments, as well as their safety and unique optical properties. Such characteristics 
make these attractive nanoparticle platforms which have been used as drug delivery 
carriers for TNF-a9 and antennas for PPTT.48
The use of ligand-directed delivery of nanoparticles to solid tumors over passive 
delivery mechanisms is desired. In most cases, maximizing the tumor localized percent 
injected dose represents the main value for this approach. Directed delivery to specific 
cells is advantageous as the imaging or therapy system may be specific to those cells. In 
drug delivery using water soluble polymers such as HPMA copolymers, for example, the 
attached anticancer drug may be specific for the target cells.49 The same is true for 
imaging modalities such as quantum dots, where labeling of tumor vasculature may be 
desired, and therefore vascular targeting approaches are used.50
Likewise efforts aimed at directed delivery of GNRs to the tumor vasculature 
would be advantageous. During hyperthermia the impact of heat on the ill-formed tumor 
vasculature is significant and results in damage.41 By localizing GNRs to the plasma 
membrane (by avp3 integrin targeting) of endothelial cells lining the neovasculature, these
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cells are particularly susceptible to damage by light activation. This is because direct 
contact with the membrane limits the amount of heat needed for photothermolysis despite 
the heat sink nature of the surrounding blood and interstitial fluid. Additionally, if one 
chooses to administer a subtherapeutic dose of heat to modulate the tumor’s vascular 
permeability and facilitate the passive delivery of other nanomedicines, directed PPTT to 
the tumor’s vasculature may dramatically reduce the light energy required for this 
approach.51
In our previous studies we demonstrated the utility of HPMA copolymer -  cyclic
28RGDfK conjugates for targeted delivery of drugs and imaging agents to solid tumors. , 
30-35 Compared to nontargetable systems, HPMA copolymer-RGD4C and -RGDfK 
conjugates have shown increased accumulation in a variety of tumors including prostate, 
lung and breast cancer xenografts. This increased localization has been correlated with 
enhanced treatment efficacy and anti-angiogenic activity of both geldanamycin and 
docetaxel.36-37
In addition to the presence of targeting moiety, however, other factors that 
influence biodistribution and tumor uptake are the size, charge, surface modification and 
architecture of nanocarriers. In many cases use of a targeting moiety does not necessarily 
guarantee better tumor accumulation. For example a variety of active delivery 
approaches for liposomes have been tested in vivo and many of the parameters which
52govern their blood clearance and tumor targeting have been identified.52 
Physicochemical properties such as particle charge and PEG length are known to
53influence the blood clearance kinetics of liposomes. Choice of targeting moiety and its 
structure also play a key role. For example, whole antibodies may be recognized by the
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RES to a higher extent than if antibody fragments are used.54-55 Finally, the architecture 
of the nanomedicine may play a significant role when comparing two systems. Besides 
the fact that carrier architecture and geometry influences biodistribution and passive 
tumor localization,56-57 it is likely that the biorecognition of the same peptide for its 
ligand on two very different platforms will be different.
In the context of angiogenesis targeting of AuNPs, there exists conflicting reports.
58Besides examples providing evidence of targeting in vitro alone,58 two other studies have 
validated this approach in vivo.59'60 In one study, RGDfK was attached to gold 
nanoshells which resulted in a slight increase in nanoshell delivery compared to the 
untargeted nanoshells alone.59 Also, when linear RGD functionalized dendrimer-GNRs 
were tested for tumor targeting, a very high (17% of the injected dose) amount of the 
targeted nanoparticles localized within the tumors.60 Alternatively, a recent study 
investigating the targeting potential of GNRs with a variety of targeting peptides 
including RGD provided evidence that such functionalization does not enable better 
tumor delivery when compared to untargeted GNRs alone.61 While attachment of 
moieties such as single-chain variable fragment (ScFv) and amino-terminal fragment 
(ATF) peptides resulted in a very slight increase in tumor delivery, use of the RGD 
peptide had a negative impact on tumor delivery.
When the binding and uptake of the RGDfK-GNRs was evaluated with both 
DU145 and HUVEC cells, the system performed as intended. GNRs with the RGDfK 
peptide on their surface had increased binding to cells which express avp3 integrins. 
Given that the expression profile of these receptors is highly dependent on cell type, it is 
expected that cells which have more avp3 integrins will have higher binding and uptake of
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the RGDfK modified GNRs. This was indeed the case where RGDfK-GNRs had more 
binding to both cell types relative to the untargeted nanoparticles, but that this difference 
was more pronounced with HUVECs (roughly 20-fold increase). This is related to the 
fact that HUVEC cells have significant expression of avp3 integrins due to their 
angiogenic phenotype.62-64 The fact that the RGDfK-GNRs had higher binding to the 
DU145 cells than the untargeted nanoparticles is also not surprising considering that 
these cells do have some expression profile of avp3 integrins, though not to the same 
extent as HUVECs.
Because there is always some concern that such binding and uptake events could 
be due to nonspecific interactions such as surface charge, inhibition of binding by co­
incubation with echistatin was performed and visualized by dark field microscopy. After 
2 hours incubation at 4°C, it is expected that minimal non-specific binding and uptake 
would occur. Because RGD-ligand binding is not an energy dependent process, such 
conditions should still result in some cell surface binding. In this way, peptide-ligand 
specificity was confirmed as HUVEC cells co-incubated with echistatin showed very 
little GNR binding while those cells without echistatin had GNRs decorating the cell’s 
surface.
Dark field microscopy in this case was used as a visualization tool as it is very 
efficient at detecting the presence of nanoparticles which scatter light to a high extent. 
However, since this imaging tool is unable to distinguish GNRs which are bound to the 
plasma membrane and those that are located intracellularly, it has some limitations. To 
address this, TEM images of the uptaken particles in HUVEC cells were acquired. The 
information gathered from the TEM images were not surprising based on previous
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findings.65-71 Large nanoparticle agglomerates were found within single membrane 
vesicles indicative of endosomes and lysosomes (Figure 4.4 A, C). However, in some 
cases these agglomerates were found within multiple membranes which may be 
suggestive of their presence within the ER (Figure 4.4 B).
Despite confirming the capacity of the RGDfK-GNRs to bind to cells undergoing 
angiogenesis, when the system was tested in vivo fast clearance of the targeted GNRs 
prevented effective targeting from occurring. Because RGD targeting of nanoparticles 
has been validated previously, we hypothesize that the fast clearance is related to the 
strong negative charge of the RGDfK-GNRs (-44.1 mV). As the presence of strong net
72negative charges is known to facilitate nanoparticle biorecognition,72 it is very possible 
that this physicochemical parameter alone may have initiated quick GNR uptake by the 
liver and spleen. Such quick RES clearance of negatively charged conjugates has been 
observed with several different nanomedicines. For example, the presence of strong 
negative charges was previously identified as the reason for quick clearance of RGDfK 
conjugated HPMA copolymers due to the presence of negatively charged 111In chelators
29attached to the side chains. Similar observations have also been made with liposomal
73 74 57 56systems, micelles, dendrimers, as well as AuNPs. Therefore, for successful 
targeting to occur lessons learned from nanoparticle systems with large surface charges 
necessitates careful consideration of particle charge in addition to other parameters such 
as targeting moiety content, as well as size and shape.
To reduce the presence of these surface charges, the number of PEG-RGDfKs on 
the gold surface may be decreased. However, because doing this alone has previously 
been shown to make little impact on the targetability of the system,61 another possibility
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is to change the PEG length to which the RGDfK moiety is attached. By attaching 
RGDfK or any other peptide to a PEG linker which is 2,000 Da in size and keeping the 
neutrally charged PEG (methoxy terminated) at 5,000 Da, a mixture of the two might 
hide the peptide and thus mask the surface charges. Of course there is a risk with this 
approach of not having the peptide available for binding to the ligand. In either case, an 
appropriate balance of enough peptide to achieve vascular targeting, but not so much that 
surface charges diminish blood circulation may be required to obtain a targeted system as 
designed.
4.5 Conclusions
In this chapter it was shown that surface modification of GNRs with the 
angiogenesis targeting peptide RGDfK results in effective targeting in vitro but not in 
vivo. Utilization of this peptide with GNRs shows excellent biorecognition with cells and 
their avp3 integrins, however the presence of strong negative charges likely accelerated 
the RES clearance of this system. In future designs, GNR surface modifications to 
maintain peptide-ligand bioactivity will need be balanced with particle surface charge to 
increase the targetability of this system. However, sufficient accumulation of 
nontargeted GNRs in the tumors was demonstrated to justify its use for further evaluation 
in PPTT and enhancing the delivery of polymeric systems.
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CHAPTER 5
GUIDED DELIVERY OF POLYMER THERAPEUTICS 
USING PLASMONIC PHOTOTHERMAL THERAPY
5.1 Introduction
Incorporation of anticancer agents within nanocarriers represents an effective way 
of delivering hydrophobic drugs in the blood as well as altering their organ distribution in 
the body.1 These nanomedicines have been designed to target sites of disease and 
enhance delivery to solid tumors. Despite substantial progress, clinical translation has 
been slow due to limited accumulation in the target site.
The delivery of targeted nanomedicines to solid tumors utilizes a two-pronged 
approach.1 First, their nanoscale size (~5-500 nm) is leveraged to reduce the 
accumulation in healthy organs while maximizing extravasation into the tumor mass. 
While the junctions between vascular endothelial cells in healthy tissues are too small 
(~2-6 nm) to allow permeation, larger gaps (up to 1.2 |im), which are present in the 
tumor’s poorly developed and leaky vasculature, allow them to partition out of the blood 
and into the tumor mass.3 Described as the EPR effect,4 this passive targeting approach 
has been applied ubiquitously in the delivery of nanomedicines.5 Second, once in the 
tumor interstitial space, contact with receptors expressed on the cancer cell surface
Reprinted with permission from Nano Today
Reference: Gormley, A. J.; et al., Nano Today. 2012, 7, 158-167.
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immobilizes them and triggers their internalization via endocytosis followed by drug 
release.6 This binding and uptake can be further increased through active targeting by
nconjugating receptor specific ligands to the nanocarriers.
Polymer-based nanomedicines have the advantage of solubilizing hydrophobic
odrugs and exhibiting stealth-like characteristics thereby evading immune recognition. In 
such systems drugs can be covalently linked to the polymer backbone and specifically 
released by enzymatic degradation or hydrolysis.9 These polymer-drug conjugates are 
typically 5-15 nm in hydrodynamic diameter and can therefore be cleared by urinary 
excretion.10 This is advantageous due to rising safety concerns of nanomedicines which 
are not eliminated from the body.11-14 The small size however comes with a cost as rapid 
renal elimination reduces the availability of the conjugates to accumulate in tumors by 
the EPR effect.15 With these advantages and limitations in mind, there is therefore a need 
to develop a strategy which maximizes the delivery of polymer therapeutics within the 
window of opportunity before renal clearance.
This need is particularly apparent considering conjugates, which aim to maximize 
tumor delivery, have to date demonstrated only moderate clinical benefit. For example, 
early generation polymer-drug conjugates such as HPMA copolymer-doxorubicin and 
PEG-camptothecin have not obtained the same success in the clinic as other 
nanomedicines such as Doxil® (liposome-doxorubicin) and Abraxane® (albumin-
opaclitaxel). While much of this may be related to other variables such as drug release 
kinetics, the lack of sufficient delivery to the tumor (<<15% of the injected dose) 
represents the primary barrier to success. Recent efforts to improve this delivery such as 
using high molecular weight biodegradable polymers which exhibit prolonged blood
circulation as well as using polymers with different architectures (i.e., dendrimers and 
branched polymers) have achieved some success. However, greater control over both 
passive and active targeting strategies is desirable.16
One method which has been described as a temporary means of enhancing the 
delivery of macromolecules such as albumin, liposomes and other nanomedicines is by
17 22inducing tumor hyperthermia. - Under conditions of elevated temperatures and 
increased blood perfusion, it has been found that the tumor microvascular permeability
23and therefore EPR effect is significantly increased. This is believed to be a result of 
cytoskeletal disaggregation in endothelial cells leading to further expansion of the
24 27fenestrae that already surround them. - Unfortunately, current techniques for inducing 
tumor hyperthermia such as radiofrequency ablation or hyperthermic intraperitoneal
perfusion are restrictive in their capacity to selectively deliver heat towards cancerous
.• 28 tissue.
More recently several laboratories have initiated hyperthermia by PPTT. In brief, 
when light with a wavelength that matches the tunable SPR of gold nanostructures 
interacts with these particles, coherent oscillations of electrons in the conduction band
29allow the light to be absorbed and photothermal conversion to occur. When such 
particles are delivered to cancerous tissue by EPR, this phenomenon can be used as a tool
30to selectively induce hyperthermia. Such PPTT has been used to achieve tumor 
selective temperatures varying from 50°C to over 70°C, well above the threshold required
31 35for vascular damage. - Previously, it has been shown in Chapter 3 of this dissertation 
as well as other works that this heat delivery technique at reduced temperatures (42- 
45°C) can be applied to selectively increase the perfusion and permeability of the tumor
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vasculature and hence the delivery of nanomedicines during laser radiation.36-40 In this 
way, the delivery of nanoworms, liposomes and micelles have shown to be recruited to 
the treatment site and sensitized for targeting and drug release.38-40
In this chapter, we aim to remotely modify the tumor microenvironment with 
laser mediated PPTT to increase both passive and active polymeric drug targeting. We 
use this technique immediately following injection of HPMA copolymers to augment 
EPR at the treatment site and drive their delivery into the tumor interstitial space while 
the copolymer is at its peak concentration in the blood (Figure 5.1). Once at the tumor 
site, we take advantage of the natural response of tissue to heat shock by conjugation of a 
targeting ligand which binds to HSPs. This is because the expression of HSPs is 
significantly increased following exposure to heat shock.26 In this way, the targetability 
of these cancer cells can be elevated so that the copolymer is retained in the tumor and 
taken up by cells to a higher extent.
A technique is introduced wherein a laser can be used to direct the localization 
and retention of polymer therapeutics in solid tumors. With this technique, it is believed 
that polymer-drug conjugates can be administered to patients by clinicians and efficiently 
guided towards the location of disease to maximize treatment efficacy, while minimizing 
toxicity.
5.2 M aterials and Methods
5.2.1 Synthesis and characterization of PEGylated GNRs 
GNRs were synthesized using the seed-mediated growth method.41 Optimization 
of silver nitrate content and seed amount yielded GNRs with an aspect ratio such that the
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Figure 5.1: Schematic of laser guided approach. Following delivery of GNRs to 
tumors, a laser is applied to the right tumor to heat the GNRs and induce a heat shock 
response. This effectively increases the pore size in the tumor vasculature as well as 
the cell surface expression of HSPs, resulting in increased tumor accumulation and 
retention.
SPR peak was between 800 and 810 nm.The GNRs were then centrifuged and washed 
three times with DI water to remove excess CTAB. PEGylation was done by addition of 
methoxy-PEG-thiol (5 kD, Creative PEGWorks, Winston Salem, NC) to the GNR 
suspension. The suspension was then thoroughly dialyzed against DI water and sterile 
filtered. In the final step, the GNRs were centrifuged, washed three times with DI water 
to remove unreacted PEG and concentrated. The final product was stored at 4°C for a 
maximum of two months before use. The size and shape of the GNRs were determined 
by TEM and the light absorption profile was measured by UV spectrometry. Zeta 
potential was measured in DI water by measuring electrophoretic mobility using laser 
doppler velocimetry (Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK).
5.2.2 Synthesis and characterization of HPMA copolymer-drug conjugates
The comonomers were synthesized as described previously.42-43 Precursor 
copolymer conjugates containing reactive carboxyl groups (thiazolidine-2-thione) were 
prepared by free radical copolymerization in methanol (50°C for 24 hours) using 
azobisisobutryonitrile (AIBN) as the initiator within a glass ampoule under N2 gas. For 
these polymerizations, monomers, AIBN and methanol content were 15, 0.5 and 84.5 
weight % respectively. Copolymerization with the monomer N-methacryloyl- 
tyrosinamide (MA-Tyr-CONH2) allows for radiolabeling of the conjugates or 5-[3- 
(methacryloylaminopropyl)thioureidyl] fluorescein (APMA-FITC) for fluorescent 
tracking of cellular uptake in cells. Weight average molecular weight (Mw), number 
average molecular weight (Mn), and polydispersity (Mw/Mn) of the precursor copolymers 
were estimated by size exclusion chromatography (SEC) using HPMA homopolymer
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fractions of known molecular weight. SEC was done on a Superose 12 column (10 mm x 
30 cm) (GE Healthcare, Piscataway, NJ) using a Fast Protein Liquid Chromatography 
(FPLC) system (GE Healthcare). Heat shock targeted conjugates were obtained by 
aminolysis of precursor copolymers with the GRP78 targeting peptide (WIFPWIQL), 
synthesized by solid phase, in DMSO for 24 hrs. Untargeted conjugates were obtained by 
hydrolysis of precursor copolymers in the presence of aqueous sodium hydroxide. 
Following polymerization, product was obtained by precipitation into diethyl ether. 
Copolymer conjugates were purified by dialysis against DI water (3.5 KDa molecular 
weight cut-off), lyophilized, and stored at -20°C. The amount of GRP78 targeting peptide
125was quantified by amino acid analysis (HPLC method). Iodine was conjugated to 
tyrosine residues to obtain radiolabeled copolymers using the Iodogen method with slight 
modification.44 Each copolymer (2 mg) and 0.5 mCi Na-125I were dissolved in 0.5M 
NaH2PO4 pH 7.0 and incubated at room temperature in Iodogen tubes for 10 minutes. 
Free radiolabel was removed by dialysis against saline and verified by SEC.
5.2.3 Cellular uptake of FITC-labeled conjugates 
Cellular uptake was evaluated qualitatively by confocal microscopy. DU145 cells 
were exposed to heat shock (43 °C / 30 min incubation) or control (37°C, continuous 
incubation). This thermal dose was chosen due to previous experiments which showed 
that treatment of cells with heat at 43°C for 30 minutes kills less than 5% of cells. Higher 
thermal doses, however, resulted in significantly more cell death. Therefore, this dose 
was chosen to minimize the impact of heat on cell viability. Eight hours post-heat shock, 
cells were incubated with 0.5 mg/mL of heat shock targeted or untargeted conjugates for
152
four hours. Cells were then washed, plasma membrane stained with TRITC-lectin (10 
|ig/ml, 10 minutes at 37°C, Sigma #L5266) and fixed with 4% paraformaldehyde in PBS. 
The cells were mounted to a slide using mounting medium containing DAPI and imaged 
using a confocal laser scanning microscope (Olympus FluoView® FV1000, Olympus, 
Center Valley, PA).
5.2.4 In vivo induction of heat shock via PPTT 
Anesthetized 6-12 week old athymic nu/nu mice were subcutaneously injected 
with 107 DU145 cells on each flank and tumors were allowed to grow until 
approximately 5-7 mm in diameter. Animals were then administered PEGylated GNRs 
(9.6 mg/kg) via tail vein injection. After 48 hours, mice were anesthetized, and tumors 
were swabbed with 50% propylene glycol to enhance laser penetration depth.45 Tumors 
on the right flank only were then radiated for 10 minutes using an 808 nm fiber coupled 
laser diode (Oclaro Inc., San Jose, CA) with collimating lens (Thorlabs, Newton, NJ). 
Intratumoral temperature was monitored using a 33 gauge needle thermocouple (Omega, 
Stamford, CT) and tumor temperature was maintained between 42°C and 43°C. This 
thermal dose (temperature and time) was chosen based on findings from Chapter 3. A 
more detailed discussion of this topic is also found in Section 3.2. Tumors on the left 
flank served as internal controls.
5.2.5 In vivo GRP78 expression in tumors following PPTT 
Eight hours following induction of heat shock, mice were euthanized and tumors 
on the right (laser) and left (control) flanks were removed and snap frozen in liquid
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nitrogen. Immunohistochemical (IHC) analysis of GRP78 expression was then performed 
on 4-micron thick sections of formalin-fixed, paraffin-embedded tissues using a goat 
polyclonal anti-GRP78 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a 
polyclonal rabbit anti-goat biotinylated antibody. Positive signal was visualized using a 
streptavidin-HRP system, utilizing DAB (3-3’ diaminobenzidine) as the chromogen. The 
sections were counterstained with hematoxylin. The sections were placed in iodine to 
remove any precipitates, and then dipped in sodium thiosulfate to clear the iodine. The 
sections were dehydrated in graded alcohols (70%, 95% x2 and 100% x2), cleared in 
xylene, coverslipped and imaged.
5.2.6 Tumor accumulation and biodistribution 
Prior to induction of heat shock via PPTT, mice were intravenously administered
125via the tail vein a single bolus dose of 50 mg/kg I radiolabeled conjugates (untargeted 
or heat shock targeted). At each time point, mice were euthanized, blood immediately 
collected, followed by blood perfusion with saline. Tumors and major organs were then 
collected and analyzed by gamma counting. Percent injected dose per gram of 
blood/tissue (%ID/g) was calculated and expressed as a function of time.
5.3 Results and Discussion
To begin, the HPMA copolymers were synthesized via free radical 
polymerization and characterized (Figure 5.2 A, Table 5.1, Figure A.1-4). Molecular 
weight for the conjugates varied from 60 -  80 kDa, and was maintained slightly above 
renal threshold to take advantage of the EPR effect by extending blood circulation. To
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generate a targetable HPMA copolymer, the WIFPWIQL peptide was conjugated to the 
HPMA copolymer side chain via aminolysis o f thiazolidine-2-thione side chains, 
resulting in copolymers with approximately 20% peptide content by weight or 
approximately 12 peptides per copolymer. This peptide was chosen due to its known 
affinity to GRP78, a member of the HSP70 family of proteins.46 Previously, it was 
shown that this receptor-ligand approach can be used to effectively deliver HPMA
42copolymer-drug conjugates to prostate cancer cells. Full details regarding the feed 
compositions and resulting polymer characteristics are given in Table 5.1.
GNRs were used in this study because they have a greater light absorption cross
47section per unit size relative to those with other geometries (i.e., shells and spheres),
31 35 37 39 48and are capable of inducing heat shock in tissue upon laser excitation. , , - , Before 
use, the GNRs were grafted with a PEG surface coating to reduce the extent of protein 
adsorption and improve blood circulation time.49 This resulted in a zeta potential of -10.0 
mV. The aspect ratio (4.1), size (58.8 x 14.4 nm ± 6.5 x 2.1 nm) and therefore SPR peak 
at 800 nm was chosen as light at this wavelength is capable of penetrating tissue several 
centimeters (Figure 5.2 B-C). By this method, as determined in a previous study, 1.22% 
of the injected dose is delivered to the tumor.50
To determine if heat shock could be used to regulate the targetability of these 
conjugates, fluorescently labeled HPMA copolymers with and without the heat shock 
targeting peptide were introduced to cells eight hours post-heat shock (43°C, 30 min) or 
control (37°C, continuous incubation). Eight hours was chosen here because previous 
studies found that receptor expression peaks at this time following heat shock.51 
Visualization by confocal microscopy (four hour incubation, Figure 5.3) of uptake in
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Figure 5.2: HPMA copolymer schematic and GNR characterization. (A) 
Representative HPMA copolymer with all monomers used in the study listed. For 
individual polymer composition, see Table 5.1. (B) TEM and (C) light absorption 
profile of synthesized GNRs.
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Table 5.1: Characteristics of HPMA copolymer conjugates. Weight average 
molecular weight (Mw) and polydispersity (Mw/Mn) were estimated by SEC. The 
amount of the GRP78 targeting peptide was quantified by amino acid analysis (HPLC 
method).
Feed composition (mol %)
MA-Tyr-







HPMA MA-GG-TT Mw /Mn
HPMA 93 5 2 0 83.9 1.6 -
HPMA-WIFPWIQL 93 5 2 0 72.4 1.6 20.9 wt%
HPMA-FITC 93 5 0 2 62.4 1.4 -
HPMA-FITC-
WIFPWIQL
93 5 0 2 64.4 1.4 18.0 wt%
cells indicates significantly increased binding and uptake of heat shock targeted
42conjugates which is in agreement with previous results. This observation was much 
more pronounced, when the cells were first treated with heat shock due to increased 
receptor expression.
Next, the overall hypothesis of enhancing the delivery of these conjugates to laser 
radiated tissue was tested in mice bearing prostate tumors. Mice bearing two tumors, one 
on each flank, were intravenously (i.v.) administered PEG coated GNRs and allowed 48 
hrs for the particles to accumulate in the tumors via EPR (Figure 5.4).50 Radiolabeled 
conjugates (heat shock targeted and untargeted) were then administered i.v. followed 
immediately by laser radiation of the right tumor only for 10 minutes. During laser 
radiation the temperature in the right tumor was maintained between 42-43°C by 
controlling laser power such that only moderate hyperthermia was induced to avoid
52vascular collapse at higher temperatures (Figure 5.5). It is important to note here that 
by directing the laser at the right tumor only, it is possible to directly compare the 
delivery of polymeric conjugates to tumors in the presence and absence of laser radiation 
in the same animal.
While the increased HSP expression profile of prostate cancer cells following heat 
shock was confirmed in vitro, it was necessary to confirm this phenomenon in vivo. The 
left (control) and right (laser treated) tumors were evaluated for GRP78 expression by 
immunohistochemistry. Heat shock treatment of the right tumors by laser resulted in 
increased HSP expression compared to the untreated tumors (Figure 5.6).
Following administration of the polymeric conjugates, a comparison of the laser 




















Figure 5.3: Visualization of cellular binding and uptake of fluorescently labeled 
(green) HPMA copolymers in cells by confocal microscopy. Blue stain is for nucleus 
(DAPI) and red stain is for plasma membrane (lectin-Rd). Scale bar, 10 |im.
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Figure 5.4: Schematic o f experimental procedure.
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Figure 5.5: Changes in intratumoral temperatures during laser radiation (10 min) of 
left (control) and right (laser) tumors. Error bars represented as ±standard deviation.
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Control Laser
Figure 5.6: Cell expression of heat shock protein GRP78 (red color) in prostate tumors 
with or without laser treatment. Scale bar, 50 |im. Tumors which have been laser 
radiated have higher expression of GRP78.
that a two to three-fold increased burst accumulation occurred in the laser radiated tumors 
(Figure 5.7). This observation indicates that the treatment of tumors with heat causes 
increased tumor blood flow and augments the EPR effect by increasing vascular pore
19 20 37size. - , This burst accumulation was not maintained after four hours for the 
untargeted conjugates. As intended in the treatment design, the heat shock targeted 
conjugates were retained in the radiated tumor up to 12 hours after which elimination 
began to occur. This observation is supported by GRP78 expression data which shows 
that HSP expression is reduced after 12 hours.51
The biodistribution of the radiolabeled conjugates in major organs was also 
evaluated (Figure 5.8). Similar concentrations in the blood were observed over 72 hours 
for untargeted and heat shock targeted conjugates. However, significant accumulation 
was observed for the heat shock targeted conjugate in the liver, spleen, and kidneys. This 
non-specific accumulation is most likely due to the increased hydrophobic nature of the 
heat shock targeted conjugate due to the presence of the hydrophobic WIFPWIQL 
peptide (cLogP = 3.9). This increased hydrophobicity can potentiate interactions with
53biological tissues and increase uptake in RES organs.
This nonspecific accumulation in healthy organs represents a significant 
disadvantage of the described therapy. It is very unlikely that such a therapy is useful its 
current form because of the expected side effects, a feature common to targeted 
therapeutics. It is anticipated that such non-specific interactions can be minimized by 
reducing the hydrophobic nature of the conjugates by either reducing the targeting 
peptide content or utilizing more hydrophilic targeting moieties. To test this, a new more 
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Figure 5.7: Tumor accumulation of radiolabeled polymers (untargeted and heat shock 
targeted) with or without laser treatment. Data expressed as experimental points with 
pharmacokinetic modeled lines. Laser radiation results in a burst accumulation (0-4 
hours), which is only maintained (>24 hours) for the heat shock targeted polymers due 


















Figure 5.8: Biodistribution of radiolabeled ( I) HPMA copolymers. Error bars 
represented as ±standard deviation.
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evaluated. Preliminary biodistribution results provide some initial confirmation of this 
hypothesis in that an x-fold reduction in liver, kidney and spleen accumulation is 
observed using this new peptide. Targeting of this new conjugate has also been 
confirmed using the same in vitro experiments. Therefore, all future studies will likely 
utilize this new peptide to reduce the chances of toxicity to these organs.
5.4 Conclusions
In this chapter, it is demonstrated that it is possible to direct the delivery of 
targeted polymer therapeutics using PPTT by exploiting the physiologic response of 
tumors to heat. These findings help overcome one of the limitations of polymer 
therapeutics which is poor tumor accumulation. By using laser directed application of 
heat via GNRs, a burst accumulation of the therapeutics in the region of interest is 
possible while they are at their highest concentration in the blood. By incorporation of a 
heat shock targeting ligand in the copolymer design, high concentration can be 
maintained as the targeting receptors become increasingly available following heat 
induction. Ultimately, in a clinical setting, it is anticipated that clinicians will value this 
additional tool to help guide drug delivery to solid tumors.
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CHAPTER 6
PLASMONIC PHOTOTHERMAL THERAPY INCREASES 
THE TUMOR MASS PENETRATION 
OF HPMA COPOLYMERS
6.1 Introduction
The conjugation of hydrophobic anticancer drugs to water-soluble polymers 
represents an effective way of solubilizing them in blood plasma, prolonging their blood 
circulation half-life, targeting their biodistribution to tumors and overcoming multidrug 
resistance.1 In this way, drugs can be retained in the blood and specifically delivered to 
the cancerous tissue with dramatically reduced accumulation in healthy organs. While 
the advantages of targeted delivery using polymer-drug conjugates are well known, 
clinical translation has been slow with no approved therapeutics to date. There are many 
reasons why this is the case, including poor drug release kinetics and carrier 
biocompatibility. However, the major barrier to obtaining favorable clinical outcome 
remains limited tumor and cancer cell delivery.
There are many available techniques to improve the delivery of polymer-drug 
conjugates. The most obvious and widely used method involves tailoring the size of the 
conjugates so that the therapeutic takes advantage of the increased vascular permeability 
of tumors to macromolecules. Coined the EPR effect, large intercellular and transcellular
openings between endothelial cells that line the tumor vasculature allow macromolecules 
up to roughly 1 |im in size to partition from the blood and enter the tumor interstitial 
space with limited lymphatic drainage.3-4 Another common approach involves the 
conjugation of biorecognizable motifs such as peptides or antibodies for cancer cell 
receptor-mediated targeting.5 Such active targeting then enables drug carriers to 
specifically bind to cancer cells which express the targeted receptor and trigger 
internalization and drug release. Finally, a number of other pharmacologic based 
methods for improving delivery have been shown including treatment with angiotensin to
6 7 8raise the patient’s blood pressure, - application of nitroglycerin, pretreatment with 
vascular disrupting9-10 or anti-angiogenic agents,11-12 as well as direct injection of
13extracellular matrix enzymes to reduce the interstitial density. Each of these tools 
provides greater selectivity of nanocarrier delivery to tumors.
Another technique which is shown to improve the delivery of nanocarriers 
involves treating the tumors with hyperthermia. Recent findings, for example, have 
shown that hyperthermia can increase the rate of both endo- and phagocytosis which may 
then potentiate macromolecular uptake and intracellular delivery.14-15 At the vascular 
level, when tumors are heated up to 43°C, tumor blood flow can increase roughly two­
fold.16 This change in blood flow then increases the overall availability of 
macromolecules to extravasate. The resulting increased vascular pressure and heat- 
induced cytoskeletal injury then causes endothelial cell damage.17-19 This causes further 
expansion of the intercellular openings and therefore increased vascular permeability to 
macromolecules.20-21
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The observed changes in tumor vascular dynamics with heating have been 
leveraged to improve the delivery of various nanomedicines. In particular, tumor 
hyperthermia has been used to facilitate the delivery of liposomes.22-26 The application of 
heat is shown to enhance the extravasation of liposomes in a thermal dose dependent
27manner for up to six hours after heat treatment. Additionally, this effect was also
dependent on nanoparticle size where the larger systems exhibited the greatest increase in
28overall delivery with heat. Precise control over heating, however, is necessary as 
vascular collapse and blood flow stasis is probable when temperatures rise above 43°C.
A major challenge with treating tumors with hyperthermia lies in the ability to 
effectively deliver the appropriate thermal dose in a site specific manner. Evolving 
technologies such as radiofrequency ablation as well as HIFU have proven useful in this
29regard,29 though these methods are not selective towards cancerous tissue and therefore 
rely on the physician to choose the regions which should receive thermal therapy. As the 
margins of tumor and normal tissue are often unknown, this adds greater risk of injury to 
healthy tissue. A recent method of selectively delivering heat to tumors takes advantage 
of the plasmonic properties of colloidal gold. Of special interest in this regard is the 
unique capacity of these colloids to scatter and absorb light. Under conditions of SPR,
30strong light absorption results in particle heating. When located within a tumor mass,
31 33direct tissue heating can occur with laser light excitation by PPTT. - This heating 
process can be used as a means to selectively induce tumor hyperthermia with therapeutic
34-36intentions.
Recent studies have shown the utility of PPTT to improve the delivery of other 
nanomedicines.37-41 In each of these studies, PPTT was applied to heat tumors between
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42-45°C and a resulting increase in conjugate accumulation was observed. In the 
previous Chapter, the tumor accumulation of heat shock targeted HPMA copolymers was
38evaluated in combination with PPTT. A peptide which has known affinity for an 
extracellular heat shock protein was incorporated in the polymer design to specifically 
target cancer cells treated with hyperthermia. PPTT for 10 minutes at 43°C caused a 
burst accumulation of the conjugates for up to 4 hours. After 4 hours, while the 
untargeted conjugates diffused back out of the tumor, the heat shock targeted conjugates 
were retained for an extended period of time (up to 12 hours) due to cell specific
38targeting. These results provided evidence for the utility of this approach.
What remains unknown, however, is the tumor tissue distribution of HPMA 
copolymers after delivery enhancement with PPTT. This information is important 
because drug delivery is not evenly distributed due to tumor vascular heterogeneity, 
particularly for nanomedicines which are large in size.42-43 The objective of the study 
described in this Chapter was to visualize the distribution of HPMA copolymers in 
prostate tumors after treatment with PPTT.
6.2 Materials and Methods
6.2.1 Synthesis and characterization of PEGylated GNRs
38GNRs were synthesized as described in Chapter 3, Section 3.2. GNR size and 
shape were characterized by TEM and the light absorption profile was measured by UV 
spectrometry. Zeta potential was calculated in DI water by measuring its electrophoretic 




6.2.2. Synthesis and characterization of HPMA copolymers 
HPMA,44 aminopropylmethacrylamide-benzyl-1,4,7,10 tetraazacyclododecane- 
1,4,7,10-tetraacetic acid (APMA-benzyl-DOTA),45 APMA-FITC,46 and 3-[(N-
47methacryloylglycyl)glycyl]thiazolidine-2-thione (MA-GG-TT) comonomers were 
synthesized as described previously. The precursor copolymer conjugates contained the 
reactive carboxyl groups (thiazolidine-2-thione) so that future studies with the same 
copolymer could incorporate targeting peptides into their design. In the present study, 
these groups were hydrolyzed to obtain untargeted conjugates. Copolymerization was 
performed by reversible addition-fragmentation chain-transfer (RAFT) polymerization 
using 2-cyano-2-propyl dodecyl trithiocarbonate as the chain transfer agent (CTA) and 
VA-044 as the initiator in a DMF/MeOH (90:10) co-solvent at 50°C for 24 hours in a 
sealed ampoule under N2 gas. Polymerization ratios were [monomers]:[CTA] = 450 and 
[CTA]:[VA-044] = 1.5. Following polymerization, product was obtained by precipitation 
into diethyl ether. The unpurified product was then dissolved in DI water with 
gadolinium (III) acetate hydrate (1.2 mol equivalent) and the pH was raised between 5.0­
5.5. This solution was stirred overnight followed by addition of 
ethylenediaminetetraacetic acid (EDTA) to remove excess Gd (EDTA:GD, 1:1). The 
product was then filtered, dialyzed and lyophilized to obtain the final product. Mw, Mn, 
and Mw/Mn were estimated by SEC using HPMA homopolymer fractions of known 
molecular weight. SEC was done on a Superose 12 column (10 mm x 30 cm) (GE 
Healthcare, Piscataway, NJ) using a Fast Protein Liquid Chromatography (FPLC) system 
(GE Healthcare). The Gd content was quantified by ICP-MS against a standard curve.
38Fluorescently labeled polymers were synthesized as described in Chapter 5.
To calculate the conjugate’s longitudinal relaxivity, four different concentrations 
of copolymer (0.1 to 0.015 mM polymer) were prepared in DI water and placed in a 
Bruker BioSpec 7.1 T horizontal-bore MRI. T1 was measured by an inversion recovery 
fast spin-echo imaging sequence using inversion times of 50, 100, 300, 500, 800, 1000,
2000, 4000, 7000 and 8000 ms, echo time (TE) of 4.2 ms, and repetition time (TR) of 
12000 ms. T1 for each vial was calculated using Bruker software and the relaxation rate 
(R1 = 1/T1) was plotted against Gd equivalent concentration. Relaxivity was measured 
as the slope of this plot.
6.2.3. Prostate tumor model
Animal experiments were performed in accordance with the IACUC of the 
University of Utah. Four-to-six week old female athymic (nu/nu) mice were anesthetized
n
using 2% isoflurane and bilaterally inoculated with 10 DU145 cells in 200 |il PBS on the 
flank of each animal. Animals were used in the study once the average tumor volume 
reached 50-100 mm (usually 10-21 days).
6.2.4. MR imaging
Prior to the experiment, those animals which were ultimately treated with PPTT 
received an intravenous dose of PEGylated GNRs roughly 48 hours before each 
experiment. This provided enough time for the GNRs to circulate and passively
48accumulate in the tumor tissue as discussed in chapter 4. The animals in the laser only 
group did not receive GNRs. Each animal was then anesthetized with 2% isoflurane, 
placed within a Bruker BioSpec 7.1 T horizontal-bore MRI and an axial T1 flash pre-scan
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was taken. Each tumor was then swabbed with 50% propylene glycol to enhance laser 
penetration depth,49 and the Gd labeled HPMA copolymers were then intravenously 
administered (0.03 mmol Gd/kg) in saline. Immediately after injection, the right tumor 
was radiated for 10 minutes using an 808 nm fiber coupled laser diode (Oclaro Inc., San 
Jose, CA) with collimating lens (Thorlabs, Newton, NJ). Intratumoral temperature was 
monitored using a 33 gauge needle thermocouple (Omega, Stamford, CT), and the laser 
power was directly controlled so that tumor temperature was maintained between 42°C 
and 43°C when treated with PPTT. Tumors on the left flank served as internal controls.
Immediately following laser treatment, the bed was placed back into the MRI and 
axial section T1 flash images of both tumors were taken. Two hours after laser treatment, 
a series of multislice T1 flash images were taken to provide anatomical information. 
Also, quantitative T1 MR images were obtained using an inversion recovery fast spin- 
echo pulse imaging sequence (slice thickness = 1 mm, number of slices = 8). This was 
done using the same acquisition parameters when the conjugate’s relaxivity was 
measured. In one animal, both T1 flash and T1 inversion recovery images were acquired 
before treatment (pre-scan), and then every 42 minutes for 5 hours after treatment. This 
was done to obtain time-dependent information on conjugate delivery.
6.2.5. Image analysis 
The quantitative T1 relaxation maps were calculated from the inversion recovery 
data sets using QuickVol II, a plugin for Image J.50 The images were then prepared in the 
following way. Using the T1 flash images, regions of interest (ROI) were drawn around 
both tumors and a mask was created for each slice. The mask was then used to isolate
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only the tumor data from the T1 relaxation maps. Due to some noise in the data, pixel 
outliers were removed using Image J. Each map was then overlayed onto its respective 
T1 flash image and a montage was created to display the whole tumor volume or the time 
dependent information as well as a 3D surface plot.
To compare the accumulation of polymers in both tumors, the average relaxation 
(R1 = 1/T1) was calculated in the skin around the tumor as well as the tumor’s center and 
periphery using Image J. This was done by first drawing ROIs on the T1 flash images 
(without the T1 map overlay) for both tumors. These ROIs were then used to calculate 
the average relaxation in each of these regions on the T1 relaxation map. The TER for 
each of these regions was then calculated by dividing R1 in the right tumor by R1 in the
left tumor ( t e r p p t t  = R1PPTT/R1control, or TERlaser only = R1laser only/R1control). This was
done for each mouse, tumor and slice. A normalized histogram of R1 values for whole 
tumors (center plus periphery) was also obtained using Image J software. This data was 
then graphically represented using GraphPad Prism.
6.2.6. Histology
After MR imaging, the animals were euthanized by CO2 inhalation and the tumors 
were removed and fixed in neutral buffered formalin. Samples were then dehydrated, 
paraffin-embedded and cut into 4-micron thick sections. Immunohistochemical analysis 
of Factor VIII expression, an endothelial cell marker, was then performed on some 
sections using a Factor VIII rabbit polyclonal antibody (Dako, Carpinteria, CA) and a 
biotinylated rabbit IgG secondary antibody. Positive signal was visualized using a 
streptavidin-HRP system, utilizing DAB (3,3’-diaminobenzidine) as the chromogen. All
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sections were then counterstained with hematoxylin. Washing with iodine, followed by 
sodium thiosulfate, removed any precipitates. Finally, sections were dehydrated in 
alcohol, cleared in xylene, coverslipped and imaged.
6.2.7. Fluorescence imaging 
Prior to the experiment, animals received an intravenous dose of PEGylated 
GNRs (48 hrs before) and both tumors were swabbed with 50% propylene glycol (10 
minutes before). Each animal (N = 4) was then intravenously administered 7.0 mg of 
FITC labeled HPMA copolymers and the right tumor was lased in the same way as the 
MRI experiment. Two hours after treatment with PPTT, each animal was then 
administered 5 mg of rhodamine labeled Concanavalin A (Vector Laboratories, 
Burlingame, CA) and euthanized 5 minutes later to visualize the vasculature. Both 
tumors were then collected, immediately placed in Tissue-Tek® OCT™ compound, 
frozen and cryo-sectioned into 12 |im thick sections (Leica CM3050, Wetzlar, Germany). 
Immediately before imaging, slides were dried and a cover slip was mounted using 
Cytoseal 60 diluted 1:5 in toluene. Large fluorescent imaging mosaics were acquired 
using a Nikon A1 confocal laser microscope system with a 10x objective.
6.2.8. Statistics
Statistical analyses were performed in GraphPad Prism. Comparisons between 
two groups (left vs. right tumors), were performed using a two-tailed, Welch-corrected 
unpaired t-test. P-values less than 0.05 were considered statistically significant. Data 
reported as mean ± SEM.
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6.3 Results
6.3.1. GNR and HPMA copolymer synthesis and characterization 
The GNRs were synthesized to be 58.6 x 15.4 ± 5.7 x 0.8 nm in size which 
corresponds to an aspect ratio of 3.8 and a SPR peak at 800 nm (Figure 6.1 A-B, Table
6.1). After PEGylation, the GNRs had a slightly negative zeta potential of -10 mV. 
These GNRs were found to be stable in a wide variety of buffers and solvents due to 
steric protection from aggregation.
The HPMA copolymers were synthesized by RAFT copolymerization to be 
roughly 65 kDa so that they were slightly above renal threshold to take advantage of the 
EPR effect (Figure 6.1 C, Table 6.1). In order for the copolymers to be imaged by MRI, 
they contained APMA-benzyl-DOTA comonomers which chelate Gd. For copolymers 
used for fluorescent imaging, APMA-FITC was used instead. An additional comonomer 
with a reactive carboxyl group, MA-GG-TT, was also incorporated so that future studies 
could incorporate receptor-mediated active targeting using the same copolymer if needed. 
In the present study, the TT group was hydrolyzed to obtain an untargeted conjugate. 
The copolymer Gd content was found to be similar to HPMA copolymer conjugates 
synthesized previously,45 and the relaxivity of the conjugates was similar to Gd- 




Figure 6.1. GNR characterization and HPMA copolymer schematic. GNRs were 
synthesized to be 60 x 15 nm in size (A) with an SPR peak at 800 nm (B). Scale 
bar, 100 nm. Two HPMA copolymers were synthesized for this study (C). The 
first was copolymerized with HPMA (i), DOTA to chelate Gd to provide MRI 
contrast (ii), and a hydrolyzed reactive carboxyl group to enable targeting in 
future studies using the same copolymer (iv). The other was copolymerized with 
HPMA (i), APMA-FITC for fluorescent imaging (iii), and a hydrolyzed reactive 
carboxyl group for the same reasons (iv).
Table 6.1. Physicochemical characteristics of GNRs and HPMA copolymers.
Size (nm) SFF (nm) Zeta potential (mV)
GNRs 56.6 x 15.4 • 5.7 x 0.8 S00 -10
HPMA fmol %1
APMA-fi&lzyl- 
DOTA-Gd (mol %) APMA-FITC (mol %) MA-GG-TT fmol %)






HPMA cQpQlymer-Gd 35 10 0 5 0.37 64.9 1.3 7.1
HPMA copolymer-FITC 93 0 2 5 - 62.4 1.4 -
6.3.2. HPMA copolymer tumor delivery two hrs after treatment by MRI 
In this experiment, half the animals were administered PEGylated GNRs (N = 3) 
and the other half saline (N = 3) 48 hours before MR imaging. On the day of the 
experiment, each animal was administered HPMA copolymer-Gd conjugates prior to 
laser radiation of the right tumor for 10 minutes. The tumors in animals which were 
previously given GNRs exhibited rapid heating which was maintained near 43°C. 
Animals without GNRs (laser alone) were slightly heated which is consistent with results
37described in Chapter 3. Two hours after laser treatment, quantitative MR imaging 
shows significantly enhanced copolymer delivery to tumors treated with PPTT (Figure
6.2). While the left tumor (control) had some polymer accumulation, the right tumor 
(PPTT) displayed signs of greater copolymer accumulation. As expected, in both tumors 
the delivery was not evenly distributed likely due to vascular heterogeneity. However, 
the extent of distribution does appear greater in tumors treated with PPTT. In animals not 
previously given GNRs, differences between the laser radiated (right) and control (left) 
tumors were not apparent (Figure 6.2).
When the relaxation rate (R1) was quantified for the skin around the tumors as 
well as the tumor’s center and periphery and expressed as a thermal enhancement ratio 
(TER, R1PPTT/R1co„trol, or R1laser only/R1control), a clear trend was observed (Figure 6.3 A). 
Treatment with PPTT resulted in increased copolymer delivery to each of these regions. 
PPTT caused a 1.36-fold increase in delivery to the skin, though this difference was not 
statistically significant relative to the laser only group due to large variability in the data 
and some enhancement to the skin with laser alone (ns, p = 0.434). For the tumor’s 
center, PPTT significantly raised the copolymer concentration by 1.42-fold relative to
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Figure 6.2. HPMA copolymer delivery two hours after treatment. Laser treatment of 
the right tumor in animals previously administered GNRs (PPTT) facilitated 
significant enhancement of HPMA copolymer delivery in terms of both 
accumulation and overall tumor distribution (A, top row). Laser alone did not cause 
any increased delivery (A, bottom row). A 3D surface plot provides better 
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Figure 6.3. Image analysis of HPMA copolymer delivery. Treatment of tumors 
with PPTT was capable of significantly enhancing the delivery of HPMA 
copolymers to the tumor’s center and periphery (A, left). Treatment with laser 
alone, absence of GNRs, did not increase delivery. Representative ROIs for this 
analysis is also shown (A, right). A histogram of R1 values of both control and 
PPTT treated tumors is shown (B). This data shows the capability of PPTT to 
increase tumor mass distribution. *Indicates a statistically significant difference 
(p < 0.05) by t-test. Error bars represented as ±standard error of the mean.
those animals treated with laser only (*, p = 0.049). The periphery of the tumors, regions 
of the tumors not including their center, saw the greatest thermal enhancement of 1.54- 
fold and was the most significant (*, p = 0.016). When the right tumors were treated with 
laser alone, i.e. no GNRs present, the same effect was not observed (Figure 6.3 A). 
Treatment with laser alone did not cause any appreciable increase in copolymer delivery 
to the skin, tumor center or periphery.
Plotting a histogram of R1 values for control and PPTT treated tumors provides 
some additional information (Figure 6.3 B). In control tumors, the majority of its volume
comprised of relatively low R1 and therefore polymer concentration values. This
2 1 distribution was Gaussian (R = 0.83) and centered at roughly R1mean = 102 s- with a
narrow standard deviation of o = 0.28. For tumors treated with PPTT, the distribution
2 1 was less Gaussian (R = 0.67), centered at R1mean = 2.31 s- and exhibited a much broader
distribution of o = 1.03. This indicates that the majority of the tumor volume received a
greater and more variable distribution of copolymer delivery, though overall its entire
volume received more copolymers. All regions in the PPTT histogram that do not
overlap with the control histogram received some benefit of delivery due to therapy.
6.3.3. HPMA copolymer tumor delivery over time 
To better understand the kinetics of delivery, one animal was imaged for 5 hours
38after treatment with PPTT (Figure 6.4). Similar to findings described in chapter 5, the 
majority of the dose was delivered to tumors within the first hour of treatment. 2 to 3 
hours after treatment, accumulation did not show any appreciable increase with time. In 
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Figure 6.4. HPMA copolymer delivery over time. The majority of delivery occurs 
within the first hour of PPTT treatment.
the increase in R1 was slight. In the right tumor treated with PPTT, large differences in 
R1 were observed mostly within the first hour.
6.3.4. Fluorescence imaging of HPMA copolymer delivery 
When the tumor delivery two hours after treatment was visualized by fluorescent 
imaging, a similar trend was observed (Figure 6.5). Treatment with PPTT facilitated 
more copolymer delivery overall. Delivery enhancement occurred mostly in the outer 
rim of the tumor, though increased delivery in the tumor’s center was also observed. By 
this method, overall enhancement o f delivery was less pronounced than those results 
obtained by MRI. In both tumors, vascularization density appeared the same. 
Interestingly, HPMA copolymer delivery did not directly correlate with location of blood 
vessels.
6.3.5. Histology of tumors after treatment with PPTT 
After imaging, the right and left tumors were evaluated for damage by histology 
(Figure 6.6). In both the control and PPTT treated tumors, many blood and lymphatic 
vessels were observed throughout and appeared to be intact (Figure 6.6 A-D). There was, 
however, one major difference between the groups. In all PPTT treated tumors, areas of 
tissue damage and cell death were observed (Figure 6.6 E-F). These regions of damage 
were typically less than 20% of the tumor’s total volume and were usually confined to the 
tumor’s center. In some cases, intact blood vessels were found in these areas indicating 
that vessel injury was not necessarily the reason for damage (Figure 6.6F). Also, tumors
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Figure 6.5. Fluorescent imaging of HPMA copolymer delivery. Two hours after 
treatment with PPTT, HPMA copolymer delivery (green) enhancement in the tumor’s 
periphery and center is observed relative to untreated controls. This effect is most 
pronounced in the tumor’s periphery. Blood vessel (red) density does not appear to 








Figure 6.6. Histology of control and PPTT treated tumors. No differences 
between the tumor periphery of both control and PPTT treated tumors were 
observed (A-B, 10x objective, scale bar = 1 0 0  |im). IHC staining of blood 
vessels in the periphery did not provide evidence of damage in either group (C­
D, 20x objective, scale bar = 50 |im). The center of tumors treated with PPTT 
had evidence of cell and tissue damage most likely due to excessive heating in 
this region (E, 10x objective, scale bar = 100 |im). A higher resolution view of 
this area shows the presence of capillary blood vessels which appear viable 
despite surrounding damage (F, 20x objective, scale bar = 50 |im).
treated with PPTT did not appear to have as many dividing cells further suggesting that 
some damage had occurred.
6.4 Discussion
It was shown previously that PPTT can be used to effectively deliver greater 
numbers of nanocarriers to solid tumors.37-41 But simply delivering more drug to tumors 
may not necessary improve overall delivery to cancerous cells. For example, excessive 
delivery of drug to only perivascular regions and not areas that are distant from viable 
vasculature may not improve overall treatment outcome. For this reason, delivery
42strategies which also increase tumor mass penetration are equally important.
There are many tumor tissue abnormalities that resist efficient transport of small 
and macromolecules to all cells. Most importantly, unregulated angiogenesis causes
52 53blood vessels to form with an abnormal and disorganized architecture. - The spatial 
distribution of blood vessels lacks order and continuity which ultimately generates a 
heterogenous distribution of tissue which is poorly perfused.54 Upon entering the tumor 
microenivornment, efficient transport through the interstitium is further restricted due to 
several other abnormalities.55 High ECM densities in the tumor interstitium prevent large 
objects such as nanocarriers from diffusing freely.56 Also, poor lymphatic drainage and 
related high IFP restricts fluid transport, particularly to the tumor’s center where pressure
57is the highest. Finally, nonspecific binding to ECM or cellular components due to 
charge-charge or Van der Waals interactions restricts motion.
Using hyperthermia to improve the delivery of polymer-drug conjugates may 
offer distinct advantages towards maximizing nanocarrier delivery in the context of
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interstitial transport. To describe interstitial transport or flux, Ji, one must consider the
55 58contributions to convective, Jc, and diffusive, Jd, molecule transport. , :
J i =Jd+Jc  = -  D ^ - C R  FK df x Equation 6.1
where D is the diffusion coefficient of the nanocarrier, C and dC/dx is the concentration 
and concentration gradient respectively, RF is the retardation factor, K  is the tissue’s 
hydraulic conductivity, and dp/dx is the pressure gradient in the tissue. During mild 
hyperthermia (T < 43°C), it is known that tumor blood flow increases most likely due to 
increases in blood flow from the host vessels or increased cardiac output.16 The result is 
increased microvascular pressure and therefore passive dilation of tumor blood vessels. 
Also during hyperthermia it has been found that IFP decreases.59 The result of these two 
phenomenon is an increase in dp/dx and therefore interstitial convective transport.
Regarding how such a combination might be beneficial from a diffusive 
standpoint, one must look at the polymer’s diffusion coefficient relative to other 
nanocarriers and the temperature of the environment. Using the Stokes-Einstein 
equation, D is calculated using the following relationship:
r v  kTD = -----  Equation 6.2
6nnR
where k is Boltzmann’s constant, T is the absolute temperature, n is viscosity and R is the 
carrier’s hydrodynamic radius. Here, it is shown that diffusive transport is higher for 
smaller nanocarriers (lower R) and at elevated temperatures (higher T, lower n). Also, as
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shown in Chapter 5, hyperthermia is able to increase the overall amount of copolymer 
delivery which therefore causes an increase in dC/dx.
The above highlights a) the importance of nanocarrier size on interstitial diffusive 
transport, and b) the advantages that mild hyperthermia provides for improving both 
convective and diffusive transport. In this context, using heat to drive the distribution of 
polymer-drug conjugates which are typically less than 15 nm in hydrodynamic diameter 
may offer the best opportunity to increase tumor tissue delivery. This may also be true as 
flexible, linear polymers such as HPMA copolymers have been shown to have greater 
transport properties than branched or rigid systems.60-61 Of course, a balance between 
favorable mass penetration and unfavorable renal clearance for these polymers is a 
necessary consideration in therapy design.
In this study, PPTT was used to selectively heat prostate tumors between 42-43°C 
to facilitate the delivery of HPMA copolymers. Using PPTT in this way decreases the 
chances of heating healthy tissue due to tumor specific delivery of GNRs by EPR and 
provides a high degree of control over heating. It is also possible that using tissue 
embedded antennas for energy generation, similar to brachytherapy, provides an 
advantage in terms of heat distribution. Also, PPTT may have other unknown benefits as
37it has clearly been shown to improve the delivery of both albumin37 and HPMA
38copolymers,38 whereas previous studies using other methods to induce hyperthermia have
28 62not shown greater delivery of each of these. ,
When PPTT was used to direct the delivery of Gd labeled HPMA copolymers to 
the right tumor of the animal and imaged by MRI, a clear difference between the tumors 
was observed (Figure 6.2). The right tumor exhibited greater T1 contrast and therefore
194
38
polymer concentration than the left, untreated tumor. In these images, it is observed that 
these treated tumors did not just receive higher amount of copolymer accumulation. 
Rather, more of the tumor volume overall received greater delivery suggesting greater 
tumor mass penetration of these copolymers due to PPTT. This is in stark contrast to 
tumors treated with laser but not previously administered GNRs, showing that PPTT is in 
fact responsible and not just laser radiation itself. Though it would be ideal to have an 
even distribution of high copolymer concentrations throughout the whole tumor volume, 
the images show that this is not the case. There still exist regions in the tumor that did 
receive less copolymer. These regions are likely to be the necrotic core of the tumor and 
are thus difficult to reach.
When these images were analyzed for thermal enhancement of delivery based on 
region (skin, tumor center and periphery), in each case thermal enhancement was 
observed (Figure 6.3 A). For the skin, this difference was not statistically significant 
from laser alone though enhanced delivery to the skin is expected during heating. Both 
the tumor’s center and periphery had a roughly 1.50-fold increase in delivery, where 
delivery to the center was barely significant and the periphery highly significant. This 
analysis further suggests that greater mass penetration to the tumor’s center was 
achieved. This interpretation should be taken with a degree of caution however. Using 
MRI, it is very difficult to delineate the viable from the necrotic regions of the tumor. 
The ROIs were drawn based on what appeared to be the tumor’s center and periphery, but 
this does not necessarily reflect the true location of the tumor’s necrotic core. Vascular 
heterogeneity often makes the location of the tumor’s core highly variable which explains 
why there is large variation in the data and limited significance in the tumor’s center.
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A better representation of mass penetration is found is Figure 6.3 B. In this 
histogram, it is easy to observe that PPTT caused more of the tumor to have higher 
concentrations of copolymer than the control tumor. For example, let us consider the 
total percent area of the tumor (area under the curve) less than and greater than R1 = 1.34 
s-1 for both tumors. In the control (untreated) tumors, 83.3% of its area had R1 values 
less than 1.34 s-1. In PPTT treated tumors, 46.5% of its area was less than 1.34 s-1 and 
53.5% of its area had R1 values over this threshold. These data further suggest that 
higher concentrations of copolymers were able to more readily be transported through the 
tumor’s interstitium when treated with PPTT.
The fact that the majority of delivery occurred within the first hour of laser 
radiation is not surprising (Figure 6.4). In the study described in the previous Chapter 
where HPMA copolymer delivery was quantified, roughly 60-70% of the copolymers
38were delivered within the first 15 minutes after laser radiation. This is likely due to two 
main reasons. First, clearance of the HPMA copolymers from the blood via the kidneys 
or RES is likely due to the conjugate’s size and negative charge which makes the window 
of opportunity for delivery within the first few hours. Second, the differential increase in 
pressure, dp/dx, which drives delivery during hyperthermia occurs over a short period of 
time (10-15 minutes). For this reason, future work aims to investigate longer periods of 
laser radiation to further improve delivery.
To corroborate the MRI results, FITC labeled HPMA copolymers were applied 
using the same experimental design to image distribution by fluorescence imaging. 
Because the location of copolymer delivery relative to vascularization is important, 
animals were administered rhodamine labeled lectin prior to euthanasia to stain the
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tumor’s vasculature. These results provide similar information in that PPTT increased 
delivery to both the tumor’s periphery and center. This observation was however less 
pronounced than the MRI results which may be due to the relative small z-direction 
cross-section; 0.012 mm vs. 1.0 mm for fluorescence and MR imaging respectively. It 
was anticipated that the location of blood vessels would directly correlate with the 
location of copolymer delivery. While this was indeed the case in the tumor’s outer rim 
where the blood vessels were of the greatest diameter (see Figure 6.6 C-D), the inner 
capillaries did not permit much delivery. This is likely because of their small and 
constricted nature due to high cellular density and interstitial pressure in these regions.
Histological evaluation of the tumors provides some insight into the impact of 
mild PPTT on tumor viability. In both tumors, control and PPTT treated, the tumor’s 
periphery appeared undamaged with a high degree of vascularization (Figure 6.6 A-D). 
No signs of vascular damage was observed which is a concern when tumors are heated 
near the 43°C vascular damage threshold.63 There was a difference though in the tumor’s 
center. In each of the PPTT treated tumors, areas of tissue damage were observed 
(Figure 6.6 E-F). This is likely to be because of the inability of the tumor’s center to 
dissipate heat effectively during hyperthermic treatment. Residual increases in 
temperature in these regions then causes direct cell death and tissue damage. What was 
interesting, however, was the presence of viable blood vessels found in these regions 
(Figure 6.6 F). These capillary blood vessels appeared to be intact, though further 
analysis of blood vessel viability in these regions is required to confirm this observation.
Effective transport of nanocarriers through the tumor’s interstitium remains a 
major challenge in nanomedicine. Large nanoparticles such as liposomes, micelles and
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inorganic nanoparticles are severely limited by this biological barrier, though strategies 
such as the one described in this study may help overcome this. An evolving and 
interesting concept to overcome the problem involves the design of multistage drug 
delivery platforms.64 In these nanoparticle systems, large nanoparticles carry drugs to the 
site of the tumor followed by release of free drug in the interstitium due to external 
stimuli such as light and heat. In this way, such systems take full advantage of EPR and 
the high diffusivity of free drugs through the tumor’s interstitium.
6.5 Conclusions
This study shows by MR and fluorescence imaging that PPTT is capable of 
improving the tumor distribution of HPMA copolymers. During laser radiation of the 
tumor, heating may facilitate both convective and diffusive interstitial transport of these 
conjugates. PPTT was capable of not only providing greater amounts of copolymer 
delivery, but also more pervasive distribution throughout the whole tumor mass. This 
observation is important for more effective drug delivery to cancerous cells. Necrotic 
and unavailable regions of the tumor were still present even after treatment with PPTT, 
and future studies improving delivery to these regions remains a significant challenge.
6.6 References
1. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer
2006, 6, 688-701.
2. Duncan, R.; Gaspar, R. Nanomedicine (s) under the microscope. Mol. Pharm.
2011, 8, 2101-2141.
199
3. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular 
permeability and the EPR effect in macromolecular therapeutics: a review. J. 
Control. Release 2000, 65, 271-284.
4. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J. W.; Thurston, G.; Roberge, 
S.; Jain, R. K.; McDonald, D. M. Openings between defective endothelial cells 
explain tumor vessel leakiness. Am. J. Pathol. 2000, 156, 1363-1380.
5. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. 
Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007,
2, 751-760.
6. Suzuki, M.; Hori, K.; Abe, I.; Saito, S.; Sato, H. A new approach to cancer 
chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. 
Natl. Cancer Inst. 1981, 67, 663-669.
7. Li, C.; Miyamoto, Y.; Kojima, Y.; Maeda, H. Augmentation of tumour delivery of 
macromolecular drugs with reduced bone marrow delivery by elevating blood 
pressure. Br. J. Cancer 1993, 67, 975-980.
8. Seki, T.; Fang, J.; Maeda, H. Enhanced delivery of macromolecular antitumor 
drugs to tumors by nitroglycerin application. Cancer Sci. 2009, 100, 2426-2430.
9. Aicher, K. P.; Dupon, J. W.; White, D. L.; Aukerman, S. L.; Moseley, M. E.; 
Juster, R.; Rosenau, W.; Winkelhake, J. L.; Brasch, R. C. Contrast-enhanced 
magnetic resonance imaging of tumor-bearing mice treated with human 
recombinant tumor necrosis factor a. Cancer Res. 1990, 50, 7376-7381.
10. Zhao, L.; Ching, L. M.; Kestell, P.; Kelland, L. R.; Baguley, B. C. Mechanisms of 
tumor vascular shutdown induced by 5, 6-dimethylxanthenone-4-acetic acid 
(DMXAA): Increased tumor vascular permeability. Int. J. Cancer 2005, 116, 322­
326.
11. Jain, R. K. Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science 2005, 307, 58-62.
12. Chauhan, V. P.; Stylianopoulos, T.; Martin, J. D.; Popovic, Z. ; Chen, O.; 
Kamoun, W. S.; Bawendi, M. G.; Fukumura, D.; Jain, R. K. Normalization of 
tumour blood vessels improves the delivery of nanomedicines in a size-dependent 
manner. Nat. Nanotechnol. 2012, 7, 383-388.
13. Magzoub, M.; Jin, S.; Verkman, A. Enhanced macromolecule diffusion deep in 
tumors after enzymatic digestion of extracellular matrix collagen and its 
associated proteoglycan decorin. FASEB J. 2008, 22, 276-284.
200
14. Vega, V. L.; Charles, W.; De Maio, A. A new feature of the stress response: 
increase in endocytosis mediated by Hsp70. Cell Stress Chaperones 2009, 15, 
517-527.
15. Vega, V. L.; De Maio, A. Increase in phagocytosis after geldanamycin treatment 
or heat shock: role of heat shock proteins. J. Immunol. 2005, 175, 5280-5287.
16. Song, C. W. Effect of local hyperthermia on blood flow and microenvironment: a 
review. Cancer Res. 1984, 44, 4721s-4730s.
17. Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G.; Kerner, T.; 
Felix, R.; Riess, H. The cellular and molecular basis of hyperthermia. Crit. Rev. 
Oncol. Hematol. 2002, 43, 33-56.
18. Fajardo, L.; Schreiber, A.; Kelly, N.; Hahn, G. Thermal sensitivity of endothelial 
cells. Radiat. Res. 1985, 103, 276-285.
19. Chen, B.; Zhou, M.; Xu, L. Study of vascular endothelial cell morphology during 
hyperthermia. J. Therm. Biol. 2005, 30, 111-117.
20. Lefor, A. T.; Makohon, S.; Ackerman, N. B. The effects of hyperthermia on 
vascular permeability in experimental liver metastasis. J. Surg. Oncol. 1985, 28, 
297-300.
21. Fujiwara, K.; Watanabe, T. Effects of hyperthermia, radiotherapy and 
thermoradiotherapy on tumor microvascular permeability. Pathol. Int. 2008, 40, 
79-84.
22. Kong, G.; Dewhirst, M. W. Hyperthermia and liposomes. Int. J. Hyperthermia 
1999, 15, 345-370.
23. Huang, S. K.; Stauffer, P. R.; Hong, K.; Guo, J. W. H.; Phillips, T. L.; Huang, A.; 
Papahadjopoulos, D. Liposomes and hyperthermia in mice: increased tumor 
uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. 
Cancer Res. 1994, 54, 2186-2191.
24. Weinstein, J.; Magin, R.; Yatvin, M.; Zaharko, D. Liposomes and local 
hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979, 
204, 188-191.
25. Gaber, M. H.; Wu, N. Z.; Hong, K.; Huang, S. K.; Dewhirst, M. W.; 
Papahadjopoulos, D. Thermosensitive liposomes: extravasation and release of 
contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 1996,
36, 1177-1187.
201
26. Matteucci, M. L.; Anyarambhatla, G.; Rosner, G.; Azuma, C.; Fisher, P. E.; 
Dewhirst, M. W.; Needham, D.; Thrall, D. E. Hyperthermia increases 
accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin. 
Cancer Res. 2000, 6, 3748-3755.
27. Kong, G.; Braun, R. D.; Dewhirst, M. W. Characterization of the effect of 
hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res.
2001, 61, 3027-3032.
28. Kong, G.; Braun, R. D.; Dewhirst, M. W. Hyperthermia enables tumor-specific 
nanoparticle delivery: effect of particle size. Cancer Res. 2000, 60, 4440-4445.
29. Ma, G.; Jiang, G. In Review o f tumor hyperthermia technique in biomedical 
engineering frontier, 2010 3rd International Conference on Biomedical 
Engineering and Informatics (BMEI), 2010; IEEE: 2010; pp 1357-1359.
30. Link, S.; El-Sayed, M. A. Shape and size dependence of radiative, non-radiative 
and photothermal properties of gold nanocrystals. Int. Rev. Phys. Chem. 2000, 19, 
409-453.
31. Hirsch, L. R.; Stafford, R. J.; Bankson, J. A.; Sershen, S. R.; Rivera, B.; Price, R. 
E.; Hazle, J. D.; Halas, N. J.; West, J. L. Nanoshell-mediated near-infrared 
thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. 
Sci. USA. 2003, 100, 13549-13554.
32. O'Neal, D. P.; Hirsch, L. R.; Halas, N. J.; Payne, J. D.; West, J. L. Photo-thermal 
tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett.
2004, 209, 171-176.
33. Stern, J. M.; Stanfield, J.; Kabbani, W.; Hsieh, J. T.; Cadeddu, J. A. Selective 
prostate cancer thermal ablation with laser activated gold nanoshells. J. Urol. 
2008, 179, 748-753.
34. Huang, X.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Gold nanoparticles: 
interesting optical properties and recent applications in cancer diagnostics and 
therapy. Nanomed. 2007, 2, 681-693.
35. Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Au nanoparticles target cancer. Nano 
Today 2007, 2, 18-29.
36. Huang, X.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Plasmonic photothermal 
therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008, 23, 217-228.
37. Gormley, A. J.; Greish, K.; Ray, A.; Robinson, R.; Gustafson, J. A.; Ghandehari,
H. Gold nanorod mediated plasmonic photothermal therapy: A tool to enhance 
macromolecular delivery. Int. J. Pharm. 2011, 415, 315-318.
202
38. Gormley, A. J.; Larson, N.; Sadekar, S.; Robinson, R.; Ray, A.; Ghandehari, H. 
Guided delivery of polymer therapeutics using plasmonic photothermal therapy. 
Nano Today 2012, 7, 158-167.
39. Park, J. H.; von Maltzahn, G.; Xu, M. J.; Fogal, V.; Kotamraju, V. R.; Ruoslahti, 
E.; Bhatia, S. N.; Sailor, M. J. Cooperative nanomaterial system to sensitize, 
target, and treat tumors. Proc. Natl. Acad. Sci. USA. 2010, 107, 981-986.
40. Park, J. H.; Maltzahn, G. v.; Ong, L. L.; Centrone, A.; Hatton, T. A.; Ruoslahti, 
E.; Bhatia, S. N.; Sailor, M. J. Cooperative nanoparticles for tumor detection and 
photothermally triggered drug delivery. Adv. Mater. 2010, 22, 880-885.
41. Von Maltzahn, G.; Park, J. H.; Lin, K. Y.; Singh, N.; Schwoppe, C.; Mesters, R.; 
Berdel, W. E.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Nanoparticles that 
communicate in vivo to amplify tumour targeting. Nat. Mater. 2011, 10, 545-552.
42. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. 
Clin. Oncol. 2010, 7, 653-664.
43. Yuan, F.; Leunig, M.; Huang, S. K.; Berk, D. A.; Papahadjopoulos, D.; Jain, R. K. 
Mirovascular permeability and interstitial penetration of sterically stabilized 
(stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54, 3352­
3356.
44. Strohalm, J.; Kopecek, J. Poly N-(2-hydroxypropyl) methacrylamide. 4. 
Heterogeneous polymerization. Angew. Makromol. Chem. 1978, 70, 109-118.
45. Zarabi, B.; Borgman, M. P.; Zhuo, J.; Gullapalli, R.; Ghandehari, H. Noninvasive 
monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance 
imaging. Pharm. Res. 2009, 26, 1121-1129.
46. Omelyanenko, V.; Kopeckova, P.; Gentry, C.; Kopecek, J. Targetable HPMA 
copolymer-adriamycin conjugates. Recognition, internalization, and subcellular 
fate. J. Control. Release 1998, 53, 25-37.
47. Subr, V.; Ulbrich, K. Synthesis and properties of new N-(2-hydroxypropyl) 
methacrylamide copolymers containing thiazolidine-2-thione reactive groups. 
React. Funct. Polym. 2006, 66, 1525-1538.
48. Gormley, A. J.; Malugin, A.; Ray, A.; Robinson, R.; Ghandehari, H. Biological 
evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment. J. 
Drug Target. 2011, 19, 915-924.
203
49. Wang, R. K.; Tuchin, V. V. Enhance light penetration in tissue for high resolution 
optical imaging techniques by the use of biocompatible chemical agents. J. XRay 
Sci. Tech. 2002, 10, 167-176.
50. Schmidt, K. F.; Ziu, M.; Ole Schmidt, N.; Vaghasia, P.; Cargioli, T. G.; Doshi, S.; 
Albert, M. S.; Black, P. M. L.; Carroll, R. S.; Sun, Y. Volume reconstruction 
techniques improve the correlation between histological and in vivo tumor 
volume measurements in mouse models of human gliomas. J. Neurooncol. 2004, 
68, 207-215.
51. Haar, P. J.; Broaddus, W. C.; Chen, Z.; Fatouros, P. P.; Gillies, G. T.; Corwin, F.
D. Gd-DTPA T1 relaxivity in brain tissue obtained by convection-enhanced 
delivery, magnetic resonance imaging and emission spectroscopy. Phys. Med. 
Biol. 2010, 55, 3451-3465.
52. Konerdingi, M.; Fait, E.; Gaumann, A.; Dimitropouloui, C.; Malkusch, W., 
Scanning electron microscopy of corrosion casts in the study of tumor. In 
Angiogenesis: models, modulators, and clinical applications, Maragoudakis, M.
E., Ed. Plenum Press: New York, USA, 1998; Vol. 298, pp 429-447.
53. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. 
Med. 1995, 1, 27-30.
54. Baish, J. W.; Jain, R. K. Fractals and cancer. Cancer Res. 2000, 60, 3683-3688.
55. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer 
Res. 1987, 47, 3039-3051.
56. Ramanujan, S.; Pluen, A.; McKee, T. D.; Brown, E. B.; Boucher, Y.; Jain, R. K. 
Diffusion and convection in collagen gels: implications for transport in the tumor 
interstitium. Biophys. J. 2002, 83, 1650-1660.
57. Baxter, L. T.; Jain, R. K. Transport of fluid and macromolecules in tumors. I. 
Role of interstitial pressure and convection. Microvasc. Res. 1989, 37, 77-104.
58. Swabb, E. A.; Wei, J.; Gullino, P. M. Diffusion and convection in normal and 
neoplastic tissues. Cancer Res. 1974, 34, 2814-2822.
59. Leunig, M.; Goetz, A. E.; Dellian, M.; Zetterer, G.; Gamarra, F.; Jain, R. K.; 
Messmer, K. Interstitial fluid pressure in solid tumors following hyperthermia: 
possible correlation with therapeutic response. Cancer Res. 1992, 52, 487-490.
60. Deen, W.; Bohrer, M.; Epstein, N. Effects of molecular size and configuration on 
diffusion in microporous membranes. AIChE J. 1981, 27, 952-959.
204
61. Sadekar, S.; Ray, A.; Janat-Amsbury, M.; Peterson, C.; Ghandehari, H. 
Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in 
ovarian-tumor-bearing mice. Biomacromolecules 2011, 12, 88-96.
62. Lammers, T.; Peschke, P.; Kuhnlein, R.; Subr, V.; Ulbrich, K.; Debus, J.; Huber, 
P.; Hennink, W.; Storm, G. Effect of radiotherapy and hyperthermia on the tumor 
accumulation of HPMA copolymer-based drug delivery systems. J. Control. 
Release 2007, 117, 333-341.
63. Song, C. W.; Kang, M. S.; Rhee, J. G.; Levitt, S. H. Effect of hyperthermia on 
vascular function in normal and neoplastic tissues. Ann. NY Acad. Sci. 1980, 335, 
35-47.
64. Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V. P.; Jiang, W.; 
Popovic, Z.; Jain, R. K.; Bawendi, M. G.; Fukumura, D. Multistage nanoparticle 
delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. 
USA. 2011, 108, 2426-2431.
CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS 
7.1: Conclusions
The work presented in this dissertation aimed to address a major barrier in drug 
delivery, i.e.; localized, tumor selective and efficient delivery to cancerous cells. The 
inability to direct drug delivery to locally advanced prostate tumors prevents its use in the 
clinic and thus limits therapy to hormone and radiotherapy. While these two treatment 
strategies have a high degree of success, the synergistic combination of targeted drug 
delivery, heat and radiotherapy may further improve outcome. In this dissertation, PPTT 
was used as a tool to guide HPMA copolymer localization to prostate tumors. This 
concept was demonstrated over four chapters. In Chapter 3, the concept of using PPTT 
to improve the delivery of macromolecules such as albumin was validated.1 Chapter 4 
sought to determine if targeting GNRs directly to the tumor’s vasculature would improve 
PPTT performance.2 In Chapter 5, PPTT was used to direct the localization of heat shock 
targeted HPMA copolymers to the site of interest. Finally, in Chapter 6 it was found that 
PPTT was also capable of enhancing the tumor mass distribution of these conjugates.4
The initial hypothesis of this work was that PPTT would be a useful tool to 
improve the delivery of polymer therapeutics. However, previous reports in the literature 
have shown that hyperthermia itself is not capable o f improving the delivery of
nanocarriers in this size range.5-6 Therefore, a necessary first step in this work was to 
validate the overall hypothesis using a well established model of macromolecular 
delivery. In Chapter 3, a mouse sarcoma tumor model (S180) with well characterized 
EPR was treated with PPTT immediately following administration of EBD to trace 
albumin delivery.1 This animal model was used in this study because of its low cost, 
availability in the lab, ease of tumor production and known permeability to albumin. 
Intratumoral temperatures were monitored during treatment to correlate delivery with 
temperature. Indeed, 10 minutes of laser treatment caused significant heating of the 
tumors. This increased the delivery of albumin by 1.7-fold over the temperatures tested. 
Results of this study validated the overall hypothesis that PPTT was capable of 
improving the delivery of macromolecules in the size range which is typical of most 
polymer therapeutics.
As PPTT is used in this dissertation to regulate blood flow and vascular 
permeability, it was hypothesized in Chapter 4 that targeting GNRs directly to the 
tumor’s vasculature would provide some benefit. This hypothesis was tested by 
conjugating the RGDfK peptide to the PEG brush and evaluating its targeting capacity 
both in vitro and in vivo. When incubated with both prostate cancer and endothelial 
cells, RGDfK conjugated GNRs were found to bind and be uptaken to a very high extent 
relative to the untargeted GNRs. This was particularly the case for endothelial cells 
which have higher expression of the targeted receptors. When both GNR conjugates 
were administered to prostate tumor bearing mice, the untargeted GNRs were found to 
accumulate in prostate tumors to a much higher extent. The reason for this discrepancy 
between the in vitro and in vivo results is likely due to fast blood clearance of the
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RGDfK-GNRs. This rapid blood clearance then reduced the opportunity of the GNRs to 
target blood vessels to a higher extent. Because of this, it was determined that vascular 
targeting GNRs, at least the ones that were tested, were not likely to provide significant 
benefit and therefore untargeted GNRs were chosen for subsequent studies.
In Chapter 5, PPTT was used to direct the delivery of HPMA copolymers to 
prostate tumors. HPMA copolymers were synthesized to contain a number of functional 
monomers including drug, imaging agents, as well as a targeting peptide. The targeting 
peptide used in this study, WIFPWIQL, was chosen because of its capacity to binding to 
surface expressed HSPs. Therefore, directed delivery in this way allows these 
copolymers to specifically target cells which have previously been treated with 
hyperthermia. To test this overall study concept, first the heat shock targeting approach 
was validated. Treatment of cells with hyperthermia was found to increase the uptake of 
heat shock targeted HPMA copolymers. To test the system in vivo, prostate tumors were 
developed in mice and the tumors were heated with PPTT immediately following 
administration of either untargeted or heat shock targeted HPMA copolymers. PPTT 
resulted in a burst accumulation of both conjugates up to four hours. After four hours, 
while the untargeted conjugates diffused back out of the tumor, the heat shock targeted 
copolymers were retained for an extended period of time due to heat shock targeting. 
This study therefore provides evidence that PPTT is capable of directing the delivery of 
HPMA copolymers. This is particularly the case when these conjugates are targeted to 
heat shock proteins as greater tumor retention and cell uptake is possible.
While Chapter 5 showed that PPTT can be used to direct HPMA copolymer 
delivery to prostate tumors, effective delivery is not possible unless the delivery strategy
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facilitates greater tumor mass penetration. This is because vascular heterogeneity 
produces large regions of unperfused tissue which are not typically accessible by 
nanocarriers. Therefore, it was hypothesized in Chapter 6 that PPTT was also capable of 
enhancing tumor mass penetration.4 This hypothesis was tested by imaging tumor 
delivery after treatment with PPTT by MR and fluorescence imaging. HPMA 
copolymers were synthesized to contain either Gd or FITC and injected in prostate tumor 
bearing mice immediately before PPTT treatment. Subsequent imaging of copolymer 
accumulation in the treated and untreated tumors provided evidence that treatment with 
PPTT is capable of increasing both the accumulation and penetration of HPMA 
copolymers. A histogram of pixel intensities showed that a higher percentage of pixels in 
the PPTT treated tumors has higher concentrations of HPMA copolymers. This study 
therefore confirms that PPTT is also a useful tool to improve HPMA copolymer 
interstitial transport.
In conclusion, as new tools to selectively and controllably heat tumors enter into 
the clinical setting, such as PPTT, it may be possible to further unlock the full potential of 
hyperthermia in adjuvant therapy of cancer. In this dissertation, it was shown that PPTT 
is useful to improve the delivery of polymer-drug conjugates. In the future, PPTT may 
be used to treat a wide variety of other diseases that are also heat sensitive.
7.2: Future Directions
The work described in this dissertation is a new project in the lab and there are 
many questions, ideas and studies that remain. Also, as the ultimate goal is to develop 
this approach for use in the clinic, a significant amount of preclinical and clinical
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development is required. Below are a few of the potential studies that may be done in the 
future.
The scope of the work described in this dissertation did not include testing the 
efficacy of this approach when the conjugates had drugs attached. Therefore, the next 
phase of this project will focus on testing efficacy. The choice in drug for this study may 
or may not be important in the context of achieving synergism with hyperthermia. As 
described in Section 2.2.2.6, the activity of some drugs such as cisplatin is potentiated 
with heat. Though the mechanism of thermal enhancement may not translate when 
bound to polymers. Therefore, before the initiation of a well-designed efficacy study, 
thermal enhancement activity of polymers with different drugs and heat shock targeting 
receptors should be tested to achieve the best study outcome.
In the bulk of this work, PPTT was applied by heating tumors between 42-43°C 
for 10 minutes to enhance delivery. While this thermal dose was chosen based on 
information available in the literature, it is well known that tumor blood flow and 
vascular permeability is highly dependent on this experimental parameter. Therefore, an 
obvious future study would be to evaluate the enhancement of HPMA copolymer 
delivery as a function of thermal dose. Varying the temperature in the tumor from 37°C 
to 43°C, including thermal ablation temperatures above this established limit, as well as 
varying the time of laser radiation could potentially identify the ideal thermal dose to 
maximize conjugate delivery. Additionally, this effect should be characterized as a 
function of conjugate size and type (i.e. PPTT with linear polymers, liposomes, micelles 
or inorganic nanoparticles). In this research, HPMA copolymers which were large in size 
(60-80 kDa) were used because this size range is slightly above the threshold for renal
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clearance. Because of this, they were able to circulate for an extended period of time. 
However, the nondegradable nature of these conjugates is of concern. Therefore, it will 
be interesting to see if smaller sized conjugates (20-45 kDa) which are capable of being 
cleared via the kidneys will experience similar delivery enhancement.
Another very interesting concept is to apply this approach to enhance the delivery 
of polymers carrying therapeutic radionuclides. For several decades, companies and 
academic labs have been using antibodies to deliver radionuclides as an alternative to 
external beam radiotherapy or brachytherapy. Previously, HPMA copolymers have also
n
been used to deliver yittrium-90 to prostate tumors. Therefore, PPTT may be used to 
enhance the delivery of these targeted radiotherapies. There is potential that this concept 
may be more effective than PPTT plus chemotherapy as hyperthermia is known to better 
potentiate radiotherapy. Extending this concept further, it may be even more interesting 
to conjugate both a chemotherapeutic agent such as docetaxel and a therapeutic 
radionuclide such as yittrium-90 to the same copolymer backbone. Then, treatment of 
prostate tumors with PPTT to enhance the delivery of both chemotherapy and 
radiotherapy would provide a highly combined approach towards treatment; 
hyperthermia plus chemotherapy plus radiotherapy.
Gold nanocages, also have a tunable SPR in the NIR spectra and are hollow such
o
that drugs can be loaded within its core. These nanocages can be surface coated with 
pNIPAAm so that during nanoparticle heating, the polymer brush collapses for triggered 
drug release. This technique is interesting and may be useful in regards to the approach 
described in this dissertation. Simultaneous release of heat and drugs which act on the 
tumor’s vasculature such as vascular disrupting agents could synergistically improve
210
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polymer therapeutic delivery. For example, DMXAA is a low molecular weight drug 
which acts to disrupt cell-cell junctions between endothelial cells and therefore increases 
vascular permeability.9 It is also known to work synergistically with hyperthermia and 
stimulate the production of TNF-a and nitric oxide, two potent agents which increase 
vasopermeability.10 Therefore, combined treatment with heat and DMXAA using PPTT 
could significantly increase the delivery of other therapeutics.
Finally, efforts to begin translation of this approach may begin once enough data 
is acquired to confirm its usefulness in the clinic. Of particular importance in this regard 
is assessing the safety of both GNRs and the HPMA copolymer conjugates. Several 
clinical trials testing similar components are either pending or completed.11-14 Full and 
satisfactory evaluation of safety will not be easy, however, as both are nondegradable. 
This is particularly the case for AuNPs which are not easily excreted. Because of this, 
many preclinical studies testing the toxic effects of these conjugates is required.
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APPENDIX A
CHARACTERIZATION DATA OF HPMA COPOLYMERS
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M n (g /  m ol) 43276.62893
M w  (g /  mol) 62419.87081
P D I ( M w /M n )  1.442345958
UV Signal
Elution Volume (ml) 
Figure A.1. SEC of HPMA-FITC precursor copolymer.
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Figure A.2. SEC of HPMA-Tyr-CONH2 copolymers.
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VIS 1 Results
FkS Retention Time Name Area Total nmol per sample
1 1.723 Cysteic 17901 3 833
3 4.660 Asp 66952 0.151
4 5.280 Thr 40280 0.086
5 5.763 Ser 121751 0.244
6 6.450 Glu 1342258 2.950
8 9.180 Gfy 4035578 9.368
Alti 0.000 BDL
Cys 0.000 BDL
9 12.613 Val 24636 0.080
Met 0.000 BDL
11 16.273 lie 1797306 4.427
12 17.450 Leu 971406 2.488
13 18.500 Tyr 348264 0.821
14 19.443 Phe 986770 2.152
16 21.900 L.ys 45954 0.088
17 22.873 NH3 7984840 15.880
His 0.000 BDL
Arg 0.000 BDL









HPMA-FITC, 0.5 m g /m l in PBS
Figure A.4. Fluorescence of HPMA-FITC copolymers.
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Figure A.5. SEC of HPMA-Gd copolymer final product.
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1-020812 1 ppm 0.82 mg/L
2-020812 10 ppm 8.6 1 0.82
3-020812 50 ppm 41.4 10 8.6
4-020812 100 ppm 82.3 50 41.4
5-020812 Sample 48.5 100 82.3
90.00
0 20 40 60 80 100 120
True (mg/L)
Polymer content 58.8 mg/L
0.37 mmol Gd/g polymer
Figure A.6. ICP-MS characterization of Gd content.
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Figure A.7. MRI relaxivity characterization of HPMA-Gd copolymer.
